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RÉSUMÉ 
L’excitotoxicité est un mécanisme physiopathologique majeur impliqué dans la pathogenèse de la 
déficience en thiamine (DT). Dans les régions cérébrales vulnérables à la DT, on observe une mort 
cellulaire induite par excitotoxicité dont l’origine semble être la conséquence d’une perturbation du 
métabolisme énergétique mitochondrial, d’une dépolarisation membranaire soutenue et d’une 
diminution de l’absorption du glutamate par les astrocytes suite à la diminution de l’expression des 
transporteurs EAAT1 et EAAT2. Il est clairement établi que le glutamate joue un rôle central dans 
l’excitotoxicité lors de la DT. Ainsi, la mise en évidence des mécanismes impliqués dans la diminution 
de l’expression des transporteurs du glutamate est essentielle à la compréhension de la physiopathologie 
de la DT. 
  
L’objectif de cette thèse consiste en l’étude de la régulation des transporteurs astrocytaires du 
glutamate et la mise au point de stratégies thérapeutiques ciblant la pathogenèse de l’excitotoxicité lors 
de l’encéphalopathie consécutive à la DT. 
 
Les principaux résultats de cette thèse démontrent des perturbations des transporteurs du 
glutamate à la fois dans des modèles animaux de DT et dans des astrocytes en culture soumis à une DT. 
La DT se caractérise par la perte du variant d’épissage GLT-1b codant pour un transporteur du 
glutamate dans le thalamus et le colliculus inférieur, les régions cérébrales affectées lors d’une DT, en 
l’absence de modification des niveaux d’ARNm. Ces résultats suggèrent une régulation post-
transcriptionnelle de l’expression des transporteurs du glutamate en condition de DT. 
Les études basées sur l’utilisation d’inhibiteurs spécifiques des facteurs de transcription NFkB et 
de l’enzyme nucléaire poly(ADP)ribose polymérase-1 (PARP-1) démontrent que la régulation de 
l’expression du transporteur GLT-1 est sous le contrôle de voies de signalisation NFkB dépendantes de 
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PARP-1. Cette étude démontre une augmentation de l’activation de PARP-1 et de NFkB dans les 
régions vulnérables chez le rat soumis à une DT et en culture d’astrocytes DT. L’inhibition 
pharmacologique du facteur de transcription NFkB par le PDTC induit une augmentation des niveaux 
d’expression de GLT-1, tandis que l’inhibition de PARP-1 par le DPQ conduit à l’inhibition de 
l’hyperactivation de NFkB observée lors de DT. L’ensemble de ces résultats met en évidence un 
nouveau mécanisme de régulation des transporteurs du glutamate par l’activation de PARP-1. 
L’accumulation de lactate est une caractéristique de la DT. Un traitement avec le milieu de 
culture d’astrocytes en condition de DT sur des cultures d’astrocytes naïfs induit une diminution de 
l’expression de GLT-1 ainsi qu’une inhibition de la capacité d’absorption du glutamate par les astrocytes 
naïfs. En revanche, l’administration de lactate exogène ne modifie pas le niveau d’expression protéique 
de GLT-1. Ainsi, des facteurs solubles autres que le lactate sont sécrétés par des astrocytes en condition 
de perturbation métabolique et peuvent potentiellement réguler l’activité des transporteurs du glutamate 
et contribuer à la pathogenèse du syncytium astroglial. 
En outre, la ceftriaxone, un antibiotique de la famille des β-lactamines, augmente de façon 
différentielle l’expression du variant-d’épissage GLT-1 dans le colliculus inférieur chez le rat DT et en 
culture d’astrocytes DT. Ces résultats suggèrent que la ceftriaxone peut constituer une avenue 
thérapeutique dans la régulation de l’activité des transporteurs du glutamate lors de DT. 
Pour conclure, la mort cellulaire d’origine excitotoxique lors de DT survient en conséquence 
d’une dysfonction mitochondriale associée à une perturbation du métabolisme énergétique cérébral. La 
modification de l’expression des transporteurs du gluatamate est sous le contrôle des voies de 
signalisation NFkB dépendantes du facteur PARP-1. De plus, l’inhibition métabolique et l’augmentation 
des sécrétions de lactate observées lors de DT peuvent également constituer un autre mécanisme 
physiopathologique expliquant la diminution d’expression des transporteurs de glutamate. Enfin, la 
ceftriaxone pourrait représenter une stratégie thérapeutique potentielle dans le traitement de la régulation 
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de l’expression des transporteurs du glutamate et de la perte neuronale associés à l’excitotoxicité 
observée lors de DT.  
Mots-clés : Excitotoxicité, transporteurs du glutamate, syndrome de Wernicke-Korsakoff, déficience en 
thiamine, stress oxydatif, mort neuronale. 
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ABSTRACT 
Excitotoxicity has been implicated as a major pathophysiological mechanism in the pathogenesis 
of thiamine deficiency (TD). Excitotoxic-mediated cell death is localized in areas of focal vulnerability 
in TD and may occur as a consequence of impairment in mitochondrial energy metabolism, sustained 
cell membrane depolarization and decreased uptake of glutamate by astrocytes due to the loss of 
excitatory amino acid transporters, (EAAT1 and EAAT2). Over the years, a number of studies have 
identified glutamate as being a major contributor to excitotoxicity in the pathophysiology of TD. Thus, 
downregulation of astrocytic glutamate transporters resulting in excitotoxicity is a key feature of TD and 
understanding the regulation of these transporters is essential to understanding the pathophysiology of 
the disorder.  
The objective of the present thesis project was to examine the underlying basis of astrocytic 
glutamate transporter regulation during TD encephalopathy. 
Major findings of the studies presented in this thesis project provide evidence for glutamate 
transporter abnormalities in TD animal models and astrocyte cultures exposed to TD. TD results in the 
loss of the glutamate transporter splice variant-1b (GLT-1b) in vulnerable areas of brain, i.e. thalamus 
and inferior colliculus, with no significant alteration in the mRNA levels of the transporters, suggesting 
that glutamate transporter regulation under conditions of TD is a posttranscriptional event.  
Studies using a specific inhibitor of the transcription factor, Nuclear factor-kappa B (NF-κB) and a 
nuclear enzyme poly (ADP)ribose polymerase-1 (PARP-1) provided evidence for the regulation of 
GLT-1 by PARP-1 dependent NF-κB signalling pathways. The major findings of this study suggested an 
increase in the activation of PARP-1 and NF-κB molecule in the vulnerable areas of TD rat brain and 
TD astrocyte cultures. Pharmacological inhibition of NF-κB showed an increase in the levels of GLT-1, 
while inhibition of PARP-1 using a specific PARP-1 inhibitor, DPQ inhibited the increased activation of 
NF-κB that was observed during TD. Overall results of this finding provided evidence for a mechanism 
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involving PARP-1 activation in the regulation of glutamate transporters.  
Given the increased lactate accumulation as a classical feature of TD, we studied the effect of 
soluble factors produced by astrocytes on glutamate transporter function. Treatment of naïve astrocyte 
cultures with TD conditioned media resulted in decreased levels of GLT-1 and inhibition of glutamate 
uptake capacity concomitant with a loss of mitochondrial membrane potential. Administration of 
exogenous lactic acid produced a similar reduction in glutamate uptake to that resulting from 
conditioned media. However, lactic acid treatment did not result in a change in GLT-1 protein levels. In 
addition, the pro-inflammatory cytokine TNF-α was shown to be increased in astrocytes treated with TD 
along with elevated levels of the phospho-IκB fragment, indicative of increased activation of NFκB. 
Inhibition of NFκB led to an amelioration of the decrease in GLT-1 that occurs in TD, along with 
recovery of glutamate uptake. Thus, soluble factors released from astrocytes under conditions of 
metabolic impairment such as lactate and TNF-α impairment appear to exert a regulatory influence on  
glutamate transporter function. 
Ceftriaxone, a β-lactam antibiotic, has the ability to differentially stimulate GLT-1b (splice-
variant) expression in the inferior colliculus in TD rats and under in vitro conditions with TD astrocyte 
cultures. Thus, ceftriaxone may be a potential therapeutic strategy in the regulation of glutamate 
transporter function during TD.  
In summary, excitotoxic cell death in TD occurs as a consequence of mitochondrial dysfunction 
associated with cerebral energy impairment and abnormal glutamate transporter status. A major 
underlying mechanism for glutamate transporter abnormalities is mediated by PARP-1 dependent NF-
κB signaling pathways. In addition, metabolic inhibition with substantial production of lactate and TNF-
α may be perhaps another mechanism responsible for glutamate transporter downregulation in TD.    
Keywords: Excitotoxicity, glutamate transporters, Wernicke-Korsakoff syndrome, thiamine deficiency, 
oxidative stress, neuronal cell death. 
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1.1 THIAMINE DEFICIENCY ENCEPHALOPATHY 
1.1.2 Thiamine, the vitamin 
1.1.2.1 History 
Thiamine or "thio-vitamine" ("sulfur-containing vitamin") is a water-
soluble vitamin of the B complex. Also named aneurin for its detrimental neurological 
effects. Phosphate derivatives of thiamine are involved in many cellular processes. The 
best-characterized form is thiamine pyrophosphate (TPP), a coenzyme essential for 
the catabolism of sugars and amino acids. Deficiency of thiamine has been implicated in 
the variety of metabolic and anatomic disturbances. First described in the Dutch East 
Indies during the 1600's, beriberi became a serious health problem in the 1900's with the 
advent of steam powered rice mills which produced widely consumed 'polished' rice 
devoid of the vitamin rich husk. A series of studies by Peters in the 1930s indicated that 
birds fed polished rice resulted in TD and the accumulation of lactate in the brainstem, 
addition of a small quantity of crystalline thiamine led to normalization of lactate levels 
and improved the polyneuritis in birds. This interesting finding at the time led to 
formulation of the concept of a biochemical lesion in TD (Kinnersley and Peters, 1930; 
Peters, 1936). However, administration of thiamine did not completely eliminate the 
features of beriberi and it was quickly realized with the neurological manifestation 
persisting despite supplementation with thiamine (Singleton and Martin 2001).   
1.1.2.2 Chemical properties 
The thiamine molecule (Fig. 1) is a water soluble, white crystalline solid. In the 
crystallized state or in an acid solution the stability of thiamine is good. In a neutral or 
alkaline solution thiamine is unstable and sensitive to heat, oxygen and ultraviolet light. 
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   Figure1. Chemical structure of thiamine  
1.1.2.3 Physiology and metabolic function 
Thiamine is actively absorbed from the small intestine and is transformed within 
the body by phosphorylation into active co-enzyme thiamine pyrophosphate. It is because 
of the inability of the body to produce thiamine and can only store up to 30mg of it in 
tissues and also the vitamin has a high turnover rate, that a continuous supply of the 
vitamin is needed. The limited stores may be depleted within 9-18 days on a thiamine-
free diet, with the appearance of the clinical signs (Ariaey-Nejad et. al., 1970; 
McCormick et. al., 1988; Rosen and Barkin, 1998). In addition, the body is readily 
depleted of thiamine by fever and other metabolic stress. The heart, kidney, liver and 
brain have the highest concentrations, followed by the leukocytes and the red blood cells 
(F. Hoffman-LaRoche, 1994). Dephosphorylation of thiamine occurs in kidney and 
excess free vitamin is rapidly excreted in the urine. The urinary excretion depends on the 
urine volume and during diuresis large amounts of thiamine may be lost. Small quantities 
of thiamine are excreted in sweat (Marks, 1975). 
1.1.2.3.1 Thiamine transport and phosphorylation in brain. 
Transport of thiamine across the blood-brain barrier is conducted through a 
carrier-mediated system (Spector 1976; Greenwood et al., 1982). This system appears to 
be independent of energy metabolism (Greenwood et al., 1986). Sharma and Quastel 
(1965) presented evidence for a saturable and energy-requiring thiamine uptake in cortex 
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slices, suggesting that nerve cells actively pump thiamine. Moreover, neuroblastomas as 
well as glial cells possess a high-affinity thiamine transport system [Km of 35 nM for 
thiamine] (Bettendorff and Wins, 1994). This high affinity carrier is responsible for the 
transport of thiamine across the cell membrane and thus contributes to the homeostasis of 
intracellular thiamine at high extracellular concentrations (Bettendorff, 1994). Thiamine 
taken up by neuroblastoma cells is rapidly phosphorylated to TDP by thiamine 
pyrophosphokinase (EC 2.7.6 .2) (Bettendorff and Wins, 1994). Phosphorylation of 
thiamine and subsequent binding of TDP to cytoplasmic transketolase (EC 2 .2.1 .1) and 
mitochondrial pyruvate (PDH, EC 1 .2.4.1) and a-ketoglutarate (KGDH, EC 1.2.4.2) 
dehydrogenases are responsible for secondary active accumulation of thiamine 
compounds in neuroblastoma cells (Fig. 2). 
 
Figure 2 Thiamine metabolism in brain 
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1.1.2.3.2 Role of thiamine in brain metabolism 
The metabolically active form of thiamine is thiamine pyrophosphate (TPP). 
Essentially TPP is required for several biochemical reactions involved in the breakdown 
of glucose to liberate energy. It acts as a co-enzyme in oxidative decarboxylation and 
transketolase reactions. Mainly there are three major enzyme systems that require TPP as 
a cofactor: pyruvate dehydrogenase (EC 1.2.4.1) complex, an organized enzyme 
assembly that connects glycolysis with the tricarboxylic acid (TCA) cycle, α-
ketoglutarate dehydrogenase (EC 1.2.4.2) complex (KGDHC), a multicomponent enzyme 
complex associated with the TCA, and transketolase (EC 2.2.1.1), a key participant in the 
pentose phosphate shunt which is involved in nucleic acid and lipid biosynthesis. 
Thiamine is thus an important factor in carbohydrate metabolism and hence in thiamine 
deficiency (TD), blood pyruvate and often blood lactate levels rise abruptly (Combs, 
1992).  
1.1.3 Etiology and epidemiology of thiamine deficiency 
Vitamin B1 deficiency can occur because of many different causes.  The most 
basic form of TD results because of impaired nutritional status associated with chronic 
diseases, such as alcoholism, gastrointestinal diseases, HIV-AIDS, and persistent 
vomiting. Following are the major factors responsible for TD: 
1.1.3.1 Lack of thiamine intake 
Lack of thiamine intake can occur with food containing a high level of 
thiaminases such as milled rice, shrimp, mussels, clams, fresh fish, and raw animal 
tissues, food high in anti-thiamine factors and processed food with a content high in 
sulfite, which destroys thiamine. In addition, diet-related factors such as alcoholic state, 
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starvation state or gastro-intestinal disorder can also reduce thiamine intake (Masumoto 
et. al., 2009; Matrana et. al., 2009; Ahmed et. al., 2011).  
1.1.3.2 Increased metabolic consumption 
Increased metabolic consumption of thiamine may occur because of pregnancy, 
hyperthyroidism, lactation, fever, severe infection and increased physical exercise. 
(Anderson et al, 1985; Braverman and Utiger, 1996). 
1.1.3.3 Increased thiamine depletion 
Increased thiamine depletion may occur in complications such as diarrhea, 
diuretic therapies, peritoneal dialysis, hemodialysis, hyperemesis gravidarum (Indraccolo 
et. al., 2005; Al-Attas et. Al., 2011). 
1.1.3.4 Decreased absorption 
The major factors responsible for the decreased thiamine absorption are chronic 
intestinal disease, alcoholism, malnutrition, gastric intestinal disorder, malabsorption 
syndrome; celiac and tropical sprue (Anderson et al, 1985).  
1.1.3.5 Consequences of chronic alcoholism  
The relation between alcohol intake and thiamine deficiency is well established 
and has been investigated in the past. Up to 80% of alcoholics in general population have 
a deficiency in thiamine (Morgan 1982), some of them will go on to develop WE and/or 
Korsakoff psychosis (WKS). However, the most debated issue regarding alcoholism in 
clinical setting is the occurrence of TD related brain damage with or without alcoholism 
(Charness 1993; Joyce1994; Butterworth 1995). In general, cerebral damage due to 
thiamine deficiency progresses with alcohol toxicity and vice versa. Therefore, 
alcoholism does not directly cause TD (Phillips et al. 1981), though it may induce such 
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deficiency because of its normal association with malnourishment and its related 
mechanism. Particularly, the low thiamine absorption rate at the mucosal level, the 
impaired hepatic function, and the raised alcohol-related thiamine metabolism may lead 
to the development of chronic thiamine deficiency (Harper 2009). Consequently, the 
effect of alcohol was investigated in metabolism (Ammon et al. 1965; Lindros 1982), 
oxidative stress, excitotoxicity (Lovinger 1993). Furthermore, ethanol and its more toxic 
oxidative metabolite acetaldehyde is involved directly or indirectly in brain damage, and 
it may be that high levels of acetaldehyde play a role in producing TD. Non-oxidative 
metabolites of alcohol metabolism particularly fatty acid ethyl esters are found increased 
in ethanol induced brain damage. Interactions between these conditions influence brain 
damage in alcoholism. Moreover, chronic alcohol administration accelerates the lesions 
of experimental TD, by up regulating NMDA receptor expression and excitotoxicity 
(Harper and Matsumoto 2005). Furthermore, the most frequently accessible target for the 
alcohol to trigger a detrimental effect in the brain, are the blood-brain barrier (BBB) and 
blood-CSF barrier (BCSFB) (Nixon et al. 2008). It is well established that the alcohol 
intoxication and thiamine deficient glucose metabolism increases the permeability of the 
blood brain barrier (BBB) leading to instability in the osmotic gradient (Calingasan et al. 
1995; Nixon et al. 2008). This results in the swelling of intra- and extracellular spaces. 
Also, observed in the periventricular regions, the BBB is physiologically less tight and 
there is a high rate of thiamine-related glucose and oxidative metabolism. Among the 
neurological manifestations, ataxia was positively associated with alcoholism without any 
obvious cerebellar lesions, while infratentorial signal-intensity alterations were only 
observed in non alcoholics. Alternatively, choroid plexus (CP) is hypothesized as the 
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other target of alcohol intoxication and it is postulated that CP is the primary source of 
brain pathology in TD and alcohol toxicity (Nixon et al.  2009). Impairment of the 
BCSFB and BBB are not considered as a primary factor in the pathogenesis of WE or of 
ethanol intoxication, only for the reason that there has been insufficient assessment of the 
BCSFB in these conditions. Thus, it can be concluded that alcohol alone is not 
responsible for TD and its related brain damages, however, alcohol abuse does potentiate 
the neurological impairment in TD encephalopathy. 
1.1.4 Major disorders of thiamine deficiency 
TD progresses with a variety of clinical signs brought about by the presence of 
complicating factors, such as infections, or by the presence of symptoms from multiple 
deficiencies such as other B vitamins, vitamin C and minerals as well as the effects of 
stresses of many kinds, such as physical labour and pregnancy. However, vitamin B1 
deficiency manifests itself principally with changes involving the nervous system, the 
cardiovascular system, and also the gastrointestinal tract (Williams, 1961; Sebrell, 1962; 
Sauberlich, 1967). 
1.1.4.1 Sub-clinical thiamine deficiency 
The factors responsible for the occurrence of sub-clinical or mild thiamine 
deficiency are intake of high carbohydrate food and low thiamine intake, raised 
physiological or metabolic demand, primarily due to pregnancy and lactation, heavy 
physical exertion, inter-current illness (cancer, liver diseases, infections, 
hyperthyroidism), surgery, and wherever absorption is reduced by regular high blood 
alcohol levels, gastrointestinal disease; dysentery, diarrhoea, nausea/vomiting (Anderson 
et al, 1985). 
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Table 1 attempts to summarize some of the typical lesions seen in specific organ systems 
of the body as a result of thiamine deficiency.  
Table 1.     Organ Systems of the body affected in thiamine deficiency 
Nervous system 
 
WE and WKS; Polyneuritis (multifactorial); autonomic, 
sensory and motor nerves are affected; paraesthesia and 
hyperesthesia, loss of ankle and knee jerks with muscle 
wasting and paralysis -typically wrist- and foot-drop 
(symmetrical). 
Eye Nutritional amblyopia  
Heart and blood vessels Enlarged heart. Congestive heart failure which is one of 
the contributory causes of peripheral oedema and results 
in increase in circulating blood volume. 
Gastrointestinal tract   Constipation (rarely diarrhea) with abdominal distension 
and colicky pains, anorexia, nausea, vomiting. 
 
The symptoms of mild thiamine deficiency are elusive and can be attributed to other 
problems therefore diagnosis is often difficult. However, anorexia, which is one of the 
early symptoms of subclinical thiamine deficiency, is regarded to be a protective 
phenomenon since a high-carbohydrate diet is more dangerous in the presence of 
thiamine deficiency (Lonsdale et al, 1980). 
1.1.4.2 Wernicke’s Korsakov Syndrome (WKS) 
WKS is characterized by symmetric hyperaemic brain lesions with glial 
proliferation, capillary dilatation, and perivascular haemorrhage. The syndrome is 
manifested by a confusional state, disorientation, ophthalmoplegia, nystagmus, diplopia, 
and gait ataxia (Wernicke’s encephalopathy, WE), with severe loss of memory for recent 
events and confabulation (Korsakov’s psychosis) occurring following recovery. It 
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appears that the disorder can have an autosomal recessive inheritance but is expressed as 
a clinical disease only in the event of TD. 
Up to 80-90 % of patients with WE go on to develop the more debilitating chronic 
Korsakoff’s psychosis. The first reports of the important role of TD in the etiology of 
WKS were described by Alexander and colleagues (1938) and Bowman et al (1939). 
DeWardner and Lennox (1947) later observed 52 malnourished prisoners of war and 
further established the important link between TD and WKS in humans. WKS is most 
commonly observed in alcoholics, the majority of them with liver disease, and is often 
precipitated abruptly by administration of glucose to patients severely deficient in 
thiamine. If untreated, death is common; even with treatment, 17% die within 3 weeks 
(Feldmann, 1988).   
 
1.2 PATHOPHYSIOLOGY OF THIAMINE DEFICIENCY ENCEPHALOPATHY 
1.2.1 Neuroanatomical damage in WE and TD 
In TD, damage to the brain is focal in nature. Typically, vulnerable areas include 
the mammillary bodies, thalamus, inferior colliculus, brainstem, and cerebellum 
(Troncoso et al., 1981; Langlais et al., 1996). Although the thiamine content of the brain 
is almost uniform (13 µg/g dry weight) (Dreyfus et al., 1959; Cooper and Pincus, 1979), 
vulnerable areas at risk of damage show marked alterations in levels depending on the 
metabolic rate. Each organ or part of the nervous system appears to have its particular 
thiamine levels for depletion (Sharma and Quastel, 1965). Cerebral levels of thiamine are 
highest in the cerebellar vermis followed by caudate nucleus, brain stem, periaqueductal 
region, mamillary region and thalamus (Dreyfus et al., 1959). However, the precise 
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relationship between thiamine levels and subsequent damage during its depletion remains 
a mystery.  
WE patients and TD animals characteristically display gross neuropathological 
changes that include brain atrophy, hemorrhages (Victor et al., 1989), edematous necrosis 
(Watanabe et al., 1981), white matter damage (Yamashita and Yamamoto, 1995; Langlais 
and Zhang, 1997), gliosis and significant neuronal loss (Witt, 1985; Todd et al., 1999; 
Mulholland, 2006). Typically, mammillary bodies as well as the medial, midline and 
intralaminar nuclei of the thalamus, inferior colliculus, periaqueductal area and floor of 
the fourth ventricle show severe damage. In addition, brainstem nuclei, cerebellum, 
cranial nerve nucleus, pretectal regions, and locus coeruleus are affected in WE (Torvik, 
1987; Victor et al., 1989), with cerebellar damage being most prominent in the anterior 
superior vermis and more severe in alcoholics with WE (Phillips et al., 1990). 
Microscopically, loss of Purkinje cells and shrinkage of the molecular and granule cell 
layers have been identfied (Phillips et al., 1987), with marked reduction in Purkinje 
dendritic arborization commonly observed both in alcoholics and TD-dependent brain 
damage (Terasawa et al., 1999). Such occurrence of cerebellar degeneration in alcoholics 
is relatively common (Kril, 1996), and due to the similarity of this damage in both 
alcoholics and TD, it has been hypothesized that alcoholic cerebellar degeneration is 
nutritional in origin (Terasawa et al., 1999). Experimentally, the thalamus  and, in 
particular, the medial dorsal nuclei, represents the area of brain most widely studied in 
TD (Langlais et al., 1992; Hazell et al., 1998a), with other affected areas including the 
anterior nuclear group, geniculate body, ventral posterior medial nucleus, dorsal nucleus, 
and lateral posterior nucleus. Moreover, the hypothalamus also displays abnormalities in 
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areas such as the suprachiasmatic nucleus, supraoptic nucleus, and medial preoptic 
nucleus. Evidence also indicates that regions of the brain such as the cerebral cortex, 
previously considered being unaffected, also sustaining damage in TD and WE. 
Histological evidence of damage to the peripheral nervous system following 
metabolic and toxic insults has led many investigators to focus on the role of thiamine 
and the effects of alcohol on the progression of these diseases. Chronic TD and alcohol 
toxicity are often causes of peripheral neuropathy (Swank et al., 1940; Victor et al., 
1989), with  the  most common being distal axonopathies, also termed “dying back” 
disease. Although the precise mechanism for this type of pathology had not yet been 
established, it was envisioned that damage to the axonal transport system and metabolic 
disturbances were the causative factor for the progression of this neuropathy (Schoental 
and Cavanagh, 1977). While 80% of the patients with WKS observed by Victor had 
evidence of a peripheral neuropathy, many of these cases exhibited alcohol-dependent 
TD, suggesting an involvement of the toxic effects of alcohol in the progression of 
peripheral neuropathy. To date, animal models of alcoholic neuropathy and its 
relationship to TD have yet to be established. 
Many cases with TD have been shown to exhibit more subtle neurological signs 
and symptoms, including the abnormalities in brain regions such as, cerebellum, 
inflammation or degeneration of peripheral nerves (neuropathy) as well as changes in 
behavior and problems with learning, memory, and decision making (Torvik 1987).  
Autopsy studies have found that a region of the cerebellum known as the anterior 
superior cerebellar vermis most frequently exhibits TD–induced damage (Baker et al. 
1999; Lavoie and Butterworth 1995; Victor et al. 1989). TD contributes to a reduction in 
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the number and size of a certain cerebellar cell type called Purkinje cells in parts of the 
cerebellar vermis (Philips et al. 1987). Cerebellum is involved primarily in muscle 
coordination and it is also recognized for its role in various aspects of cognitive and 
sensory functioning (Parks et al. 2003). Accordingly, cerebellar degeneration is 
associated with difficulties in movement coordination and involuntary eye movements, 
such as nystagmus. Cerebellar degeneration is found both in alcoholics with WKS and 
alcoholics alone, but because WKS patients typically have a higher degree of cerebellar 
atrophy, it appears likely that TD also is the predominant cause of cerebellar 
degeneration.  
In addition to the cerebellum, numerous other brain regions and structures are 
damaged in people with WKS. Although animal studies have suggested that thiamine 
deficiency may contribute to damage to these structures, the exact role of TD and the 
level of sensitivity of these structures to thiamine deficiency have not yet been 
determined. Further studies are certainly needed in this area. 
 
1.2.2 Effects of thiamine deficiency on enzyme activity 
The pathophysiological mechanisms involved in TD are complex. Compromised brain 
energy metabolism is a major consequence of the disorder. Thiamine in the form of TPP 
is an important cofactor of three major enzyme systems: pyruvate dehydrogenase (EC 
1.2.4.1) complex, an organized enzyme assembly that connects glycolysis with the TCA 
cycle, α-ketoglutarate dehydrogenase (EC 1.2.4.2) complex (KGDHC), a 
multicomponent enzyme complex associated with the TCA, and transketolase (EC 
2.2.1.1), a key participant in the pentose phosphate shunt which is involved in nucleic 
acid and lipid biosynthesis. Chronic thiamine deprivation is accompanied by region-
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selective reductions in levels of these thiamine-dependent enzymes in brain (Butterworth, 
1986). However, decreased activity of KGDHC appears to be responsible for many of the 
reversible changes accompanying TD (Gibson et al., 1984; Butterworth and Heroux, 
1989) (see Fig. 3). A fourth thiamine-dependent enzyme system, branched-chain α-
ketoacid dehydrogenase complex, is associated with a rare inborn error of metabolism, 
maple syrup urine disease, involving an accumulation of the branched chain amino acids 
leucine, isoleucine, and valine (Wendel et al., 1983). 
 
Figure 3. Schematic of pathophysiological mechanisms during TD 
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1.2.3 Lactic acid accumulation 
During TD, oxidative decarboxylation of pyruvate and α-ketoglutarate is 
inhibited, resulting in decreased ATP production, pyruvate accumulation and lactate 
production (Aikawa et al., 1984; Navarro et al., 2005). This net synthesis of lactic acid 
within the brain of thiamine-deprived animals is a phenomenon that has been well 
recognized for many years (Kinnersley and Peters, 1930; Holowach et al., 1968; 
McCandless and Schenker, 1968). Lactic acidosis induced by TD is type B (i.e. acidosis 
in the presence of good tissue perfusion and oxygenation), with a pH of 7 and blood 
lactate below15 mmol/l and is typically unresponsive to alkalinization (Chadda et al., 
2002). Unless thiamine is rapidly supplemented, refractory acidosis and death can occur 
within twenty four hours. Areas of increased lactic acidosis are localized to brain regions 
that subsequently develop histological lesions (McCandless, 1982; Hakim, 1984; 
Munujos et al., 1993), and likely play a significant role in the pathophysiology in TD 
animals.  
1.2.4 Disruption of membrane potential  
Thiamine and its derivatives are crucial in stabilizing the resting membrane 
potential (Itokawa and Cooper, 1970; Fox and Duppel, 1975), thereby maintaining ionic 
balance and conduction of the action potential (Cooper et al., 1963). Chronic deprivation 
of thiamine impairs this function and the electrophysiological characteristics of the cell, 
which can lead to severe pathological consequences.  
1.2.5 Blood-brain barrier alterations in TD 
Integrity of the BBB is crucial for normal CNS function. The first report of BBB 
damage in TD was proposed by Scholz (1949) and was described in more detail by 
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Pentschew and Garro (1966) in which they suggested blood vessels and, in particular, 
capillary endothelial cells, to be the primary site of damage, proposing the term "system-
bound dysoric encephalopathy" for WE. Since then, considerable evidence for BBB 
damage has been described, with disturbances localized to brain regions vulnerable to TD 
(Calingasan et al., 1995b), and including the presence of hemorrhagic lesions (Torvik, 
1985, Vortmeyer and Colmant, 1988). Such a process may also contribute to previous 
reports of brain edema identified in both TD and in cases of WE (see below).  
Impairment in oxidative metabolism plays a significant role in BBB breakdown in 
TD in which oxidative stress mediated by eNOS is involved (Beauchesne et al., 2009a), 
and is likely also the case for several neurodegenerative disease states. In addition, 
inflammatory processes occur in TD (see below) which are known to disrupt the BBB 
(Guenther and Neu, 1984). CNS pathologies often involve BBB disturbances in which 
astrocyte-endothelial cell interaction is abnormal, and astrocytes secrete transforming 
growth factor-β, which downregulates brain capillary endothelial expression of the 
fibrinolytic enzyme tissue plasminogen activator and the anticoagulant thrombomodulin 
(Tran et al., 1999). Indeed, several chemical agents circulating in plasma or secreted from 
cells associated with the BBB are capable of increasing brain endothelial permeability 
and impairing its transport and metabolic function (Kis et al., 2001). A number of studies 
have evaluated BBB integrity, both spatially and temporally in experimental TD and 
acute WE. For example, findings have revealed disruption of BBB integrity adjacent to 
the third ventricle, cerebral aqueduct and fourth ventricle in acute WE (Schroth et al., 
1991), consistent with the location of histological lesions. Increased BBB permeability 
was also reported in whole brain (Warnock and Burkhalter, 1968) and in vulnerable brain 
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regions in TD (Manz and Robertson, 1972), with a likely factor contributing to this 
susceptibility being the cerebral energy deficit. Interestingly, amyloid beta peptide (Aβ) 
has been reported to increase neuronal membrane fluidity and lipid peroxidation 
(Avdulov et al., 1997), which may contribute to the observed BBB changes in TD. 
Additionally, Aβ has been shown to increase endothelial cell permeability to albumin 
(Blanc et al., 1997), a finding which might explain the leakage of this protein into the 
brain parenchyma during TD (Harata and Iwasaki, 1995). Furthermore, this effect was 
also shown to be reversible following treatment with antioxidants (Blanc et al., 1997). 
Since Aβ may also play a role in excitotoxicity and is capable of inducing apoptosis 
(Forloni et al., 1993; Loo et al., 1993), a feature also reported in TD (Matsushima et al., 
1997), altogether, these findings suggest this peptide plays a role in increased BBB 
permeability and possibly neuronal cell death in TD. Recent evidence also indicates that 
BBB tight junction proteins such as occludin and associated scaffolding proteins are 
decreased, concomitant with increased matrix metalloproteinase-9 levels in TD 
(Beauchesne et al., 2009b). The underlying basis for these changes, however, remains 
currently unresolved. 
1.2.6 Oxidative stress 
Maintenance of an optimal redox environment is the primary requirement for 
proper cellular functioning, and this environment is preserved by enzymes that maintain a 
reduced state through normal energy metabolism. Disturbances in this redox state can 
cause toxic effects through the production of net reactive oxygen species (ROS), 
particularly in the mitochondria (Lin and Beal, 2006), that can damage vital components 
of the cell, including proteins, lipids, and DNA. This imbalance in ROS metabolism, or 
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development of oxidative stress is an important factor in the pathogenesis of TD (Gibson 
and Blass, 2007). Increased ROS production in TD can trigger cell membrane damage, 
including lipoperoxidation (Valko et al., 2007) and alterations in the functional integrity 
of ion channels and transporters. Persistent net ROS formation in TD can initiate a 
cascade of cell death pathways via intracellular messengers, e.g. intracellular caspase-3-
mediated apoptosis. Development of oxidative stress also leads to disturbances in brain 
function, including an inhibition of glutamate uptake due to transporter protein 
nitrosylation following peroxynitrite formation (Volterra et al., 1994; Trotti et al., 1996; 
Hazell, 2007). Under conditions of oxidative stress, levels of heme oxygenase-1, 
endothelial nitric oxide synthase (eNOS), the inducible form of NOS (iNOS), 
intracellular adhesion molecule-1, and microglial activation are increased (Calingasan et 
al., 1999,2000; Gibson et al., 2000). Thus, oxidative stress can lead to profound 
neuropathological consequences in TD.  
1.2.7 Excitotoxicity 
Excitotoxicity is the pathological process by which nerve cells are damaged and 
killed by excessive stimulation of receptors for the excitatory neurotransmitter glutamate. 
The normal levels of glutamate approach 10 mmol/kg during synaptic transmission, while 
extracellular concentrations remain approximately 25 nM (Schousboe, 1981; Herman and 
Jahr, 2007). These low extracellular levels of glutamate are essential to ensure 
appropriate signal to noise for excitatory signaling and to limit excessive activation of 
glutamate receptors that can cause excitotoxicity (Choi, 1992; Conti and Weinberg, 
1999). The only process known to actively clear extracellular glutamate is mediated by a 
family of Na+-dependent transporters also known as glutamate or excitatory amino acid 
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transporters (Schousboe, 1981; Danbolt, 2001). These transporters couple the movement 
of 3 Na+ ions and 1 H+ to the inward transport of glutamate, providing sufficient energy 
to maintain a transmembrane concentration gradient of up to one million-fold (Zerangue 
and Kavanaugh, 1996).  
Excitotoxicity may be involved in spinal cord injury, stroke, traumatic brain 
injury, hearing loss (orototoxicity) and in neurodegenerative diseases such as, 
Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's 
disease, alcoholism or alcohol withdrawal, and Huntington's disease (Kim et. al., 2002; 
Hughes, 2009). Other common conditions that cause excessive glutamate concentrations 
around neurons are hypoglycemia (Camacho, 2006), status epilepticus (Fujikawa, 2005) 
and mitochondrial dysfunction (Jhala and Hazell, 2011). Consequences of excitotoxicity 
during TD are discussed in more detail in section 1.3 
1.2.8 Inflammation 
 Cerebral inflammation is now recognized as a key component of the 
neurodegenerative process, and occurs e.g. in AD, PD, multiple sclerosis (Bojinov, 1971; 
Allen et al., 1981; Aisen and Davis, 1994), along with other neurological conditions such 
as stroke and brain trauma (Garcia, 1975; Mathew et al., 1994)  Previous studies 
describing alterations in glial cell morphology in TD including evidence of swelling and 
the appearance of phagocytic vacuoles (Collins, 1967; Robertson et al., 1968) indicate 
that although neuronal damage is a feature of this disease process, glial elements are also 
profoundly affected. Evidence in support of the existence of an inflammatory process has 
been described in TD, including the early development of increased microglial reactivity 
(Todd and Butterworth, 1999), while production of pro-inflammatory cytokines in both 
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vulnerable and non-vulnerable regions of brain has been reported (Ke et al., 2006; 
Vemuganti et al., 2006; Karuppagounder et al., 2007). In a recent study, we demonstrated 
that in vulnerable brain regions in TD, inflammatory genes represent the largest 
functional group of transcripts upregulated (e.g. pro-inflammatory cytokines including  
IL-6, IL-18, TNF-α, AIF1, and osteopontin), interferons (IFNs), IFN-inducible proteins, 
and chemokines (Gro1, MCP-1, MIP-1α, and MIP-1β) (Vemuganti et al., 2006). 
Interestingly, many of these genes are also known to be expressed strongly in astrocytes 
during inflammation and may therefore be a contributing factor to astrocyte dysfunction 
in TD. In addition, many transcription factors known to control inflammatory gene 
expression such as Egr-1, c-EBP-β, c-EBP-δ, CPBP and Klf-4 are also upregulated 
following TD. During impaired oxidative metabolism, Egr-1 and c-EBP-β may play an 
important role in starting the inflammatory cascades. Furthermore, levels of these various 
inflammatory-related gene products in different brain regions may be an important 
determining factor for selective vulnerability in TD. Recent studies have also 
demonstrated that alcohol induces inflammatory responses in brain that include 
microglial activation and cytokine production (Qin et al., 2008; He and Crews, 2008). 
Such findings may also be relevant in the brains of cases of WE. Additional studies 
aimed at identifying how these expression changes are occurring in TD and in alcoholics 
are required to better understand the way in which the process of inflammation develops. 
Such investigations may also yield important details regarding the process of 
inflammation in neurodegenerative disease states, given the similarities of impaired 
oxidative metabolism between TD and these maladies. 
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1.2.9 Induction of immediate early genes 
Immediate-early genes (IEGs) are induced rapidly and transiently in response to a 
wide variety of cellular stimuli. They represent a mechanism that is activated at the 
transcription level at a very early stage as a response to stimuli before any new proteins 
are synthesized. The earliest known and best characterized IEGs are c-fos, c-myc and c-
jun, a group of genes homologous to retroviral oncogenes. Many of these transcription 
factors can bind to consensus sites on the promoter region of other genes, thus allowing 
regulation of downstream gene expression that may play a significant role in alterations 
in cell function that occur as a consequence of TD. Expression of IEGs has been found to 
be increased dramatically in association with cell death (Colotta et al. 1992; Dragunow et 
al. 1993; Estus et al. 1994), and in TD (Hazell et al., 1998c), and has provided additional 
support for an excitotoxic event, in which IEG induction is linked to membrane 
depolarization, L-type voltage-sensitive calcium channel activation, SCC activation, and 
subsequent loss of Ca2+ homeostasis (Morgan and Curran, 1986; Murphy et al., 1991), all 
features of this disorder.  
 
1.3 GLUTAMATE-MEDIATED EXCITOTOXICITY 
1.3.1 Cerebral vulnerability to glutamate mediated excitotoxicity 
             Glutamate is a principal excitatory neurotransmitter in the central nervous system 
and almost 90% of the synaptic connections in the brain are estimated to be 
glutamatergic. At chemical synapses, glutamate is stored in vesicles. Nerve impulses 
trigger release of glutamate from the pre-synaptic cell. In the opposing post-synaptic cell, 
glutamate receptors, such as the NMDA receptor, bind glutamate and are activated. 
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Because of its role in synaptic plasticity, glutamate is involved in cognitive functions like 
learning and memory in the brain. The form of plasticity known as long-term potentiation 
takes place at glutamatergic synapses in the hippocampus, neocortex, and other parts of 
the brain (Doble, 1999). Glutamate works not only as a point-to-point transmitter but also 
through spill-over synaptic crosstalk between synapses in which summation of glutamate 
released from a neighbouring synapse creates extrasynaptic signalling/volume 
transmission (Pellerin, 2005). Hence, it is the glutamate concentration in the surrounding 
extracellular fluid that determines the extent of receptor stimulation. Any disturbance in 
glutamate homeostasis may therefore have severe pathological consequences and may 
lead to glutamate excitotoxicity (Fig. 4). Thus, it appears that the cerebral vulnerability to 
glutamate excitotoxicity is associated with selective increase in extracellular glutamate 
concentration. Glutamate is constantly being released from cells and is continually being 
removed from the extracellular fluid by the action of high affinity Na+ dependent 
glutamate transporters or excitatory amino acid transporters. Five excitatory amino acid 
transporters cDNAs have been identified and cloned (EAAT1–5) thus far. The 
predominant glutamate transporters in the brain are GLAST and GLT-1, also identified in 
the rodent as glutamate/aspartate transporter (GLAST) and glutamate transporter-1 
(GLT-1), respectively, which are primarily expressed in astrocytes, while EAAT3, 
EAAT4, and EAAT5 are found primarily in neurons. Downregulation of glutamate 
transporter followed by accumulation of glutamate in the extracellular fluid have been 
documented in chronic and debilitative neurological disorders of diverse etiology. Thus, 
any disturbance in the physiological processes implicated in the regulation of glutamate, 
namely glutamate release/transport/uptake and energy status, may increase the likelihood 
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of the brain to excitotoxic insult, i.e. making it vulnerable to glutamate mediated 
excitotoxic damage (Fig. 4). 
1.3.2 Glutamate transport and release  
Transport and release of excitatory neurotransmitter, glutamate, is an essential 
event in glutamate neurotransmission. Glutamate taken up by cells can be used either for 
metabolic purposes (protein synthesis, energy metabolism, ammonia fixation) or it can be 
reused as a transmitter. In nerve terminals, glutamate is transported into synaptic vesicles 
by vesicular glutamate transporters and subsequently released by exocytosis. It seems 
likely that glutamate is also released, to some extent, directly from cytosol (non-
vesicularly) through plasma membrane proteins. In astrocytes, glutamate taken up from 
the extracellular fluid may be converted to glutamine which is released to the 
extracellular fluid, taken up by neurons and reconverted to glutamate inside neurons 
(Doble, 1999). Synaptic glutamate transmission requires two types of neurotransmitter 
transporters. First, vesicular neurotransmitter transporters remove transmitters from the 
cytosol and transport them into the lumen of secretory vesicles to allow exocytotic 
release (Moriyama and Omote, 2008). Four types of vesicular transporters have thus far 
been identified which include VAChT, VMATs, VGAT (or VIAAT) and vesicular 
glutamate transporters (VGLUTs). VGLUT1 and 2 are expressed in complementary 
subsets of glutamatergic neurons in the CNS. In contrast, the most recently identified 
isoform, VGLUT3, is co-expressed with VAChT and VMAT2 in a number of cholinergic 
and aminergic cell types (Fei et. al., 2008). Synaptic transporters then remove excess 
neurotransmitter from the synaptic cleft and transport them to the interior of the synaptic 
terminal for recycling. In addition to these transporters another essential group of proteins 
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involved in synaptic transmission are the complexions. They are small, cytosolic and 
highly charged molecules (molecular mass of approximately 15 kDa) that are localized in 
presynaptic nerve terminals. They bind to the neuronal SNARE (soluble N-
ethylmaleimide-sensitive factor-attachment protein receptors) complex and are involved 
in regulating calcium-dependent neurotransmitter release (Hazell and Wang 2011). 
Current evidence suggests that loss of VGLUTs and complexins may destabilize synaptic 
terminal release of glutamate, contributing to dysfunction of circuitry with possible 
pathological consequences. Alterations in the function and/or expression of these proteins 
is a complicating factor which can contribute to the excessive sustained release of 
glutamate which may lead to excitotoxicity. 
1.3.3 Glutamate receptors and excitotoxicity 
Excessive release of glutamate in the synaptic cleft leads to activation of several 
types of pre and post-synaptic glutamate receptors. The consequent rise in intracellular 
calcium concentration may lead to mitochondrial dysfunction, generation of reactive 
oxygen species, and the activation of proteases, phospholipases, and endonucleases, 
leading to cell death.  
1.3.3.1 Ionotropic glutamate receptors  
There are three known types of ionotropic glutamate receptors based on their 
pharmacological properties; the N-methyl-D-aspartate (NMDA) receptor, α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, and the kainate receptor. 
The NMDA and AMPA/kainate receptors are all glutamate gated ion channels 
(conducting only Na+ or both Na+ and Ca2+). The AMPA receptors open readily upon 
glutamate exposure, but desensitize quickly and are of low affinity. In contrast, the 
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NMDA receptors have much higher affinities and are slowly inactivating. To be activated 
they need both glutamate binding and an already depolarized membrane. Additionally, 
NMDA receptors are highly permeable to calcium and distributed widely on CNS 
neurons and, are the major initiators of excitotoxicity (Fig. 4). Moreover, pretreatment 
with (+)-5-methyl-10, ll-dihydro- 5H-dibenzocyclohepten-5, lO-imine hydrogen maleate 
(MK-801 ), a noncompetitive antagonist of the NMDA type glutamate receptor, protects 
against TD-induced lesions and suggests that TD-induced neuronal loss, particularly 
within thalamus, may be mediated by glutamate excitotoxicity (Langlais and Zhang, 
1993; Todd and Butterworth, 1998). However, activation of Ca2+ permeable AMPA or 
kainate receptors can also trigger neuronal cell death. Antagonists of these receptors 
display a higher protective efficacy than NMDA receptor antagonists in some 
experimental neurodegenerative conditions. Thus, neuroprotective influence exerted by 
NMDA receptor antagonists, as well as by AMPA and kainate receptor antagonists 
following brain injury in animal models, including TD, further supports the notion that 
excessive glutamate receptor stimulation contributes to damage via an excitotoxic 
process.  
1.3.3.2 Metabotropic glutamate receptors 
Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors 
which produce their effects via signalling mechanisms involving phosphoinositide-
dependent processes, cyclic AMP or protein kinase C. Recent studies have identified 
mGluRs as a way in which neural cells regulate the release of glutamate and its uptake. 
Three groups of mGluRs have been characterized to date. Group I mGluR agonists have 
been reported to cause a downregulation of the EAAT1 transporter, while the Group II 
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agonist DCG IV upregulates its expression. Group II mGluRs are found on both pre- and 
post-synaptic membranes as well as glial cells, are negatively coupled to cyclic AMP, 
and regulate glutamate release via presynaptic Group II autoreceptors. Group III mGluRs 
are also negatively coupled to cyclic AMP. TD results in decreased ATP levels, a source 
of cyclic AMP via activity of adenylate cyclase. Thus, it is conceivable that loss of 
glutamate transporter regulation occurs as a consequence of changes in activity of 
mGluRs due to the declining ATP status (Hazell, 2009).  
1.3.4 Glutamate transporters  
Of the five types of glutamate transporters cloned to date, considerable evidence 
indicates that GLT-1 contributes to excitotoxicity and neuronal death in a number of 
neurological disorders, including ischemic stroke, traumatic brain injury, and ALS. 
Previous studies indicate that extracellular glutamate concentration is increased in 
vulnerable brain regions in TD (Langlis and Zhang, 1993; Hazell et al., 1993). This effect 
of TD on glutamate transporter levels was also demonstrated in primary cultures of 
astrocytes (Hazell et al., 2003).  
Table 2. Nomenclature and expression pattern of glutamate transporters 
Glutamate  
transporter  
subtype 
Human 
homolog 
Cell type       Anatomic localization 
GLAST  EAAT1 Astrocytes, Cerebellum, cortex, spinal cord 
oligodendrocytes 
GLT1  EAAT2 Astrocytes Throughout brain and spinal cord 
GLT1b  EAAT2b Astrocytes and neurons Throughout brain and spinal cord 
 
EAAC1  EAAT3 Neurons Hippocampus, cerebellum, 
striatum 
EAAT4 EAAT4 Purkinje cells Cerebellum 
EAAT5  EAAT5 Photoreceptors and  
bipolar Cells 
Retina 
Furthermore, it has recently been demonstrated that loss of GLT-1 and GLAST also 
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occurs in the cerebral cortex of alcoholic cases of WE (Hazell et. al., 2010). Based on the 
evidence it is likely that downregulation of glutamate transporters exacerbate glutamate 
mediated brain damage or excitotoxicity in TD. Focal accumulation of lactic acid is a 
classical feature of TD and one of the major consequences is gliotoxicity (Navarro et. al., 
2005). Astrocytes are particularly sensitive to lactate. Thus, exposing them for extended 
periods to lactic acidosis leads to an inability of these cells to maintain ATP production 
(Bender et. al., 1997). The resulting decrease in ATP levels then causes a collapse of the 
ionic gradients across the astrocyte cell membrane due to suppression of Na+ /K+ ATPase 
activity, leading to movement of Na+ into the cell along its concentration gradient. 
Elevated intracellular Na+ concentration results in transport of glutamate from the 
astrocyte to the extracellular space. Moreover, astrocytic swelling due to glutamate 
uptake or excessive K+ spatial buffering can also lead to the depolarization of these cells, 
leading to release of glutamate via transporter reversal (Chan et. al., 2004; Danbolt 2001). 
The major consequence of this transporter reversal is an increase in extracellular 
glutamate concentration which is a major causative factor implicated in excitotoxicity 
(Danbolt 2001).  
 
 
 
 
 
 
 
Figure 4. Glutamate trafficking in neurons and astrocytes. 
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1.4 REGULATION OF GLUTAMATE TRANSPORTER 
Glutamate is the major neurotransmitter of the excitatory signaling pathway in the 
brain; in addition, it is involved in changes in the protein repertoire through the activation 
of signaling cascades, which regulate protein synthesis at transcriptional and translational 
levels. Activity-dependent differential gene expression by glutamate is related to the 
activation of ionotropic and metabotropic glutamate receptors and its subsequent removal 
from the extra-synaptic space by Na+-dependent astrocytic glutamate transporter. 
Moreover, glutamate receptor stimulation is involved in processes of learning and 
memory as well as in other plastic changes in the CNS such as synapse induction and 
elimination during development. Excessive accumulation of extracellular glutamate and 
overactivation of glutamate receptors is associated with decreased expression and 
function of astrocyte glutamate transporters (Rothstein etal., 1996). In addition, a number 
of acute CNS diseases have been shown to be associated with astrocyte glutamate 
transporter dysfunction including CNS ischemia (Martin et al., 1997) and trauma (Yi and 
Hazell, 2006) as well as chronic neurodegenerative disorders such as Alzheimer’s disease 
(AD) (Masliah et.al., 1996), and ALS (Lin et al., 1998), hepatic encephalopathy (Knecht 
et al., 1997), epilepsy (Mathern et al., 1999; Tanaka et al., 1997) and TD/WE (Jhala et.al., 
2011; Hazell et.al., 2001, 2003, 2010). Glutamatergic synaptic transmission is involved in 
many important brain functions and elevated concentrations of extracellular glutamate 
can cause severe excitotoxic damage to the receiving neurons. It is therefore crucial to 
maintain efficient glutamate uptake. Recent studies involving targeted gene disruption 
confirmed significance of glutamate transporters in maintaining glutamate homeostasis 
(Tanaka et al. 1997). Based on these studies it is critical for our understanding to study 
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the regulation of glutamate transporter for its use as a pharmaceutical target in the 
treatment of neurodegenerative diseases. The mechanisms of glutamate transporter 
regulation are not well defined, and little is known about the factors that are responsible 
for regulating protein expression and activity. Regulation of transporter protein can occur 
at multiple levels, including DNA transcription and protein translation or 
posttranslational modification, consequently it may affect glutamate transporter activity, 
localization and protein targeting. Thus, it is likely that a combination of all of these 
mechanisms is important for the regulation of glutamate transporters. 
1.4.1 Transcriptional regulation 
1.4.1.1 Neuron derived factors 
Studies over the past years have identified numerous chemical factors that are responsible 
for the transcriptional regulation of glutamate transporters. Among these factors most 
important are those that are derived from neurons. Upregulation of both types of 
astrocytic glutamate transporters, GLT-1/EAAT2 and GLAST/EAAT1 by neuron derived 
factors were reported previously (Drejer et al. 1983; Gegelashvili et al. 1997; Schlag et 
al. 1998). In the absence of neurons, astrocytes maintain polygonal shapes and express 
only the GLAST transporter. When co-cultured with neurons, astrocytes exhibit more 
complex morphologies and show increased expression for GLT-1 (Swanson et al. 1997), 
thus suggesting that there are neuronal soluble factors that increase the levels and 
expression of glutamate transporter protein and mRNA. Although the soluble factors 
present in neuron conditioned media (NCM) have not been yet identified, progress have 
been made in identifying their signal transduction pathways. Previously it has been 
proposed that upregulation of glutamate transporters depends on the activation of p42/44 
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MAP kinases via the tyrphostin sensitive receptor tyrosine kinase (RTK) signalling 
pathway (Swanson et al. 1997), and phosphatidylinositol 3-kinase (PI3K), tyrosine kinase 
(TKs), or nuclear transcription factor κB (NF-κB) inhibition almost completely blocked 
neuronal factors-induced glutamate transporters upregulation (Swanson et al. 1997; 
Zelenaia et al. 2000) (Fig. 5).  
1.4.1.2 Growth factors 
Other extracellular factors that regulate glial glutamate transporter expression are the 
epidermal growth factor receptor (EGFR) ligands, epidermal growth factor (EGF), and 
transforming growth factor α (TGFα) (Fig. 5) (Zelenaia et al., 2000). Interestingly, the 
expression levels of both EGF and TGFα growth factors increase after brain injury 
(Lisovoski et al., 1997), thus pointing to a crucial role of reactive brain processes in the 
restoration of glial glutamate uptake function. Additionally, it was proposed that EGF and 
TGF α induces upregulation of GLT-1 in cultured astrocytes, while platelet-derived 
growth factor (PDGF) showed no effect on the GLT-1 levels (Zelenaia et al. 2000). 
Similarly, basic fibroblast growth factor (bFGF), insulin, and nerve growth factor (NGF) 
showed no effect on GLT-1 expression in cultured astrocytes, while there was a 
significant upregulation of GLT-1 caused by dibutyryl-cAMP (dbcAMP) (Swanson et al. 
1997; Zelenaia et al. 2000). The effects of EGF and dbcAMP were blocked by inhibitors 
of PI3K and NF-κB, similar to that observed for neuron conditioned media treated 
astrocytes (Zelenaia et al. 2000). However, inhibition of the EGF receptor during 
treatment with NCM did not block the increased expression of GLT-1 (Zelenaia et al. 
2000). This suggests that there are independent signalling pathways responsible for the 
regulation of glutamate transporters in astrocytes.  
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1.4.1.3 Nuclear factor kappa B (NF-κB) signaling pathways 
NF-κB is a heterodimeric protein composed of different combinations of members of the 
Rel family of transcription factors. The Rel/NF-κB families of transcription factors are 
involved mainly in stress-induced, immune, and inflammatory responses. More recently, 
NF-κB family members have been implicated in neoplastic progression and the formation 
of neuronal synapses. NF-κB is also an important regulator in cell fate decisions, such as 
programmed cell death and proliferation control, and is critical in tumorigenesis 
(Baldwin, 1996).   
Upregulation of glutamate transporters expression by NCM or EGF, TGF-α, and 
dbcAMP, as well as bromo-cAMP is significantly blocked by NF-κB inhibition 
(Swanson et al. 1997; Zelenaia et al. 2000). On the other hand, NF-κB inhibition restored 
GLT-1 promoter activity during treatment with TNF-α. These findings were further 
confirmed when the GLT-1 promoter was cloned. The EAAT2 sequence revealed the 
presence of a consensus sequence for NF-κB binding within the 5′-untranslated region of 
the GLT-1/EAAT2 complementary DNA (cDNA) clones (Meyer et al. 1996), indicating 
the involvement of NF-κB mechanism in EAAT2 transcriptional regulation.  
NF-κB can act both positively and negatively depending on the agent 
administered; however, the molecular basis of this phenomenon is still unclear. It has 
been proposed that EGF-induced NF-κB activation is independent of IκB degradation 
(Sitcheran et al., 2005), a common step in the signaling cascade upstream of NF-κB 
activation (Yamamoto and Gaynor 2004). Also, TNFα-mediated repression is dependent 
on the recruitment of N-myc, another transcription factor whose binding site is also 
present on the EAAT2 promoter sequence (Sitcheran et al. 2005). 
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1.4.1.4 Pituitary adenylate cyclase-activating polypeptide (PACAP) 
PACAP is a neuron-derived factor that has been proposed to regulate the 
expression of GLT-1 and GLAST. Exposure of cortical glial cultures to PACAP 
increased glutamate uptake and protein expression of GLT-1 and GLAST as well as 
glutamine synthetase (Figiel and Engele 2000). This effect was significantly blocked by 
PACAP-inactivating antibodies or by PACAP receptor (PAC1) antagonists. The 
signalling pathways involved in the PACAP dependent regulation of GLT-1 expression 
are protein kinase A (PKA) and PKC pathways, while GLAST upregulation was only 
dependent on activation of PKA. 
 
 
 
  
 
 
 
 
 
 
Figure 5. Suggested pathways effecting glutamate transporter expression. 
Loss of PAC1 or knock-out of PAC1 showed a significant reduction in GLAST 
expression in the dentate gyrus, but not in the cortex, while expression of GLT-1 was 
found to be unaffected (Zink et al. 2004). 
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1.4.1.5 Glutamate 
Most of the studies have identified soluble factors released by neurons that may 
promote GLT-1 expression; however, regulation of GLAST seems to be mediated 
through different signalling pathways. In a recent study L-glutamate as one soluble 
neuron-derived factor acting as a GLAST regulator (Gegelashvili et al. 1996) was 
identified. Glutamate induced an increase in glutamate uptake capacity in primary 
astrocyte culture and increased the levels of GLAST protein. Treatment with a specific 
inhibitor for glutamate receptors (specifically, AMPA/kainate) blocked this upregulation.  
The glutamate-mediated increase in GLAST protein levels was not accompanied by an 
increase in mRNA levels, suggesting regulation instead of transcriptional regulation. On 
the other hand, when cells were treated with dbcAMP, both mRNA and protein levels 
were significantly elevated compared to non-treated cultures (Gegelashvili et al. 1996; 
Swanson et al. 1997). This illustrates again that the regulation of glutamate transporters 
occurs at different levels and through different signaling pathways depending on the 
stimulating factor. 
1.4.1.6 Steroids 
Exposure of primary astroglial cells to estrogen was reported to cause a significant 
increase in GLAST (and GLT-1) mRNA levels as well as protein levels, which was 
accompanied by increased glutamate uptake (Pawlak et al. 2005). Similar observations 
were made with human cultured astrocytes derived from the cortex of AD patients (Liang 
et al. 2002). The authors suggested that upregulation of glutamate transporters may be 
one mechanism by which estrogens provide neuroprotection against excitotoxic 
glutamate overflow (Liang et al. 2002; Pawlak et al. 2005). 
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1.4.2 TRANSLATIONAL REGULATION 
Past studies on molecular structure and membrane topology of glutamate 
transporters have provided the essential information on posttranslational regulation of 
glutamate transporters. Structurally, the transporter molecules are made of eight helical 
transmembrane domains (TMD) and two helical hairpin loops. Both, the N- and C-
terminus are cytoplasmic with a large extracellular hydrophilic region between the third 
and fourth TMD (Slotboom et al. 1999). Using high-resolution spectroscopy of the 
bacterial glutamate transporter homolog GltPh, it has been suggested that the transporter 
is assembled as a trimer (Yernool et al. 2004). The potential regulatory mechanisms 
based on the structure homologue are discussed in the following sections. 
1.4.2.1 Glycosylation and maturation 
Glycosylation of proteins is a posttranslational modification that plays a role in 
molecular trafficking, protein folding, endocytosis, receptor activation, signal 
transduction, and cell adhesion (Ohtsubo and Marth, 2006). Two common forms of 
protein glycosylation include N-linked glycosylation and O-linked glycosylation. N-
linked glycosylation is the covalent linkage of oligosaccharides to asparagines residues of 
proteins. N-glycosyl residues are processed as proteins are trafficked through the 
endoplasmic reticulum and golgi.  
In addition to the glycosylated proteins which are subsequently transported to the 
plasma membrane, some proteins are retained in the ER and therefore develop into an 
immature, non-glycosylated protein. The mechanism for this ER retention involves an  
arginine based motif (RXR) in the nascent polypeptide that regulates ER retention 
  35
 
signals, and studies have reported an adjacent leucine based motif that function to 
suppress the ER retention signals by RXR (Kalandadze et al. 2004). The EAATs) are N-
glycosylated proteins and they are regulated or dysregulated differentially by either of 
these glycosylation mechanisms, as discussed below. 
1.4.2.1.1 EAAT1/GLAST 
EAAT1 is variably expressed throughout the brain in astrocytes (Rothstein et al., 
1994; Chaudhry et al., 1995; Lehre et al., 1995). Glycosylation sites were identified on 
GLAST in the extracellular loop of transmembrane helices 3 and 4 at Asn206 and 
Asn216 (Conradt et al. 1995). The two GLAST isoforms, 70-kDa and 64-kDa, differs 
only by the degree of N-glycosylation at Asn206 and Asn195 (Conradt et al., 1995). 
Glycosylation of this transporter may serve an important functional role because 
nonglycosylated GLAST does not form homomultimers, which are the native 
conformation of GLAST in vivo (Conradt et al., 1995). In addition, glycosylation of 
GLAST has been correlated with trafficking of GLAST to plasma membrane and 
increased glutamate uptake (Escartin et al., 2006).  
1.4.2.1.2 EAAT2/GLT1 
EAAT2 is an astrocytic transporter responsible for the majority of glutamate 
uptake in the cortex. Deglycosylation of the rodent isoforms of EAAT2 (GLT-1) resulted 
in a 10-15 kDa shift in molecular weight of the monomer band (Kalandadze et al., 2004). 
There is conflicting literature describing the functional effects of EAAT2 glycosylation. 
One group found that glycosylation-deficient GLT-1 (the rodent form of EAAT2) had a 
decreased rate of glutamate transport due to decreased expression in the plasma 
membrane (Trotti et al., 2001). This may be due to the retention of GLT-1 in the 
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endoplasmic reticulum, because mutant GLT-1 expressing an altered extracellular 
leucine-based motif is immaturely glycosylated and retained in the ER (Kalandadze et al., 
2004). However, another group found no effect of N-glycosylation on the trafficking or 
transport activity of GLT-1 in transfected BHK cells, but increased stability at the plasma 
membrane, which may be critical for transporter localization in vivo (Raunser et al., 
2005). 
1.4.2.1.3 GLYCOSYLATION OF HUMAN EXCITATORY TRANSPORTER 
Glycosylation of the EAATs in human brain has not been evaluated in detail, 
however, a recent study reported the identification of a splice variant of the human 
glutamate transporter EAAT1, EAAT1ex9skip (Vallejo-Illarramendi et al. 2005). This 
splice variant lacks the entire exon 9 of EAAT1, and its mRNA is translated into a 
truncated protein localized to the ER. Furthermore, when co-expressed with full-length 
EAAT1, EAAT1ex9skip acts as a negative regulator of EAAT1. This is quite similar to 
previous reports of alternate splice products of EAAT2 described by Lin et al. (1998). 
Interestingly, exon 9 includes the leucine-based motif and excludes the RXR motif. This 
confirms the repressor properties of the leucine-rich motif on RXR-induced ER retention 
and may explain the ER-restricted localization and functional inactivity of 
EAAT1ex9skip.  
1.4.2.2 PROTEIN TARGETING AND STABILIZATION 
1.4.2.2.1 Membrane domains 
Efficient synaptic transmission requires a highly ordered arrangement of 
specialized membrane domains, including presynaptically localized vesicles, postsynaptic 
glutamate receptors and astrocytic or peri-synaptically localized glutamate transporters. 
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The close vicinity of all of these membrane domains is critical in shaping the amplitude 
of postsynaptic responses. (Jackson et al. 2001; Zhou and Sutherland 2004).  
These specialized membrane domains include lipid rafts, which are lipid-protein 
microdomains of the plasma membrane that are enriched with cholesterol and 
glycosphingolipids (Simons and Toomre 2000). They participate in a number of cellular 
processes including regulation of trafficking and clustering of membrane-associated 
proteins and their intracellular signaling molecules (Becher et al. 2001). The role of these 
membrane domains in glutamate transporter regulation was first confirmed by Butchbach 
et al. (2004), they showed that depletion of membrane cholesterol by methyl-β-
cyclodextrin reduced Na+-dependent glutamate uptake in primary cortical cultures. 
Biochemical analysis further confirmed the association of glutamate transporters with 
cholesterol-rich lipid raft microdomains of the plasma membrane (Butchbach et al. 2004). 
The reduced glutamate uptake in the absence of cholesterol was accompanied by a 
decrease of transporter protein at the cell surface, which was blocked by a non-specific 
inhibitor of receptor internalization. This suggests that endocytosis of the transporters 
may be increased when there is no membrane cholesterol present to stabilize the 
transporters at the cell surface, resulting in decreased glutamate uptake.  
1.4.2.2.2 Excitatory transporters interacting proteins 
Localization and stabilization of membrane proteins is often dependent on their 
interaction with intracellular anchoring proteins. This assembly of multiprotein 
complexes influences both specificity and efficiency of biological processes within the 
cell. In the brain, multiprotein assemblies of receptors, ion channels, and transporters 
have been studied extensively (Levitan, 2006; Muller et al., 2010). These complexes 
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execute critical biological functions, including stabilizing receptors near synapses, 
tethering kinases and phosphatases to limit nonspecific modification of proteins, and 
assembling enzymes to increase the efficiency of substrate transfer (Genda et al., 2011).  
Glutamate transporter-mediated glutamate uptake is regulated by several 
excitatory transporters-interacting proteins that have been studied over the years 
(Danbolt, 2001; Jackson et al., 2001; Lin et al., 2001; Marie et al., 2002; Watanabe et al., 
2003.). The excitatory transporter-interacting proteins utilize diverse mechanisms to 
modulate glutamate transport activity. 
1.4.2.2.2.1 EAAT2/GLT1 interacting protein 
The two GLT-1 interacting proteins Ajuba and G protein pathway suppressor-1 
(GPS-1) were identified using yeast two-hybrid technique (Marie et al., 2002; Watanabe 
et al., 2003), where Ajuba interacts with the amino terminus of GLT-1 and may act as a 
scaffolding protein, linking GLT-1 with the cytoskeleton and various signaling pathways 
(Marie et al., 2002). GPS-1 is a subunit of COP9 signalosome, interacts with the C-
terminus of GLT-1, and may be involved in the surface trafficking of GLT-1 via its 
leucine zipper-like motif. Coexpression of GPS-1 with GLT-1 in human embryonic 
kidney cells downregulates glutamate reuptake activity (Watanabe et al., 2004; 2003). 
1.4.2.2.2.2 EAAT1/GLAST interacting protein 
The consensus motif (last 8 residues) at C-terminus of GLAST consists of 
sequence homology to PDZ domain that might regulate the selective localization and 
function of GLAST in astrocytes. PDZ domains are a family of protein-protein 
interaction domains named after the first three proteins in which they were identified; 
post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), 
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and zonula occludens-1 protein (zo-1). In a recent study two novel PDZ related 
scaffolding proteins, the Na+/H+ exchanger regulatory factors 1 and 2 (NHERF-1 and 
NHERF-2) were discovered. Studies using primary cortical astrocytes revealed that these 
cells are highly enriched in NHERF-2 relative to NHERF-1. Moreover, knockdown of 
NHERF-2 in astrocytes showed a significant reduction in GLAST activity, followed by 
corresponding decrease in expression of GLAST protein and reduced half-life, suggesting 
that NHERF-2 interaction with GLAST in astrocytes enhances GLAST stability and 
activity. However, this interacting at the C-terminus may also modulate a transporter’s 
glutamate affinity. In one study (Marie and Attwell 1999), it has been suggested that 
disruption of an interaction between an intracellular protein and the last eight amino acids 
of the GLAST C-terminus, increases the glutamate affinity of GLAST. Thus, the 
interacting protein decreases the affinity of GLAST transporters. Consequently, this 
interaction may significantly slow the removal of low concentrations of glutamate from 
the extracellular space. Therefore, whether these protein interactions for GLAST motifs 
are acting as positive or negative modulators is still unknown and requires further 
investigation. 
1.4.2.3 Glutamate transporter trafficking 
Other mechanism for regulating neurotransmitter transport involves changes in 
membrane trafficking of the transporter. Trafficking of membrane proteins between the 
plasma membrane and intracellular stores that is mediated by an interplay of 
internalization and membrane insertion can occur in a very short period and therefore 
allows for very fast regulation of functional protein activity. Trafficking of other 
membrane proteins such as neurotransmitter receptors has been studied extensively, 
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however the regulation of glutamate transporter trafficking is yet to be studied. One of 
the major mechanisms for regulating membrane protein trafficking to and from the 
plasma membrane is PKC dependent direct phosphorylation of the membrane protein or 
its interacting scaffolding proteins. Protein kinase-C also (PKC) is a family of protein 
kinase enzymes that are involved in controlling the function of other proteins through 
the phosphorylation of hydroxyl groups of serine and threonine amino-acid residues on 
these proteins. PKC enzymes in turn are activated by signals such as increases in the 
concentration of diacylglycerol (DAG) or calcium ions (Ca2+). Hence PKC enzymes play 
important roles in several signal transduction pathways. Protein kinase C directly 
phosphorylate GLAST and reduces the transport activity up to 25% with no change in 
cell surface expression (Conradt and Stoffel, 1997). Elimination of protein kinase C 
consensus sites does not eliminate the effect, suggesting that the phosphorylation occurs 
at a novel site. GLT1 was originally reported to be stimulated by protein kinase C 
mediated phosphorylation of serine-113 when expressed in HeLa cells (Casado et al., 
1993). However, protein kinase C activation in MDCK cells with stable expression of 
human GLT1 leads to a reduced GLT1 cell surface expression (Carrick and Dunlop, 
1999). Thus, the phosphorylation varies between different cell types because of the 
different intracellular machinery which respond differently to the phosphorylation 
mechanism (Carrick and Dunlop, 1999). 
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1.4.3 GLUTAMATE TRANSPORTER MODIFICATION  
1.4.3.1 Arachidonic acid 
Arachidonic acid (AA) is a polyunsaturated fatty acid present in 
the phospholipids and is a precursor for the cellular synthesis of prostaglandins, 
prostacyclins, thromboxanes and leukotrienes. AA is released from neurons and glial 
cells during synaptic activity and can modulate synaptic transmission (Dumuis et al., 
1988; Stella et al., 1994) upon activation of glutamate receptors. In addition, AA has been 
reported to inhibit the glutamate uptake capacity in neuronal synaptic terminals and 
astrocytes (Dorandeu et al. 1998; Lundy and McBean 1995).  
1.4.3.2 Sulfhydryl based redox mechanisms 
Glutamate transporters are further modified and regulated by sulfhydryl based 
redox mechanisms (extensively reviewed by Trotti et al. 1998). Exposure of cortical 
astrocytes to H2O2 or xanthine/ xanthine oxidase decreases glutamate uptake 
dramatically, and the effect was partly reversible by DTT (Albrecht et al., 1993) or free 
radical scavenger enzymes (Volterra et al. 1994). The inhibitory effect produced by 
sulfhydryl based redox mechanism is attributed to the cysteine residues of transporters 
polypeptide. Mutation of cysteine residues in GLAST (canine origin) showed oligomer 
formation, plasmamembrane localization, and the transport kinetics similar to wildtype 
GLAST (Tamahara et al. 2002).  In addition, it has been suggested that cysteine residues 
are not critical for the functional expression of GLAST. While oxidative processes play 
an important role during pathological conditions and could explain decreased functional 
activity of glutamate transporters in disease, the physiological role of these oxidative 
processes in regulation of glutamate transporter function is still unclear.  
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1.4.4 Summary of glutamate transporter regulation 
The most common dysfunction of glutamate transport in neurodegenerative 
disease seems to be caused by a decrease in transporter protein level. The mechanisms for 
loss of protein (transcriptional/translational) are generally not known. Protein 
downregulation is found in acute neurodegenerative diseases, such as ischemia/hypoxia 
(Chen et al. 2005; Fukamachi et al. 2001; Inage et al. 1998; Martin et al. 1997) and a 
number of chronic neurodegenerative disorders, including HD (Behrens et al. 2002), PD 
(Ginsberg et al. 1995; Levy et al. 1995), AD (Masliah et al. 2000), and ALS (Rothstein et 
al. 1995). The downregulation of transporter protein was not always paralleled by 
decreases in mRNA levels. For example, our thiamine deficiency model showed 
decreased glutamate uptake and protein levels for GLAST (Hazell et. al., 2003) and GLT-
1a/b, but had no effect on the mRNA expression for GLT-1a/b (Jhala et. al., 2011). 
Similar findings were observed in mice expressing mutant amyloid precursor protein 
(Masliah et al. 2000) and from a postmortem analysis of frontal cortex of AD patients. A 
possible explanation for the loss in transporter protein without a loss in mRNA could be a 
dysregulation of transporter protein degradation processes. Irrespective of the mechanism 
for loss of transporter protein following different neurological insults, overcoming this 
loss is therapeutically significant. Few studies in the past have made significant progress 
using pharmacologically intervening agents against the loss of transporter protein in 
different diseases. In one study, transgenic mice overexpressing GLT-1 (1.5- to 5-fold 
over wildtype mice) (Sutherland et al. 2001) were crossed with transgenic mice 
overexpressing a mutant form of SOD1 (an animal model for ALS), the animals showed 
a delayed onset of motor neuron degeneration and increased survival, suggesting that 
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increasing the total number of GLT-1 molecules protects against neurodegeneration. In 
another study (Rothstein et al., 2005) discovered that β-lactam antibiotics increase protein 
expression of GLT-1, both in vitro and in vivo. Moreover, treatment SOD1 mutant mice 
with ceftriaxone significantly delayed disease onset as well as increases neuron survival, 
confirming a neuroprotective effect of β-lactam antibiotics through upregulation of 
glutamate transporter protein. Similar findings were obtained with ceftriaxone, our TD 
animal model and astrocyte cultures treated with TD (Jhala et. al., 2011).   
Thus, glutamate transporters can be regulated via multiple mechanisms, earlier at 
the level of gene transcription to modulations of the transporter protein through 
posttranslational modifications. The understanding of these processes has provided us 
with an alternative to identify the signaling pathways involved in a transporter 
dysfunction under different pathological conditions. More importantly, the identification 
of these pathways has further advanced the development of new strategies for 
pharmacological intervention and therapy in diseases associated with a dysfunction of 
glutamate transporters. 
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1.5 THE GLUTAMATE HYPOTHESIS OF TD  
In TD, considerable evidence now exists for excitotoxic-mediated cell death 
localized in areas of focal vulnerability. Over the years, a number of studies have 
identified glutamate as being a major factor in the pathophysiology of TD. Early reports 
of glutamate levels being reduced in whole brain of TD animals (Gubler et al., 1974) 
were consistent with decreases in the conversion of [14C]glucose to glutamate in TD rats 
(Gaitonde et al., 1975) and reduced Ca2+-dependent release of glutamate in hippocampal 
slices from symptomatic TD animals (Lê et al., 1991), suggesting a role for glutamate in 
this disorder. Studies also reported similarity in the appearance and development of 
thalamic lesions in TD to that of damage observed following excitotoxic conditions 
(Armstrong-James et al., 1988; Zhang et al., 1995). In addition, treatment with the 
noncompetitive NMDA receptor antagonist MK-801 was shown to lead to a reduction in 
the extent of neuronal damage in rats with TD (Langlais and Mair, 1990; Todd and 
Butterworth, 1998), providing further support for excitotoxic-mediated pathology in this 
disorder.   
The first direct evidence for existence of a glutamate-mediated excitotoxic event 
was reported when Hazell and colleagues (1993) and others demonstrated that 
extracellular glutamate concentration was increased in vulnerable brain regions during 
the symptomatic stage of TD following the appearance of neurological dysfunction 
(Hazell et al., 1993). Figures 3 and 5 show some of the major pathophysiological 
consequences of TD, including the development of excitotoxicity. At the same time, L-
type voltage-sensitive calcium channels (VSCCs) are activated (Hazell et al., 1998b), 
synonymous with sustained depolarization, suggesting the entry of Ca2+ into cells, and 
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which together with the rise in interstitial glutamate levels strongly indicates the 
likelihood of an excitotoxic event in affected regions of the brain in TD. 
 
 
 
 
 
 
 
Figure 6. Excitotoxic mechanism in thiamine deficiency 
 
Previous studies have demonstrated that such an imbalance in Ca2+ homeostasis is one of 
the most significant factors involved in excitotoxic cell death (Olney, 1971; Schanne et 
al., 1979; Arundine and Tymianski, 2003). Similarly, In TD the focal brain regions 
experiencing these changes in glutamate levels and depolarization also sustain a large 
downregulation of the astrocytic glutamate transporters GLT-1 and GLAST (Hazell et al., 
2001). This was also confirmed in cultured astrocytes made thiamine-deficient, in which 
a decrease in the Vmax for glutamate uptake and downregulation of EAAT1 were a 
consequence (Hazell et al., 2003). Such findings were also consistent with other evidence 
suggesting the extracellular glutamate rise observed in the thalamus in TD rats is due to a 
Ca2+-independent processs (Hazell and Hakim, 1994).  
 
  
 
 
 
 
OBJECTIVE AND HYPOTHESIS 
 
Hypothesis: Loss of the astrocytic glutamate transporter splice-variant GLT-1b is 
involved in brain lesions resulting from thiamine deficiency.  
The specific goals are to investigate i) the effects of TD on glutamate transporter GLT-1b 
expression and protein levels, and ii) the mechanism(s) involved in altered regulation of 
GLT-1b during TD using the pyrithiamine-induced rodent model of TD and in our in 
vitro model of TD involving primary cultures of astrocytes. 
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CHAPTER 2 
 
Loss of the glutamate transporter splice-variant GLT-1b in inferior colliculus 
and its prevention by ceftriaxone in thiamine deficiency
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Abstract 
Downregulation of astrocytic glutamate transporters is a feature of thiamine deficiency 
(TD), the underlying cause of Wernicke’s encephalopathy, and plays a major role in its 
pathophysiology. Recent investigations suggest that ceftriaxone, a β-lactam antibiotic, stimulates 
GLT-1 expression and confers neuroprotection against ischemic and motor neuron degeneration. 
Thus, ceftriaxone treatment may be a protective strategy against excitotoxic conditions. In the 
present study, we examined the effects of ceftriaxone on the glutamate transporter splice-variant 
GLT-1b in rats with TD and in cultured astrocytes under TD conditions. Our results indicate that 
ceftriaxone protects against loss of GLT-1b levels in the inferior colliculus of rats during TD, but 
with no significant effect in the thalamus and frontal cortex by immunoblotting and 
immunohistochemistry. Ceftriaxone also normalized the loss of GLT-1b in astrocyte cultures 
under conditions of TD. These results suggest that ceftriaxone has the ability to increase GLT-1b 
levels in astrocytes during TD, and may be an important pharmacological strategy for the 
treatment of excitotoxicity in this disorder. 
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1. Introduction 
Excitatory amino acid transporters (EAATs) are considered to be a potential target for 
neuroprotection against excitotoxicity, normally removing extracellular glutamate by an efficient 
uptake process (Anderson and Swanson, 2000; Danbolt, 2001; Sattler and Rothstein, 2006). 
Several glutamate transporter proteins have been cloned and sequenced, including EAAT1 (Storck 
et al., 1992), EAAT2 (Pines et al., 1992), EAAT3 (Kanai and Hediger, 1992), EAAT4 (Fairman et 
al., 1995) and EAAT5 (Arriza et al., 1997). Of three major glutamate transporters identified in the 
rodent forebrain, glutamate transporter 1 (GLT-1) (or EAAT2) and glutamate/aspartate transporter 
(GLAST) (or EAAT1) are expressed mainly in astrocytes (Danbolt et al., 1992; Rothstein et al., 
1994; Lehre et al., 1995), while excitatory amino acid carrier 1 (or EAAC1) is expressed in 
neurons. GLT-1 is considered the major glutamate transporter responsible for clearance of 
glutamate from the extracellular space (Lehre and Danbolt,1998; Rothstein et al., 1996; Selkirk et 
al., 2005). In addition, considerable evidence indicates that GLT-1 contributes to excitotoxicity 
and neuronal death in a number of neurological disorders, including ischemic stroke, traumatic 
brain injury, and amyotrophic lateral sclerosis (Rao et al., 2001; Allen et al., 2004; Maragakis and 
Rothstein, 2004).  
Previous studies indicate that extracellular glutamate concentration is increased in 
vulnerable brain regions in thiamine deficiency (TD) (Hazell et al., 1993; Langlais and Zhang, 
1993), the cause of Wernicke’s encephalopathy (WE), and in which loss of GLT-1 and GLAST 
also occurs (Hazell et al., 2001). This effect of TD on glutamate transporter levels was also 
demonstrated in  primary cultures of astrocytes (Hazell et al., 2003). Furthermore, it has recently 
been demonstrated that loss of GLT-1 and GLAST also occurs in the cerebral cortex of alcoholic 
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cases of WE (Hazell et al., 2010), consistent with evidence that TD produces an impairment of 
glutamate uptake in this area of the brain (Carvalho et al., 2006).  
Recently, studies have reported an upregulation of GLT-1 by β-lactam antibiotics 
following downregulation of this transporter in in vitro models of ischemic brain injury and motor 
neuron degeneration (Rothstein et al., 2005). The β–lactam antibiotic ceftriaxone alters glutamate 
transport and upregulates GLT-1 levels via an NFκB-mediated activation of the GLT-1 promotor 
(Lee et al., 2008). Thus, administration of ceftriaxone may have therapeutic potential against 
excitotoxicity in various neurodegenerative conditions. Ceftriaxone also confers protection against 
glutamate toxicity by inducing the glutamate/cystine-antiporter system, independent of glutamate 
transporter regulation (Lewerenz et al., 2009). 
This study examines the effect of ceftriaxone on excitotoxicity associated with TD. Our 
results indicate that ceftriaxone completely blocks loss of the splice-variant GLT-1b in the inferior 
colliculus but is ineffective in the medial thalamus, another vulnerable brain region in this 
disorder. 
 
2. Materials and methods 
2.1. Rat model of TD 
Male Sprague–Dawley rats (Charles River, St-Constant, QC, Canada) were used for all 
experiments. Animals were housed individually under constant conditions of temperature, 
humidity and 12 h light/dark cycles. Rats were acclimatized for at least 2 days prior to the 
initiation of treatment, and neurological assessment of the animals (ataxia, opisthotonus, loss of 
righting reflexes, convulsions, nystagmus) were made on a daily basis. All experimental 
procedures were approved by the Animal Ethics Committee of Saint-Luc Hospital (CHUM) and 
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the University of Montreal. Rats in the TD group (n = 9) were fed a thiamine-deficient diet (ICN 
Nutritional Biochemicals, Cleveland, OH, USA) and administered daily pyrithiamine 
hydrobromide (Sigma–Aldrich, St Louis, MO, USA) (0.5 mg/kg body weight, i.p.). Control rats (n 
= 9) were pair-fed to TD animals using the same thiamine5 deficient diet and supplemented with 
daily i.p. injections of thiamine (0.1 mg per kg body weight). Treatments were continued until the 
symptomatic stage (loss of righting reflex). Any animals exhibiting spontaneous seizures were 
eliminated from the study. Separate groups of rats were treated with ceftriaxone (200 mg/kg, i.p. 
for 5 days commencing at day 7 of TD. 
2.2. Cell culture preparation 
Primary astrocyte cultures from newborn rats were prepared as previously described (Hazell et al., 
1997). Briefly, cerebral cortices were removed and the tissue was dissociated, passed through 
sterile nylon sieves, and then suspended in Dulbecco’s modified Eagle medium (DMEM; Life 
Technologies, Burlington, Ontario, Canada) containing 10% fetal calf serum. Cells were then 
seeded in 35 mm culture dishes, which were maintained in an incubator at 37°C provided with a 
mixture of 5% CO2 and 95% air. After 2 weeks, cells attained confluency, at which point the fetal 
calf serum was replaced by horse serum. Cultures were grown for 3-5 weeks, during which the 
medium was changed twice a week, and supplemented with dibutyryl cyclic AMP after 2 weeks. 
At least 95% of cells were determined to be astrocytes, based on GFAP immunohistochemistry.  
To induce TD, cells were exposed to a custom-designed DMEM media for 10 days lacking 
in thiamine (Invitrogen Canada, Burlington, ON, Canada) and containing 5% horse serum, in the 
presence of pyrithiamine (20 μM). Control astrocytes were treated with TD media in which 
normal levels of thiamine (10 μM) had been added. 
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2.3. Immunoblotting studies 
At the appropriate time, animals were sacrificed by decapitation, the brains were removed 
and flash frozen in isopentane on dry ice and stored at -800C. The frontal cortex, medial thalamus 
and inferior colliculus were then dissected out according to the rat brain atlas of Paxinos and 
Watson (1998). Samples of rat brain tissue were homogenized in buffer containing 50 mM Tris, 
150 mM NaCl, 0.1% 6 sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate (pH 
8.0) and protease inhibitor cocktail, and centrifuged at 10,000g for 10 min at 4oC. Preliminary 
studies carried out on the pellet and supernatant indicated that GLT-1b was completely soluble in 
this buffer under our conditions. Thus, the supernatant was retained and used for study. Astrocyte 
cultures were harvested in the same buffer. Protein content of all samples was determined by the 
method of Lowry et al. (1951) using bovine serum albumin as the standard. Sample buffer was 
added to aliquots of the tissue (30 μg) or cultures (50 μg) and the samples boiled for 5 min. 
Aliquots were subjected to (SDS)-polyacrylamide gel electrophoresis (8% polyacrylamide) and 
the proteins subsequently transferred to polyvinylidene difluoride membranes by wet transfer at 20 
V over 24 h. The transfer buffer consisted of 48 mM Tris (pH 8.3), 39 mM glycine, 0.037% SDS, 
and 20% methanol. Membranes were subsequently incubated in blocking buffer (10 mM Tris, 100 
mM NaCl, 5% non fat dried milk) followed by incubations with rabbit polyclonal antisera directed 
against GLT-1b (B1b558; Ab #358) (0.05 μg/ml). Reblocking was followed by incubation with 
HRP-coupled antirabbit IgG (0.01 μg/mL) secondary antiserum. Each incubation step was of 1 h 
duration following which blots were washed several times with buffer (10 mM Tris, 100 mM 
NaCl, and 0.1% Tween-20). For the detection of specific antibody binding, the membranes were 
treated in accordance with the ECL-kit instructions and developed on X-OMAT film. Signal 
intensities were subsequently measured by densitometry using Image J software (NIMH, USA). 
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Linearity of the relationship between optical density and protein concentration was verified using 
appropriate standard curves. Blots were reversibly stained with Ponceau-S to monitor protein 
transfer efficiency and equal loading. 
2.4. Immunohistochemistry and histology 
At the appropriate time, animals were deeply anesthetized with pentobarbital (60 mg/kg, 
i.p.) 7 and perfused transcardially as described previously (Hazell et al., 2001). Brains were 
removed and postfixed overnight in neutral-buffered formalin containing 4% formaldehyde, 0.5% 
sodium phosphate buffer, and 1.5% methanol, pH.7.0. Coronal sections (23.8 to 25.8 mm relative 
to bregma) of 40-μm thickness were cut using a vibrotome according to the rat brain atlas of 
Paxinos and Watson (1998). Immunohistochemistry was performed according to Hazell et al. 
(2001). Briefly, rat brain sections were incubated for 10 min in phosphate-buffered saline (PBS) 
containing 0.3% hydrogen peroxide to block endogenous peroxidase activity. Tissue sections were 
washed in PBS (10 min), blocked for 20 min in 0.5% Triton X-100 and 5% donkey serum, and 
incubated with or without 0.5% Triton X-100, along with 5% donkey serum and primary rabbit 
antisera directed against GLT-1b (B1b558; Ab #358) (0.02 μg/ml) at room temperature or 4oC 
overnight. Sections were then washed (10 min) and incubated in PBS containing biotinylated 
donkey anti-rabbit/mouse IgG (1:100). Sections were then incubated for 1 h in streptavidin-HRP 
conjugate (1:100) followed by washing (10 min), and then incubation with DAB (0.05%) in PBS 
containing in some cases 25 mg/mL nickel ammonium sulfate for signal enhancement and in the 
presence of H2O2 (0.03%) for 2-10 min. Sections were then mounted on poly L-lysine coated 
slide (Fisher Scientific, Ottawa, ON, Canada), dehydrated in graded alcohols, cleared in xylene, 
and coverslipped with Permount. Negative controls consisted of omission of primary or secondary 
antibody, resulting in loss of immunoreactivity. Sections of rat brain were stained with cresyl 
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violet for histological evaluation. Neuronal cell numbers were counted in four adjacent boxes 
(0.06 mm2 each) at a magnification of 400X using an Olympus BX51 microscope and attached 
Spot RT digital camera (Diagnostics Instruments, Inc., Sterling Heights, MI, USA). 
2.5. Real-time reverse-transcription polymerase chain reaction (qRT-PCR) 
Total RNA was isolated from rat brains (frontal cortex, posterior medial thalamus and 8 
inferior colliculus) using the Trizol reagent (Invitrogen Canada Inc., Burlington, ON, Canada), 
according to the manufacturer’s instructions. Expression levels were assessed by real-time PCR in 
which cDNA was synthesized using a thermoscript RT-PCR system (Invitrogen). One microgram 
of RNA was reverse transcripted in a RotorGene 3000t Real time DNA detection system (Corbett 
Life Science, Sydney, Australia) using the QuantiTect SYBRGreen I PCR kit (Qiagen, Valencia, 
CA, USA). The PCR program was 95°C 15 min, followed by 35 or 45 cycles (94°C 15 sec, 55°C 
30 sec and 72°C 30 sec). Oligonucleotide primer sequences were designed using the Primer 3 
software (Rozen and Skaletsky, 2000) based on the following GenBank accession numbers: 
NM_017215 (GLT-1a), NM_001035233 (GLT-1b), and NM_031144 (β-actin). The specificity of 
the oligonucleotide primers was verified using the program BLASTN from the National Center for 
Biotechnology Information (NCBI, Bethesda, MD, USA). The forward and reverse primers 
employed were: GLT-1a, 5'-gaccaagacgcagtccattt-3', and 5'-ggctgagaatcgggtcatta-3'; GLT-1b, 5'-
aggaatcatgtcacccaagc-3', and 5'-atcttggcccaaagagtgaa-3'; β-actin, 5'-gtcgtaccactggcattgtg-3', and 
5'-ctctcagctgtggtggtgaa-3'. Expression levels were normalized to the housekeeping gene β-actin. 
2.6. Statistical analysis 
Statistical analysis was performed using one way ANOVA with post-hoc Friedman’s test. 
A probability of p < 0.05 was chosen to establish significance between groups. Data were 
analyzed using Prism 4.0 software (GraphPad Software, Inc., San Diego, CA). 
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3. Results 
3.1. General observations 
TD in the rat led to neurological changes at the symptomatic stage that included ataxia, 
opisthotonic episodes and nystagmus, culminating in a loss of righting reflexes. PFC animals at 9 
equivalent time points did not show any such neurological changes. Histological evaluation of rats 
with TD revealed a major loss of neurons in the inferior colliculus at the symptomatic stage (66 
±1%) (Fig. 1). As reported in previous studies from our laboratory, the medial thalamus also 
showed significant neuronal loss (not shown). In contrast, the frontal cortex showed no obvious 
changes in neuronal cell numbers. Primary astrocyte cultures exposed to TD showed no apparent 
changes in cell morphology. 
3.2. Effect of ceftriaxone on the expression of GLT-1 splice-variants in TD 
Real-time PCR analysis of GLT-1a and GLT-1b mRNA revealed that treatment with 
ceftriaxone during TD did not increase the expression of either splice-variant in the inferior 
colliculus, medial thalamus and frontal cortex (data not shown). Interestingly, levels of GLT-1a 
were in general higher in the frontal cortex than the thalamus and inferior colliculus (Fig. 2). 
3.3. Effect of ceftriaxone on protein levels of GLT-1b in TD 
Treatment with TD resulted in decreased levels of GLT-1b in the thalamus and inferior 
colliculus of 58.3 % and 65.8 % respectively (p < 0.05), with no change in levels of the splice-
variant in the frontal cortex, as determined by immunoblot analysis (Fig. 3). Ceftriaxone co-
treatment almost completely prevented the decrease in GLT-1b in the inferior colliculus, restoring 
transporter levels to 96 % of the normal value (Fig. 3A,B). However, no significant improvement 
was observed in the thalamus and frontal cortex (Fig. 3C-F), compared to the PFC group. To 
further confirm the effect of the drug in TD, primary cultures of astrocytes were first treated with 
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pyrithiamine (20 μM) to induce TD for 10 days followed by co-treatment with ceftriaxone (300 
μM) for 5 days. Immunoblotting showed a 33.1 % decrease in GLT-1b in astrocytes with TD (p < 
0.05), with ceftriaxone treatment completely preventing this loss of the GLT-1b splice-variant 
(Fig. 4). 
 Immunohistochemical staining of the TD rat brain showed a decrease in GLT-1b 10 
immunoreactivity in thalamus and inferior colliculus (Fig. 5). However, the effect was reduced in 
the ceftriaxone-treated TD group, consistent with a ceftriaxone-dependent regulation of this 
splice-variant. 
 
4. Discussion 
Ceftriaxone belongs to the family of β-lactam antibiotics that has been described as a 
potent positive regulator of the glutamate transporter GLT-1 in amyotropic lateral sclerosis 
(Rothestein et al., 2005), Huntington disease (Miller et al., 2008), hypobaric hypoxia (Hota et al., 
2008), and stroke (Lipski et al., 2007). In the present study, we investigated the effect of 
ceftriaxone in TD. Previous studies indicate that excitotoxicity is a major pathophysiological event 
in TD characterized by increased extracellular glutamate concentration (Hazell et al., 1993), 
increased depolarization (Hazell et al., 1998), and profound loss of astrocytic glutamate 
transporters in both TD (Hazell et al., 2001) and Wernicke’s encephalopathy (Hazell et al., 2010). 
Our findings indicate that ceftriaxone upregulates GLT-1 protein levels in the inferior 
colliculus in TD rats and in an in vitro astrocyte model of the disorder. The reason for the selective 
effect on the inferior colliculus is unclear but previous studies have reported differences in the 
pathology of the thalamus and inferior colliculus due to TD (Vortmeyer and Colmant, 1988). 
Thus, the focal response of this brain region may be related to differences in the underlying 
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pathophysiologic mechanisms between the colliculus and thalamus. Since ceftriaxone is reported 
to enhance GLT-1b levels via NFkB-linked stimulation of the GLT-1 promotor, such regional 
differences in the response to this antibiotic may be mediated via this mechanism. We are 
currently investigating this possibility in more detail. 
While ceftriaxone treatment upregulated GLT-1b transporter protein levels in the inferor 
11 colliculus, no changes in mRNA expression of either GLT-1a or GLT-1b were observed due to 
TD conditions. Since TD produces a downregulation of GLT-1 in vulnerable brain regions, this 
suggests that post-transcriptional changes are involved in this process, and are selectively 
responsive to ceftriaxone in the inferior colliculus. 
Co-treatment of astrocyte cultures with ceftriaxone completely protected against the  
decrease in GLT-1b protein occurring due to TD. Loss of the GLAST transporter in astrocytes 
exposed to TD conditions was earlier reported by us (Hazell et al., 2003); this finding of decreased 
levels of a GLT-1 splice-variant in TD is to our knowledge the first to be described. The ability of 
ceftriax one to prevent loss of GLT-1b in TD under in vitro conditions should provide a means by 
which to further investigate the mechanism(s) underlying this process in the future. Interestingly, 
ceftriaxone also upregulates the catalytic subunit of the cystine-glutamate exchanger (Knackstedt 
et al., 2010). Cystine, a dimeric amino acid formed by the oxidation of two cysteine residues, is a 
provider of cysteine in the cell which is required for synthesis of glutathione, an important 
naturally occurring endogenous antioxidant in astrocytes, and upregulation of the cystine-
glutamate exchanger is likely to result in increased entry of cystine, and ultimately increased 
protection against oxidative stress for these cells (Shih et al., 2006). Importantly, decreased 
cystine levels may lead to glutathione depletion and cell death (Lewerenz et al., 2009). Recently, 
we demonstrated that co-treatment of rats with TD and N-acetylcysteine, a well-established 
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antioxidant, protected against loss of GLT-1 and neuronal cell death in the vulnerable medial 
thalamus (Hazell et al., 2010). Thus, ceftriaxone may positively regulate GLT-1b in the inferior 
colliculus and in cultured astrocytes via an oxidative-stress-related mechanism, although why this 
effect is not apparent in the thalamus remains unclear, suggesting a combination of 
pathophysiologic processes may be involved. 
In conclusion, the findings of this study indicate that the β-lactam antibiotic ceftriaxone 12 
exerts a protective influence on GLT-1 protein levels under conditions of TD. Excitotoxicity is a 
major consequence of TD, and the present results suggest that ceftriaxone treatment may be 
beneficial in minimising the associated pathology. 
 
Acknowledgments 
We are grateful to Dr. Niels C. Danbolt (University of Oslo) for kindly providing the GLT-
1b antibody used in this investigation. This study was supported by a grant from the Canadian 
Institutes of Health Research (MOP-84497). 
 
 
 
 
 
 
 
 
 
 60
REFERENCES 
Allen, N.J., Káradóttir, R., Attwell, D., 2004. Reversal or reduction of glutamate and GABA 
transport in CNS pathology and therapy. Pflugers Arch. 449, 132-142. 
 
Anderson, C.M., Swanson, R.A., 2000. Astrocyte glutamate transport: review of properties, 
regulation, and physiological functions. Glia 32, 1-14. 
 
Arriza, J.L., Eliasof, S., Kavanaugh, M.P., Amara, S.G., 1997. Excitatory amino acid 
transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc. Natl. 
Acad. Sci. 94, 4155-4160. 
 
Carvalho, F.M., Pereira, S.R., Pires, R.G., Ferraz, V.P., Romano-Silva, M.A., Oliveira-Silva, 
I.F., Ribeiro, A.M., 2006. Thiamine deficiency decreases glutamate uptake in the prefrontal 
cortex and impairs spatial memory performance in a water maze test. Pharmacol. Biochem. 
Behav. 83, 481-489. 
 
Danbolt, N.C., 2001. Glutamate uptake. Prog. Neurobiol. 65, 1-105. 
 
Danbolt, N.C., Storm-Mathisen, J., Kanner, B.I., 1992. An [Na+ + K+]coupled L-glutamate 
transporter purified from rat brain is located in glial cell processes. Neuroscience 51, 295-310. 
 
 61
Fairman, W.A., Vandenberg, R.J., Arriza, J.L., Kavanaugh, M.P., Amara, S.G., 1995. An 
excitatory amino-acid transporter with properties of a ligand-gated chloride channel. 375, 599-
603. 
 
Hazell, A.S., Butterworth, R.F., Hakim, A.M., 1993. Cerebral vulnerability is associated with 
selective increase in extracellular glutamate concentration in experimental thiamine 
deficiency. J. Neurochem. 61, 1155-1158. 
 
Hazell, A.S., Itzhak, Y., Liu, H., Norenberg, M.D., 1997. 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J. Neurochem. 
68, 2216-2219. 
 
Hazell, A.S., Hakim, A.M., Senterman, M.K., Hogan, M.J., 1998. Regional activation of L-
type voltage-sensitive calcium channels in experimental thiamine deficiency. J. Neurosci. Res. 
52, 742-749. 
 
Hazell, A.S., Rao, K.V., Danbolt, N.C., Pow, D.V., Butterworth, R.F., 2001. Selective 
downregulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial 
thalamus in experimental Wernicke's encephalopathy. J. Neurochem. 78, 560-568. 
 
Hazell, A.S., Pannunzio, P., Rama Rao, K.V., Pow, D.V., Rambaldi, A., 2003. Thiamine 
deficiencyresults in downregulation of the GLAST glutamate transporter in cultured 
astrocytes. Glia 43, 175-184. 
 62
 
Hazell, A.S., Sheedy, D., Oanea, R., Aghourian, M., Sun, S., Jung, J.Y., Wang, D., Wang, C., 
2010. Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia 58, 148-156. 
 
Héroux, M, Raghavendra Rao, V.L., Lavoie, J., Richardson, J.S., Butterworth, R.F., 1996. 
Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's 
disease. Metab. Brain Dis. 11, 81-88. 
 
Hota, S.K., Barhwal, K., Ray, K., Singh, S.B., Ilavazhagan, G., 2008. Ceftriaxone rescues 
hippocampal neurons from excitotoxicity and enhances memory retrieval in chronic hypobaric 
hypoxia. Neurobiol. Learn. Mem. 89522-89532. 
 
Kanai, Y., Hediger, M.A., 1992. Primary structure and functional characterization of a high-
affinity glutamate transporter. Nature 360, 467-471. 
 
Knackstedt, L.A., Melendez, R.I., Kalivas, P.W., 2010. Ceftriaxone restores glutamate 
homeostasis and prevents relapse to cocaine seeking. Biol. Psychiatry 67, 81-84. 
 
Langlais, P.J., Zhang, S.X., 1993. Extracellular glutamate is increased in thalamus during 
thiamine deficiency-induced lesions and is blocked by MK-801. J. Neurochem. 61, 2175-2182. 
 
 63
Lee, S.G., Su, Z.Z., Emdad, L., Gupta, P., Sarkar, D., Borjabad, A., Volsky, D.J., Fisher, P.B., 
2008.Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression 
and glutamate uptake in primary human astrocytes. J. Biol. Chem. 283, 13116-13123. 
 
Lehre, K.P., Danbolt, N.C., 1998. The number of glutamate transporter subtype molecules at 
glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J. 
Neurosci. 18, 8751-8757. 
 
Lehre, K.P., Levy, L.M., Ottersen, O.P., Storm-Mathisen, J., Danbolt, N.C., 1995. Differential 
expression of two glial glutamate transporters in the rat brain: quantitative and 
immunocytochemical observations. J. Neurosci. 15, 1835-1853. 
 
Lewerenz, J., Albrecht, P., Tien, M.L., Henke, N., Karumbayaram, S., Kornblum, H.I., 
Wiedau- Pazos, M., Schubert, D., Maher, P., Methner, A., 2009. Induction of Nrf2 and xCT 
are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 
111, 332-343. 
 
Lipski, J., Wan, C.K., Bai, J.Z., Pi, R., Li, D., Donnelly, D., 2007. Neuroprotective potential of 
ceftriaxone in in vitro models of stroke. Neuroscience 146, 617-629. 
 
Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the 
Folin phenol reagent. J. Biol. Chem. 193, 265-275. 
 
 64
Maragakis, N.J., Rothstein, J.D., 2004. Glutamate transporters: animal models to neurologic 
disease. Neurobiol Dis. 15, 461-473. 
 
Miller, B.R., Dorner, J.L., Shou, M., Sari, Y., Barton, S.J., Sengelaub, D.R., Kennedy, R.T., 
Rebec, G.V., 2008. Up-regulation of GLT1 expression increases glutamate uptake and 
attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153, 329-337. 
 
Olney, J.W., Collins, R.C., Sloviter, R.S., 1986. Excitotoxic mechanisms of epileptic brain 
damage. Adv. Neurol. 44, 857-877. 
 
Palmer, A.M., Marion, D.W., Botscheller, M.L., Swedlow, P.E., Styren, S.D., DeKosky, S.T., 
1993. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact 
model. J. Neurochem. 61, 2015-2024. 
 
Paxinos, G., Watson, C., 1998. The Rat Brain in Stereotaxic Coordinates, fourth ed. Academic 
Press, New York. 
 
Pines, G., Danbolt, N.C., Bjørås, M., Zhang, Y., Bendahan, A., Eide, L., Koepsell, H., Storm-
Mathisen, J., Seeberg, E., Kanner, B.I., 1992. Cloning and expression of a rat brain L-
glutamate transporter. Nature 360, 464-467. 
 
 65
Rao, V.L., Bowen, K.K., Dempsey, R.J., 2001. Transient focal cerebral ischemia down-
regulates glutamate transporters GLT-1 and EAAC1 expression in rat brain. Neurochem. Res. 
26, 497-502. 
 
Rothstein, J.D., 1996. Excitotoxicity hypothesis. Neurology 47, 19-25. 
 
Rothstein, J.D., Martin, L., Levey, A.I., Dykes-Hoberg, M., Jin, L., Wu, D., Nash, N., Kuncl, 
RW., 1994. Localization of neuronal and glial glutamate transporters. Neuron. 13, 713-725. 
 
Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., Jin, L., 
Dykes Hoberg, M., Vidensky, S., Chung, D.S., Toan, S.V., Bruijn, L.I., Su, Z.Z., Gupta, P., 
Fisher, P.B., 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate 
transporter expression. Nature 433, 73-77. 
 
Rothstein, J.D., Dykes-Hoberg, M., Pardo, C.A., Bristol, L.A., Jin, L., Kuncl, R.W., Kanai, Y., 
Hediger, M.A.,Wang, Y., Schielke, J.P.,Welty, D.F., 1996. Knockout of glutamate transporters 
reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. 
Neuron 16, 675–686. 
 
Sattler, R., Rothstein, J.D., 2006. Regulation and dysregulation of glutamate transporters. 
Handb. Exp. Pharmacol. 175, 277-303. 
 
 66
Selkirk, J.V., Stiefel, T.H., Stone, I.M., Naeve, G.S., Foster, A.C., Poulsen, D.J., 2005. 
Overexpression of the human EAAT2 glutamate transporter within neurons of mouse 
organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal 
cells. Eur. J. Neurosci. 21, 2291-2296. 
 
Shih, A.Y., Erb, H., Sun, X., Toda, S., Kalivas, P.W., Murphy, T.H., 2006. Cystine/glutamate 
exchange modulates glutathione supply for neuroprotection from oxidative stress and cell 
proliferation. J. Neurosci. 26, 10514-10523. 
 
Storck, T., Schulte, S., Hofmann, K., Stoffel, W., 1992. Structure, expression, and functional 
analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc. Natl. Acad. 
Sci. 89, 10955-10959. 
 
Vortmeyer AO, Colmant H.J. 1988. Differentiation between brain lesions in experimental 
thiamine deficiency. Virchows Arch A Pathol Anat Histopathol. 414(1):61-7. 
 
Younes-Mhenni, S., Derex, L., Berruyer, M., Nighoghossian, N., Philippeau, F., Salzmann, 
M., Trouillas, P., 2004. Large-artery stroke in a young patient with Crohn's disease. Role of 
vitamin B6 deficiency-induced hyperhomocysteinemia. J. Neurol. Sci. 221, 113-115. 
 
 
 
 
 67
FIGURE LEGENDS 
Figure 1. Histological analysis of the inferior colliculus from pair-fed control (A, C) and acute 
symptomatic thiamine-deficient (TD) rats (B, D). Photomicrographs show cresyl violet staining of 
brain sections. Panels C and D display higher magnification images of the boxed areas shown in A 
and B respectively. Scale bars: 400 μm (A,B); 200 μm (C,D). 
 
Figure 2. Real-time PCR analysis of the splice-variant glutamate transporter GLT-1a in the frontal 
cortex (FC), medial thalamus (MT), and inferior colliculus (IC) of PFC, TD, and TD rats co-
treated with ceftriaxone (C). *p < 0.05 compared to PFC group (one-way ANOVA with posthoc 
Friedman’s test for multiple comparisons). 
 
Figure 3. Effect of ceftriaxone on GLT-1b in the rat brain in thiamine deficiency. The inferior 
colliculus, medial thalamus and frontal cortex were examined in pair-fed controls (PFC), acute 
symptomatic TD and ceftriaxone-treated TD rats (TD-CEF) for protein levels of the glutamate 
transporters GLT-1b by immunoblotting. Results show representative blots of each brain region 
and their quantitative analysis. Levels of GLT-1b were decreased in the inferior colliculus (A,C) 
and thalamus (B,D) but not in the frontal cortex of TD animals. Co-treatment with ceftriaxone 
completely prevented the loss of GLT-1b in inferior colliculus but not in the medial thalamus. *p 
< 0.05 compared to PFC group (one-way ANOVA with post-hoc Friedman’s test for multiple 
comparisons). 
 
Figure 4. Effect of ceftriaxone on GLT 1b protein levels in astrocyte cultures treated with TD. 
 68
A) Representative immunoblot for control, thiamine deficient (TD) and ceftriaxone-treated TD 
astrocyte culture (TD+CEF). B) Immunoblot analysis shows that TD resulted in a downregulation 
of GLT-1b that was prevented by ceftriaxone. *p < 0.05 compared to PFC group (one-way 
ANOVA with post-hoc Friedman’s test for multiple comparisons). 
 
Figure 5. Immunohistochemical staining of the glutamate transporter splice-variant GLT-1b in the 
inferior colliculus of representative PFC (A,B), TD rats (C,D), and ceftriaxone-treated TD rats 
(E,F). Photomicrographs show decreased GLT-1b immunoreactivity in TD animals compared to 
PFC and an amelioration of this downregulation in ceftriaxone-treated animals. Panels B,D,F 
show higher power images of sections shown in A,C,E respectively. Scale bars: 300 μm (A,C,E); 
150 μm (B,D,F) 
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ABSTRACT 
Downregulation of the astrocytic glutamate transporters GLT-1 and GLAST and ensuing excitotoxic 
damage are important features of the pathophysiology of thiamine deficiency (TD), the cause of 
Wernicke’s encephalopathy. Exactly how the levels of these transporters are altered in this disorder, 
however, is unknown. Poly (ADP) ribose polymerase-1 (PARP-1), an important enzyme of poly 
(ADP)-ribosylation with a key role in the regulation of transcription and the development of 
excitotoxicity is associated with the pathogenesis of various disorders of the CNS. In addition, 
nuclear factor (NF)-kB has previously been linked to the regulation of GLT-1, and PARP-1 is 
required and sufficient for specific transcriptional activation of NF-kB. To better understand the 
relationship between PARP-1 and the regulation of glutamate transporters in TD, we treated primary 
cultures of astrocytes with TD. Using a combination of immunoblotting, flow cytometry, and 
immunocytochemistry, we show that cells treated with TD displayed a profound increase in the 50 
kDa cleaved fragment of PARP-1 and IkB phosphorylation suggestive of NF-kB activation and 
nuclear translocation. These changes occurred in association with a decrease in levels of the splice-
variant GLT-1b and were also apparent in a well-established rat model of TD. Using specific PARP-
1 and NF-kB inhibitors, we demonstrate a strong likelihood that excessive PARP activation due to 
impaired energy status or oxidative insult as a consequence of TD promotes NF-κB-dependent 
downregulation of GLT-1b.  Our findings indicate that PARP-1 activation and NF-kB play an 
important role in the loss of astrocytic glutamate transporters in TD. 
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1. INTRODUCTION 
Thiamine is an essential cofactor for the enzymes involved in cellular energy metabolism and 
thus mitochondrial dysfunction and its associated cerebral energy depletion are major consequences 
of thiamine deficiency (TD) (Pannunzio et  al., 2000; Jhala and Hazell, 2011). Bioenergetic 
depletion, excessive glutamate accumulation, astrocytic dysfunction and downregulation of 
glutamate transporters as a consequence of TD have previously been reported (Aikawa et al., 1984; 
Hazell et al., 1993, 2003; Jhala et. al., 2011), and are key features of this disorder.  
In recent studies, poly (ADP) ribose polymerase-1 (PARP-1), an important enzyme of 
poly(ADP) -ribosylation has been linked to the pathogenesis of various disorders of the CNS, 
including excitotoxicity and ischemic injury (Meng et. al., 2000; Ying et. al., 2001; Tang et. al., 
2010). It is a nuclear chromatin-associated protein which catalyzes the synthesis of large branched 
polymers of ADP-ribose units by using β-nicotinamide adenine dinucleotide (NAD+) as substrate 
(Hassa and Hottiger, 1999). Reduction in neuronal necrosis, improvement in neurological status, 
protection against white-matter damage and AIF translocation has been observed following 
pharmacological inhibition of PARP-1 enzyme and in PARP-1 deficient animal models of stroke, 
traumatic brain injury and Parkinson disease. (Eliasson, 1997; Zingarelli et. al., 1998; Virag, and 
Szabo, 2002). 
An important physiological role of PARP is its ability to regulate transcription. For example, 
PARP-1 is required and sufficient for specific transcriptional activation of NF-kB in response to pro-
inflammatory stimuli and genotoxic stress (Hassa and Hottiger, 1999; Ha et. al., 2002). Thus, 
expression of several inflammatory response genes such as TNF-α, IL-6, IFNy, VCAM, ICAM, P-
Selectin and iNOS were shown to be drastically reduced (60-90%) in PARP-1 deficient mice after 
treatment with inflammatory stimuli such as LPS or streptozotocin (Shall and Murcia, 2000). It is 
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therefore possible that PARP-1 along with other inflammatory precursors can synergistically co-
activate NF-kB in response to any oxidative injury. However, poly (ADP) ribosylation affects 
neither the DNA binding activity of NF-kB nor required for NF-kB dependent gene expression 
(Hassa and Hottiger, 1999; 2002). In brain, poly (ADP) ribosylation and its associated PARP-1 
enzyme activation and/or cleavage has been implicated in neural cell loss under in vitro and in vivo 
conditions (Eliasson, 1997; Meng et. al., 2000; Ha et. al., 2002).   
The cause of PARP activation in brain is associated with metabolic stress and mitochondrial 
dysfunction, important features of TD, and it has been suggested that PARP activation under these 
conditions can exacerbate the extent of damage associated with the disorders (Trushina and 
McMurray, 2007). Previous literature indicates that astrocytes are more vulnerable to ribosylation or 
PARP activation than neurons (Ha et. al., 2002; Tang et. al., 2010). Given that astrocytes appear to 
be targeted in TD (Hazell, 2009; Hazell et al., 2010), in the present study we investigated a potential 
linkage between glutamate signalling and NF-kB activation in relation to poly (ADP) ribosylation in 
both astrocyte cultures exposed to TD and in rats treated with TD.  
 
2. Experimental procedure 
2.1. Rat model of TD  
All the experimental procedures were approved by the Animal Ethics Committee of Saint-
Luc Hospital (CHUM) and the University of Montreal. Male Sprague–Dawley rats (Charles River, 
St-Constant, QC) were used for all experiments. Animals were housed individually under constant 
conditions of temperature, humidity and 12 h light/dark cycles. Thiamine deficiency was produced 
by administering pyrithiamine hydrobromide as previously described (Hazell et al., 1998a). Briefly, 
rats were acclimatized for at least 2 days before the treatments and behavioural assessment of the 
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animals preceding neurological signs of TD (ataxia, opisthotonus, loss of righting reflexes, 
convulsions, nystagmus) were made on a daily basis. Rat in the TD group (n = 9) were fed a 
thiamine-deficient diet (ICN Nutritional Biochemicals, Cleveland, OH) and administered daily 
pyrithiamine (0.5 mg/kg body weight) with or without PDTC (20 mg/kg body weight) (Sigma-
Aldrich, St Louis, MO) intraperitoneally. Control rats (n = 9) were pair-fed to equal food 
consumption with the thiamine deficient rat using the same thiamine-deficient diet and 
supplemented with daily i.p. injections of thiamine (0.1 mg per kg body weight). Treatment was 
continued until the symptomatic stage (loss of righting reflex). Any rat exhibiting spontaneous 
seizures were removed from the study.  
 
2.2. Cell Culture Preparation 
Primary astrocyte cultures from newborn rats were prepared using a modification of the 
method of Booher and Sensenbrenner (1972). Briefly, cerebral cortices were removed and the tissue 
was dissociated, passed through sterile nylon sieves, and then suspended in Dulbecco’s modified 
Eagle medium (DMEM; Invitrogen, Burlington, ON) containing 10% fetal calf serum. Cells were 
then seeded in 35 and 100 mm culture dishes, which were maintained in an incubator at 37°C 
provided with a mixture of 5% CO2 and 95% air. Cultures were grown for 3–5 weeks, during which 
the medium was changed twice a week. To induce TD, cells were exposed to a custom-designed 
DMEM media lacking in thiamine (Invitrogen, Burlington, ON) and containing 5% horse serum, in 
the presence of pyrithiamine. Control astrocytes were treated with TD media in which normal levels 
of thiamine (11 µM) had been added. Astrocyte cultures treated with TD were administered 
inhibitors against PARP (DPQ, 25uM) and NF-kB (PDTC, 50uM) for 3 days. Growth media was 
changed regularly every 3-4 days, depending on treatment conditions. All culture plates for each 
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experiment were harvested on the same day. 
 
2.3. Flow cytometry 
Astrocytes were harvested in papain solution (Worthington Biochemical Corp., Lakewood, 
NJ) for 15-20 min and resuspended in flow cytometry buffer, consisting of 1X PBS, pH 7.2, 1% fetal 
bovine serum (Invitrogen, Burlington, ON). Cells were counted and diluted to a density of 1x106 
cells per milliliter of buffer. Aliquotes of 1 x 105 cell were incubated with polyclonal antisera 
directed against PARP-1 (Cell Signalling Technology, Inc., Danvers, MA), and GFAP (1:200, Santa 
Cruz Biotechnology, Santa Cruz, CA), or GLT-1b (1:500) and phospho-IkB (1:1000, Cell Signalling 
Technology, Inc., Danvers, MA) for 30 min on ice. Cells were washed in buffer, and then specific 
Alexa Fluor-592 conjugated IgG and Alexa Fluor-488 conjugated IgG secondary fluorescent-
conjugated antibodies (Invitrogen, Burlington, ON) added at the appropriate dilution (1:100) and 
incubated on ice for 15 minutes.  Viable cells were gated by light scatter and were analyzed by 
FACScan (BD LSRII) (BD Biosciences, Mississauga, ON) using a Cell Quest program (BD 
Biosciences, Mississauga, ON). Fluorescence background was measured using unlabeled cells and 
cells labeled with secondary antibody alone; these set gating parameters between positive and 
negative cell populations. Cell aggregates and small debris were excluded from analysis or isolation 
on the basis of side scatter (measuring cell granularity) and forward scatter (measuring cell size). 
Fluorescent intensities for cells in the population were plotted as quadrants and/or histograms using 
CellQuest software (BD Biosciences, Mississauga, ON). All statistical calculations were done using 
GraphPad Prism (GraphPad, software, Inc. La Jolla, CA).  
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2.4. Glutamate uptake 
Glutamate uptake study was done as described according to Hazell et al. (1997) with some 
modifications. Briefly, cells were incubated in DMEM media containing the glutamate analogue D-
aspartate and 0.2 µCi/ml of [3H]-D-aspartate in 5% CO2 /95% air at 37°C, incubation time for all 
experiments was 2 min. Uptake was stopped by aspiration of the media and rapid washing of cells 
three times with ice-cold PBS. Cells were then harvested with 0.5 ml of 1 M NaOH. Sample aliquots 
were measured for protein content (Lowry et al., 1951) and the radioactivity for calculation of the 
uptake rate was measured by liquid scintillation counting.  
 
2.5. Immunocytochemistry 
Media was aspirated and cells were washed for three times in PBS. Cells were then fixed for 
10 min with 10% neutral buffered formalin. After 10 min incubation cells were again washed in PBS 
(3 x 10 min), blocked for 20 min with 5% donkey serum in PBS, and then incubated with 5% 
donkey serum and polyclonal mouse antisera directed against GFAP (1: 250, Santa Cruz 
Biotechnology, Santa Cruz, CA) and polyclonal rabbit antisera directed against PARP-1 (1:250, Cell 
Signalling Technology, Inc., Danvers, MA) for overnight at 4°C. Cells were then washed (3 x 10 
min) and incubated for 1 h with Alexa Fluor-488 (green) and Alexa Fluor-592 (red) secondary 
antibodies (1:200), then mounted in Prolong Gold AntiFade reagent and examined using an Olympus 
BX51 microscope and attached Spot RT digital camera. Negative controls consisted of omission of 
primary or secondary antibody, resulting in loss of immunoreactivity. Images were processed using 
Image-Pro Plus 6.2 image analysis software (Media Cybernetics, Inc., Bethesda, MD, USA).  
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2.6. Immunoblotting 
Cells were harvested in RIPA buffer containing 50 mM Tris,150 mM NaCl, 0.1% sodium 
dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate (pH 8.0), and protease inhibitor 
cocktail and centrifuged at 10,000 g for 10 min at 4°C. Protein content of all samples was 
determined by methods of Lowry and colleagues (Lowry et al., 1951) using bovine serum albumin 
as the standard. Aliquots were subjected to (SDS)-polyacrylamide gel electrophoresis (8% 
polyacrylamide) and the proteins subsequently transferred to PVDF membranes by wet transfer at 
20V over 24 h. The transfer buffer consisted of 48 mM Tris (pH 8.3), 39 mM glycine, 0.037% SDS, 
and 20% methanol. Membranes were subsequently incubated in blocking buffer (10 mM Tris, 100 
mM NaCl, 5% non fat dried milk) followed by incubations with rabbit polyclonal antisera directed 
against GLT-1b (1:1000), Phospho-IkB (1:1000), PARP-1 (1:1000) overnight at 4°C. Reblocking 
was followed by incubation with HRP-coupled anti-rabbit IgG (0.01 µg/mL) secondary antiserum. 
Each incubation step was of 1h duration following which blots were washed several times with 
buffer (10 mM Tris, 100 mM NaCl, and 0.1% Tween-20). For the detection of specific antibody 
binding, the membranes were treated in accordance with the ECL-kit instructions and developed on 
a photosensitive X-OMAT film. Signal intensities were subsequently measured by densitometry 
using an Image J (Image processing and analysis system, NIHM, USA). Linearity of the relationship 
between optical density and protein concentration was verified using appropriate standard curves. 
Blots were reversibly stained with Ponceau-S to monitor protein transfer efficiency and equal 
loading.  
 
2.7. Statistical analysis  
Statistical analysis was performed using Man-Whitney test for two group comparison with 
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one-way ANOVA being used for multiple comparisons. A probability of p < 0.05 was chosen to 
establish significance between groups. Data were analyzed using Prism 4.0 software (GraphPad 
Software, Inc., San Diego, CA). Data are expressed as mean ± S.E.M. values. 
 
3. RESULTS 
3.1. Increased PARP-1 in TD 
PARP-1 is specifically proteolysed by caspases to a 24 kDa DNA-binding domain and to a 
89 kDa catalytic fragment during execution of the apoptotic program. Significant DNA damage 
associated with severe energy depletion may initiate a necrosis with a cleavage at 50 kDa, which is 
believed to prevent execution of the apoptotic program (Eguchi et al., 1997; Leist et al., 1997). 
Cultured astrocytes exposed to TD displayed an increased PARP-1 immunoreactivity (Fig. 1).  This 
pattern of cleavage of PARP-1 was also observed using immunoblot analysis, indicating atypical 
cleavage with a band intensity at approximately 50 kDa (Fig. 2A). Astrocytes under TD conditions 
treated with the PARP inhibitor DPQ (25µM) or exogenous NAD+ (1mM) blocked this PARP-1 
activation and cleavage (Fig. 2A). Treatment of rats with TD resulted in large increases in the 24 kD 
fragment of PARP-1 in the vulnerable thalamus and inferior colliculus (Fig. 2B). In contrast, no 
significant change was observed in the non-vulnerable frontal cortex compared to control animals. 
Co-treatment of TD animals with PDTC resulted in no significant improvement in PARP-1 levels 
relative to PFC animals.  
Figure 3 shows flow cytometry analysis of PARP-1 in TD astrocyte cultures. Treatment of 
astrocytes with TD conditions produced  an almost 4-fold increase in PARP-1 levels compared to 
control astrocytes. In the presence of DPQ and NAD+, increased PARP-1 levels were attenuated by 
61% and 30%, respectively. No significant change was observed in the levels of PARP-1 after 
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PDTC administration. 
3.2. Regulation of NF-κB by PARP-1 in cultured astrocytes with TD 
PARP is involved in the regulation of transcription of several genes by interaction with 
specific transcription factors (Qu et. al., 1994; Meisterernst et. al., 1997; Rawling et. al., 1997; JM 
et. al., 1997 ). To investigate the relationship between PARP and NF-κB during TD, we examined 
NF-κB activation in TD astrocyte cultures treated with or without the PARP-1 specific inhibitor 
DPQ. Transcription factor- NF-κB is located in the cytosol as an inactive complex p50/p65(Rel 
A)/IκB. The NF-κB complex is activated by dissociation of IκB through several signaling pathways 
and it involves phophorylation of IκB (Ghosh et. al., 1998). Using immunoblotting and flow 
cytometry we analysed the levels of phospho-IκB in astrocytes treated with TD. Immunoblotting 
showed that treatment with TD conditions dramatically induced IκB levels in these cells (Fig. 4), 
while co-treatment with the PARP-1 inhibitor DPQ (25 µM) completely blocked this effect, 
indicating that NF-κB activation is responsive to PARP-1. In contrast, NAD+ treatment showed no 
effect on the levels of phospho-IκB.  
 
3.3. Regulation of GLT-1 by NF-κB in TD 
Downregulation of astrocytic glutamate transporters during TD has been reported in our lab 
previously (Hazell et. al., 2003, 2010). However, the mechanism(s) of this downregulation remains 
unknown. Studies using pharmacological and genetic inhibitors suggest that these effects can depend 
on the signaling pathways through PI3K and NF-κB mechanisms (Ghosh et. al., 2011). Figure 5A,B 
shows flow cytometry analysis of GLT-1b in TD astrocyte cultures. Cells treated with TD showed a 
reduction in GLT-1b levels of 54.7% compared to the control group. This downregulation of GLT-
1b protein was blocked in the presence of (DPQ, 25µM) and/or NF-κB inhibitors (PDTC: 50 µM) 
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and NAD+(1mM), suggesting that GLT-1b levels are dependent on both NF-κB and PARP-1. In 
addition, increased levels of phospho-IκB were observed under conditions of TD which were 
partially blocked in the presence of DPQ and PDTC (Fig. 5A,C). However, NAD+ treatment showed 
no effect on the increased levels of phospho-IkB in these TD treated cells.. 
 
3.4. Increased PARP activation inhibits glutamate uptake in astrocytes with TD 
Measurement of glutamate transport in astrocytes co-treated with TD and pharmacological 
specific inhibitors for PARP and NF-κB indicated an impairment of glutamate uptake. Treatment 
with DPQ restored the glutamate uptake capacity of TD astrocytes and this effect was also observed 
after NF-κB inhibition. (Fig. 7).  
 
4. DISCUSSION 
TD results in mitochondrial dysfunction and oxidative stress with major impairment in the 
production of high energy phosphates and nucleotides (Jhala and Hazell, 2011). This increase in 
oxidative stress and onset of an excitotoxic environment can lead to activation of PARP-1 which 
catalyses the synthesis of polyADP-ribose attached to protein acceptors both in neurons and 
astrocytes. The use of PARP inhibitors has therefore been proposed as a protective therapy in 
decreasing excitotoxic neuronal cell death (Eliasson et al., 1994; Zhang et al., 1994; Ha and Snyder, 
2000). In the present study using pharmacological specific inhibitors for NF-κB and PARP; we have 
investigated the relationship between poly (ADP) ribosylation and NF-κB and its role in the 
regulation of glutamate transporters, specifically the GLT-1b splice-variant under conditions of TD. 
Our results suggest that TD produces increased activation of PARP, resulting in the 
activation of NF-κB. The relationship between excessive PARP activation and IκB phosphorylation 
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as a function of NF-κB activation was studied using PARP inhibitor (DPQ) treatment. Our 
findings show that this PARP inhibitor treatment completely blocked the activation of PARP and 
inhibited NF-κB activation in astrocyte cultures. This decreased NF-κB activity under conditions of 
TD in astrocytes also promoted GLT-1b protein expression and increased the overall glutamate 
uptake capacity. In addition, both PARP and NF-κB inhibition were found to promote glutamate 
transporter activity and expression of GLT-1b. Overall, our findings suggest that excessive PARP 
activity induces NF-κB activation leading to its translocation to the nucleus, and this activated NF-
κB complex then leads to the downregulation of glutamate transporters during TD.  
NF-κB is primarily a transcription activator (Baldwin, 1996) and has been shown to promote 
the transcription of many genes including glutamate transporters (Sitcheran et al., 2005; Ghosh et. 
al., 2011). However, there are specific examples where it can also act as a transcriptional repressor 
(Gires et al., 2001; Ke et al., 2001). Thus, our current findings suggest that under conditions of TD, 
PARP-1 overactivation regulates NF-κB-dependent modulation of glutamate transporter GLT-1b in 
astrocytes. 
PARP-1 was one of the first identified substrates of caspases and thus most of the studies on 
PARP-1 and cell death were mostly focused on its possible role in apoptosis (Alnemri et. al., 1996; 
Schreiber et. al., 2006). In apoptosis, caspase 7 and caspase 3 cleave PARP1 into two fragments: 
89kDa and 24kDa. The cleavage of PARP1 separates its DNA binding domain from its catalytic 
domain, which inactivates the enzyme. Interestingly, PARP-1 cleavage occurs differently in necrosis 
from that observed during apoptosis, generating major fragments at 89kDa and 50 kDa and minor 
fragments at 40kDa and 35 kDa (Shah et. al., 1996). However, PARP-1 cleavage is more 
appropriately considered as a marker, rather than an executor of apoptosis (Herceg and Wang, 1999). 
It is well known that NF-κB-related protein family is located in cytosol as an inactive 
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complex (p50/p65(Rel A)/IκB) (Ghosh et al., 1998) and the complex is activated by dissociation 
of IκB through several signalling pathways which involve IκB phosphorylation, and then the 
activated NF-κB complex is targeted to the nucleus (Gilmore, 2006; Perkins, 2007). Activated NF-
κB molecule regulates transcription of several genes primarily as a transcriptional activator 
(Baldwin, 1996). However, under condition of stress in certain pathological conditions NF-κB can 
also act as a transcriptional repressor (Gires et al., 2001; Ke et al., 2001). A very recent report 
indicate that PARP inhibitors, DHIQ and 3-AB, possess free radical scavenging properties (Czapski 
et al., 2004); since oxidative stress has been implicated in TD and in PARP-1 activation, it is 
possible that PARP inhibitors with antioxidative potency contribute indirectly and non-specifically 
to decreased NF-κB dependent transcriptional activity by reduction of reactive oxygen species. 
Thus, poly (ADP) ribosylation is not directly required for repression or stimulation of the 
transcriptional activity of NF-κB under physiological conditions, rather it is involved in indirect 
regulation of NF-κB transcription. 
In conclusion, the findings of this study provide evidence that excessive PARP activation due 
to impaired energy status or oxidative insult as a consequence of TD, promotes NF-κB-dependent 
regulation of the astrocytic glutamate transporter GLT-1b and may be a major contributor to 
excitotoxicity in this disorder. Excitotoxicity is a major pathophysiological event in several 
neurodegenerative diseases, and the present results in TD may provide new insight into mechanisms 
of glutamate transporter dysfunction in these conditions. 
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FIGURE LEGENDS 
 
Figure 1. Photomicrographs of representative astrocyte cultures with or without exposure to TD, 
showing increased PARP-1 immunoreactivity. Bar, 100µM  
 
Figure 2. Immunoblot analysis of PARP-1 cleavage patterns in cultured astrocytes and rats exposed 
to TD. A) Astrocytes exposed to TD showed increased levels of the cleaved 50kDa fragment of 
PARP-1. PARP-1 cleavage was almost completely blocked by the PARP-1 specific inhibitor, 3,4-
dihydro-5[4-(1-piperindinyl) butoxy]-1(2H)-isoquinoline DPQ (25µM), and after exogenous NAD 
(1mM) exposure of astrocytes to TD. B) Rats with TD showed an increase in levels of the PARP-1 
cleaved 24kDa fragment in the vulnerable thalamus and  inferior colliculus compared to PFCs. In 
comparison, the non-vulnerable frontal cortex did not display any changes in the levels of this 
cleavage fragment in any of the three regions examined. Co-treatment of rats with the NF-κB 
inhibitor PDTC did not prevent these changes when compared to animals exposed to TD alone. 
Graphs show relative band intensities of the various treatments. Values are mean ± SEM. 
 
Figure 3. Flow cytometry analysis of PARP-1 in thiamine deficient astrocyte cultures. Astrocytes 
were cultured for two weeks prior to the experiments. TD in astrocytes resulted in an almost 4-fold 
increase in PARP-1 levels compared to control astrocytes. In the presence of DPQ and NAD, PARP-
1 levels were reduced by 61% and 30%, respectively. No significant change was observed in the 
levels of PARP-1 after PDTC administration. The top panel (A) shows percent immunoreactivity for 
GFAP/ PARP-1 in total cell population. The values in each quadarant represent the percentage of 
GFAP+ and PARP-1+ cells. Numbers indicate percentages of main population events within each 
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quadrant for this experiment only. The bottom panel (B) showing the histogram plotted with the 
values obtained as a percent mean of three individual experiments. Values are mean ± SEM. 
 
Figure 4. Immunoblot analysis of phospho-IκB in cultured astrocytes during TD. Cells exposed to 
TD conditions showed a large induction of phospho-IκB which was blocked using the PARP-1 
inhibitor DPQ. However, TD treated astrocytes exposed to exogenous NAD+ (1mM) showed no 
significant change in phospho-IkB levels. Values are mean ± SEM. 
 
Figure 5. Flow cytometry analysis of phopho-IkB and GLT-1b in astrocyte cultures treated with TD. 
Exposure of cells to TD resulted in a downregulation of GLT-1b that was blocked following PARP-
1 (DPQ) and NF-κB (PDTC, NAD+) inhibition (A,B). Increased levels of phospho-IkB were 
observed during TD and were blocked following  PARP-1 (DPQ) and NF-κB (PDTC, NAD+) 
inhibition (A,C). Panel A shows percentage of total immunoreactivity for GLT-1b and IκB following 
different treatments (TD, DPQ, PDTC, NAD+). The values in each quadrant represent the percentage 
of GLT-1b+ and phosphor-IκB-1+ cells. Numbers indicate percentages of main population events 
within each quadrant for this experiment only. B and C shows the histogram plotted with the values 
obtained as a percent mean of three individual experiments for GLT-1b and IκB. Values are mean ± 
SEM. 
 
Figure 6. Effect of PARP-1 or NF-κB inhibition on GLT-1b in astrocytes treated with TD.Cells 
exposed to TD conditions showed a reduction in GLT-1b levels which was ameliorated following 
co-treatment with either the PARP-1 inhibitor DPQ or NF-κB inhibitors PDTC or NAD. Values are 
mean ± SEM. 
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Figure 7. Effect of PARP-1 or NF-κB inhibition on glutamate uptake in astrocytes treated with TD. 
Decreased uptake observed with exposure to TD conditions was ameliorated following co-treatment 
with either the PARP-1 inhibitor DPQ or NF-κB inhibitor PDTC. Values are mean ± SEM. 
Glutamate uptake was measured using the non-metabolized glutamate analogue [3H]-D-aspartate 
(nmol/mg protein/min). Values are mean ± SEM. 
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ABSTRACT 
Loss of astrocytic glutamate transporters is a major feature of both TD and human cases of 
Wernicke’s encephalopathy, in which cerebral energy metabolism is significantly affected. 
However, the underlying basis of this process remains unclear presently. Previous studies have 
reported evidence for the involvement of soluble neuronal factors that can regulate the levels of 
these glutamate transporters. In the present study we have investigated the possibility of release of 
astrocytic soluble factors that might be involved in the regulation of the glutamate transporter GLT-1 
on these cells. Treatment of naïve astrocytes with conditioned media from astrocytes exposed toTD 
conditions resulted in a progressive decrease in glutamate uptake over 24h, along with increased 
release of glutamate. Immunoblotting and flow cytometry measurements indicated this was 
accompanied by a 20-40% loss of GLT-1 in these cells. Lactic acid, produced in astrocytes as a 
consequence of TD, was found to decrease glutamate uptake as with TD conditioned media but 
exerted no effect on the downregulation of GLT-1. Determination of the mitochondrial membrane 
potential (Δψm) in naïve astrocytes using the membrane potential-dependent aggregate-forming 
lipophilic cation JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazole carbocyanide iodide) 
indicated that treatment of astrocytes with either TD or TD conditioned media showed increased 
disruption of Δψm compared to control cells.Treatment of astrocytes with TD resulted in an increase 
in the pro-inflammatory cytokine TNF-α and elevated levels of the phospho-IκB fragment, 
indicative of increased activation of NFκB. Inhibition of TNF-α activity with the use of a 
neutralizing antibody blocked the increased NFκB activation, while inhibition of NFκB ameliorated 
the decrease in GLT-1 and reversed the decrease in glutamate uptake occurring with TD treatment. 
Interestingly, inhibition of either TNF-α activity or NFκB activation failed to prevent the loss in 
glutamate uptake following treatment of astrocytes with TD conditioned media, suggesting that 
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TNF-α and NFκB contribute to loss of glutamate transporter function in astrocytes with TD but 
that these factors are not effective in, or sufficient for, reducing transporter function in normal 
astrocytes exposed to TD-conditioned media. Together, these findings indicate that astrocytes 
exposed to TD conditions show a number of responses suggesting that soluble factors released by 
these cells under conditions of TD play a regulatory role in terms of glutamate transport function and 
mitochondrial integrity.  
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INTRODUCTION 
Thiamine deficiency (TD), the cause of Wernicke’s encephalopathy (WE), is implicated in 
the impairment of mitochondrial energy metabolism in both neurons and astrocytes. These two cell 
types have fundamental differences in their responses in various CNS pathologies (Pekny and 
Nilsson, 2005.). Astrocytes are highly abundant cells in the brain and play an important role in 
normal synaptic transmission (Araque et al., 2001; Muyderman et al., 2001; Fields and Stevens-
Graham, 2002). Many functions of astrocytes are likely to be important in determining the tissue 
response to TD or other CNS pathology, including their role in the control of fluid movements 
between the intracellular and extracellular space, the ability to take up glutamate and reduce 
excitotoxicity, and their involvement in spatial buffering (Anderson et al., 2003).  
TD is a metabolic disorder that occurs due to inhibition of oxidative decarboxylation of 
pyruvate and α-ketoglutarate, leading to decreased ATP production, pyruvate accumulation and 
increased lactate production (Aikawa et al., 1984; Navarro et al., 2005). During TD, both neuronal 
and astrocytic intermediary metabolism is impaired and protective astrocytic functions, such as 
glutamate uptake, K+ buffering, or elimination of reactive oxygen species (ROS) become 
compromised (Jhala et. al., 2011; 2010; Hazell et al., 2003; Hazell et al., 1998).  
Treatment with pyrithiamine, a thiamine antagonist, results in downregulation of the 
astrocytic glutamate transporters GLT-1 and GLAST (Jhala et. al., 2011; Hazell et. al., 2001; 2003), 
a process also occuring in human cases of WE (Hazell et. al., 2010). Although the mechanism of this 
transporter dysfunction is still unclear, a few studies have reported the role of extrinsic factors in the 
regulation of glutamate transporter activity. Exogenous lactate administration to cultured astrocytes 
inhibit glutamate uptake capacity by its effects on astrocyte cell swelling and acidification (Bender 
et al., 1997). Lactic acid acidosis may inhibit glutamate uptake directly by its effect on the 
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transporters, possibly by affecting charged groups on the glutamate carrier proteins thereby 
altering the tertiary structure of the transporter (Barbour et. al., 1988). Thus, decreased glutamate 
uptake could also occur due to ionic imbalance. In addition, increased release of ROS along with 
increased TNF-α, are known to induce glutamate neurotoxicity by inhibition of glutamate uptake 
(Zou and Crews, 2005).  
Treatment of astrocytes with lactate leads to a reduction in glutamate uptake (Bender et al., 
1997). In addition, increased pro-inflammatory cytokine production has been shown to inhibit 
glutamate uptake capacity and has been linked to the pathogenesis of excitotoxicity (Zou and Crews, 
2005). In the present study, we therefore investigated whether TD-induced loss of glutamate 
transporter activity is due to accumulation of lactate or an inflammatory-based process.  
 
2. EXPERIMENTAL PROCEDURE 
2.1 Cell culture preparation 
Astrocyte cultures from newborn rats were prepared using a method described by Booher and 
Sensenbrenner (1972) with slight modifications. Briefly, cerebral cortices were removed and the 
tissue was dissociated mechanically and passed through sterile nylon sieves, and then suspended in 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Burlington, ON) containing 10% fetal 
calf serum. Cells were then seeded in 35 mm culture plates, which were maintained in an incubator 
at 37°C provided with a mixture of 5% CO2 and 95% air. Cultures were grown for 3–5 weeks, 
during which the medium was changed twice a week. To induce TD, cells were exposed to a 
custom-designed DMEM media lacking in thiamine (Invitrogen, Burlington, ON) and containing 5% 
horse serum, in the presence of the thiamine antagonist pyrithiamine (10 µM). Control astrocytes 
were treated with TD media in which normal levels of thiamine (4 mg/L) had been added. Media 
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was changed every 3-4 days. 
2.2 Production of GLT-1b antibody 
A polyclonal antibody against the synthetic peptide ECKVPFPFLDI ETCI corresponding to 
the last 15 amino acids of (amino acid 548–562) of the GLT-1b splice-variant and conjugated to 
keyhole limpet hemocyanin (Sheldon Biotechnology Centre, Montreal, QC) was generated in rabbits 
using a standard protocol (Comparative Medicine & Animal Resources Centre, Mcgill University). 
The GLT-1b sequence that was chosen represents a unique carboxyl terminal region and has no 
similarity with other sequences in the standard gene database (Chen et. al., 2002; Bassan et. al., 
2008). The specificity of the antiserum was initially evaluated by immunoblotting as previously 
described (Hazell et. al., 2003). Immunodetection was performed using the primary antiserum at a 
range of dilution (0.01- 0.1 µg/mL).  
 
2.3 Immunoblotting studies 
Cell culture plates were harvested in buffer containing 50 mM Tris, 150 mM NaCl, 0.1% 
sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate (pH 8.0) and protease 
inhibitor cocktail, and centrifuged at 10,000g for 10 min at 4oC. Preliminary studies carried out on 
the pellet and supernatant indicated that GLT-1 was completely soluble in this buffer under our 
conditions. Thus, the supernatant was retained and used for study. Protein content of all samples was 
determined by the method of Lowry et al. (1951) using bovine serum albumin (BSA) as the 
standard. Sample buffer was added to aliquots of the cells (30 µg) and the samples boiled for 5 min. 
Aliquots were subjected to (SDS)-polyacrylamide gel electrophoresis (8% polyacrylamide) and the 
proteins subsequently transferred to PVDF membranes by wet transfer at 20 V over 24 h. The 
transfer buffer consisted of 48 mM Tris (pH 8.3), 39 mM glycine, 0.037% SDS, and 20% methanol. 
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Membranes were subsequently incubated in blocking buffer (10 mM Tris, 100 mM NaCl, 5% 
non fat dried milk) followed by incubations with rabbit polyclonal antisera directed against GLT-1b, 
phosphor IκB (Cell Signaling Technology, Inc., Danvers, MA). Reblocking was followed by 
incubation with HRP-coupled anti-rabbit IgG (0.01 lg/mL) secondary antiserum. Each incubation 
step was of 1h duration following which blots were washed several times with buffer (10 mM Tris, 
100 mM NaCl, and 0.1% Tween-20). For the detection of specific antibody binding, the membranes 
were treated in accordance with the ECL-kit instructions and developed on a photosensitive X-
OMAT film. Signal intensities were subsequently measured by densitometry using ImageJ software 
(National Institutes of Health , Bethesda, ML). Linearity of the relationship between optical density 
and protein concentration was verified using appropriate standard curves. Blots were reversibly 
stained with Ponceau-S to monitor protein transfer efficiency and equal loading.  
 
2.4 Immunocytochemistry 
Immunocytochemistry was perfomed as previously described, Hazell et al. (2001). Briefly, 
astrocytes were washed in  PBS and fixed for 10 min with 10% neutral buffered formalin. After 
washing cells were blocked for 30 min with 1% donkey serum in PBS, and then incubated with 1% 
donkey serum and polyclonal goat antisera directed against GFAP (1:200, Santa Cruz 
Biotechnology, Santa Cruz, CA). Sections were then washed (10 min) and incubated for 1 h with 
Alexa Fluor-488 (green) secondary antibody (1:200), then mounted in Prolong Gold AntiFade 
reagent and examined using an Olympus BX51 microscope and attached Spot RT digital camera. 
Negative controls consisted of omission of primary or secondary antibody, resulting in loss of 
immunoreactivity. Images were processed using Image-Pro Plus 6.2 image analysis software (Media 
Cybernetics, Inc., Bethesda, MD). 
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2.5 Changes in Mitochondrial Membrane Potential 
Cultured astrocytes were analyzed for changes in the mitochondrial membrane potential 
(Δψm) using the potential-dependent aggregate-forming lipophilic cation JC-1 (5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazole carbocyanide iodide) (Invitrogen, Burlington, ON). Cells were 
assayed according to the manufacturer’s instructions. Changes in astrocytic Δψm in TD and TD 
media treated astrocytes were quantified by FACScan flow cytometry. Images were captured using 
an Olympus BX51 microscope (original magnification ×100) and merged using Image J software 
(Wayne Rasband, NIH). 
 
2.6 Flow cytometry 
Astrocytes were harvested in papain solution (Worthington Biochemical Corp., Lakewood, 
NJ) for 15-20 min and resuspended in flow cytometry buffer, consisting of 1X PBS, pH 7.2, 1% fetal 
bovine serum (Invitrogen, Burlington, ON). Cells were counted and diluted to a density of 1x106 
cells per milliliter of buffer. Aliquotes of 1 x 105 cell were incubated with polyclonal antisera 
directed against GLT-1b (Cell Signalling Technology, Inc., Danvers, MA) and polyclonal goat 
antisera directed against GFAP (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), for 30 min on 
ice. Cells were washed in buffer, and then specific secondary fluorescent-conjugated antibodies, 
Alexa fluor-592 conjugated anti-mouse IgG and Alexa fluor-488 conjugated anti-rabbit IgG 
(Invitrogen, Burlington, ON) was added at the appropriate dilution (1:100) and incubated on ice for 
15 minutes.  Viable cells were gated by light scatter and were analyzed by FACScan (BD LSRII) 
(BD Biosciences, Mississauga, ON) using a Cell Quest program (BD Biosciences, Mississauga, 
ON). Fluorescence background was measured using unlabeled cells and cells labeled with secondary 
antibody alone; these set gating parameters between positive and negative cell populations. Cell 
   
 
 
117
aggregates and small debris were excluded from analysis or isolation on the basis of side scatter 
(measuring cell granularity) and forward scatter (measuring cell size). Fluorescent intensities for 
cells in the population were plotted as quadrants and/or histograms using CellQuest software (BD 
Biosciences, Mississauga, ON). All statistical calculations were done using GraphPad Prism 
(GraphPad, software, Inc. La Jolla, CA).  
 
2.7 Glutamate uptake 
Glutamate uptake study was performed as described according to Hazell et al (2003) with 
some modifications. Briefly, cells were incubated in DMEM media containing the glutamate 
analogue D-aspartate and 0.2 µCi/ml of [3H]-D-aspartate in 5% CO2 /95% air at 37°C, the 
incubation time for all experiments being of 2 min duration. Uptake was stopped by aspiration of the 
media and rapid washing of cells three times with ice-cold PBS. Cells were then harvested with 0.5 
ml of 1 M NaOH. Sample aliquots were measured for protein content (Lowry et al., 1951) and the 
radioactivity for determination of the uptake rate was measured by liquid scintillation counting. 
 
2.8 Glutamate release 
Glutamate release was performed using D-[3H] aspartate, a non-metabolizable  analog of 
glutamate. D-Asp is very commonly used to study L-Glu release, although the release rates may 
differ slightly for L-Glu and D-Asp. Briefly, cells were incubated for 15 min with 1 ml of D-Asp 
(1.0 µCi/ml) at 37oC to radiolabel the cells. After washing, release was measured by incubating the 
cells with 1 ml of DMEM media, which was replaced every 5 min (Bender et. al., 1997). The 
radioactivity was measured for the collected medium (media collected every 5 min for 30 min) by 
liquid scintillation counting. 
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2.9 Lactate assay 
L(+)-Lactate was assayed in medium collected from the TD astrocyte cultures at 0, 4, 7 10 
days, using a lactate assay kit (K627-100, BioVision Inc., Milpitas, CA) according to the 
manufacturer’s instructions. The assay was performed after the medium collected and mixed with 
the appropriate reagents as provided with the kit. The optical density of the samples was measure at 
450nm in a microplate reader. The absorbances were initially converted to nmol/µl using standard 
curves prepared at different concentration supplied with the kit. 
 
2.10 Measurement of TNF-α using ELISA and treatment of astrocytes with anti-TNF-α 
neutralizing antibody 
Protein levels of TNF-α was measured in astrocyte cultures using a commercial ELISA kit 
(R&D Systems, Minneapolis, MN; Invitrogen, Burlington, ON) according to the manufacturer’s 
instructions. The plates were read at 450 nm and the absorbances were converted to pg/mL using 
standard curves prepared with recombinant cytokines. Astrocytes were treated with anti-TNF-α 
neutralizing antibody (R&D systems, Minneapolis, MN) at a concentration of 0.5µg/ml according to 
the manufacturer’s guidelines. 
2.11 Statistical analysis 
Data are expressed as mean ± S.E.M. values. Statistical analysis was performed using one 
way ANOVA for multiple  comparisons. A probability of p < 0.05 was chosen to establish 
significance between groups. Data were analyzed by using Prism 4.0 software (GraphPad Software, 
Inc., San Diego, CA). 
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3. RESULTS 
3.1 General observations 
When astrocytes were stimulated with dBcAMP (0.5 mM), polygonal astrocytes 
differentiated into process bearing, stellate cells. Treatment with TD for 10 days produced 
alterations in cell morphology (Fig. 1). TD resulted in a reduction of astrocytic processes, towards a 
less fibrous shape compared to controls. However, naïve astrocytes treated for 24h with conditioned 
media from TD treated cells showed no change in morphology from that observed in control 
astrocytes. 
 
3.2 Treatment with TD conditioned media 
To examine if astrocyes respond to conditioned media from TD treated cells, we studied its 
effect on glutamate uptake and release in naïve astrocytes exposed to conditioned media for 24h. 
Figure 2A shows a progressive decrease in glutamate uptake with time with uptake reduced by over 
70% after 24h. Treatment with conditioned media resulted a 2-fold increase in glutamate release 
(Fig. 2B). Next, we assessed whether these alterations in glutamate transport were caused by a 
change in the regulation of GLT-1 using immunoblotting. Immunoblot analysis of conditioned 
media-treated astrocytes indicated a 40% loss of GLT-1 compared to controls (Fig. 3A,C). To 
further confirm and quantify this finding we used flow cytometric analysis, with 24h treatment with 
TD conditioned media showing a 20% decrease in the level of GLT-1, consistent with the 
immunoblotting results given its limitations (Fig. 3B,C). Together, these findings indicate that 
soluble factors released from astrocytes exposed to TD conditions downregulate glutamate 
transporter levels. 
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3.4 Involvement of lactate in TD-induced glutamate transporter dysfunction 
To specifically address the involvement of lactate accumulation in TD-induced loss of 
glutamate transporter function, we measured lactate concentration in the culture medium at 0, 4, 7, 
10 d after exposure of the cells to TD. The extracellular lactate concentration on day 4 of TD was 0.4 
± 0.0 nmol/µl compared to that in the media from control cells showing 0.3 ± 0.0 nmol/µl (Fig. 4A). 
TD did not increase bulk lactate concentration in the medium at this time point, but increased lactate 
concentration was observed after 7 and 10 days (0.6 ± 0.0 and 0.5 ± 0.0 nmol/µl respectively) 
compared to control plates. To determine if extracellular lactate accumulation under conditions of 
TD might be responsible for glutamate transporter dysfunction, we treated naïve astrocytes with 25 
mM exogenous lactate. Lactate treatment decreased glutamate uptake after 24h treatment to a similar 
extent as did conditioned media (Fig. 4B), suggesting an involvement of extracellular lactate 
accumulation in glutamate transporter dysfunction in TD. However, immunoblot analysis of cultured 
astrocytes exposed to lactate showed no change in protein levels of GLT-1 (Fig. 4C).  
 
3.5 Effect of TD conditioned media on mitochondrial function  
We used JC-1 to probe mitochondrial function by imaging the monomeric form (green) and 
the aggregate form (red) of this fluorescent probe. A decrease in red fluorescence and an increase in 
green fluorescence in TD astrocytes were observed, indicating Δψm collapse (Fig. 5I). CCCP (1 
µM/ml) treatment for 10 min was used as a positive control in these experiments. TD astrocytes 
showed abrupt change in Δψm values and, similar to TD, treatment with TD conditioned media 
(24h) showed increased mitochondrial depolarization in naïve astrocyte cultures. Next, to 
quantitatively assay JC-1 signals, we used flow cytometry to compare the ratio of the monomeric 
form to that of the aggregate form (Fig. 5II). Accumulative fluorescence intensity for JC-1 monomer 
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representing the extent of Δψm depolarization was significantly higher in TD (~46%) and TD 
conditioned media treated astrocytes (~27%) relative to control astrocytes (~4%). The data obtained 
from flow cytometry confirmed the findings of cellular imaging with the results indicating that 
soluble factors released from TD treated astrocytes produce mitochondrial dysfunction in naïve 
astrocytes. 
 
3.6 Influence of oxidative stress on the effects of TD conditioned media on glutamate transport 
function 
To examine if oxidative stress may play a role in the effects of TD conditioned media on 
glutamate transporters in TD, astrocytes treated with TD conditioned media were also exposed to the 
antioxidants DTT and glutathione. Treatment with DTT and reduced glutathione ameliorated the 
increase in release of glutamate but had no effect on decreased glutamate uptake compared to 
conditioned media treated naïve astrocytes (Fig. 6A,B, respectively).  
 
3.7 Involvement of TNF-α dependent NFκB activation in glutamate transporter dysfunction 
To investigate the role of TNF-α and its associated NFκB activation in the loss of glutamate 
transporters under conditions of TD, we used ELISA and immunoblotting respectively to 
specifically measure the relative levels of TNF-α in astrocytes exposed to TD conditions. TD 
treatment resulted in increased production of TNF-α (Fig. 7A) and elevated levels of the phospho-
IκB fragment, indicative of increased activation of NFκB (Fig. 7B). Inhibition of TNF-α activity in 
astrocytes with TD by treatment with a specific anti-TNF-α neutralizing antibody prevented the 
increase in levels of phospho-IκB fragment (Fig. 7B). In addition, exposure to the specific NFκB 
inhibitor PDTC (100µM) produced an amelioration of the loss of GLT-1 in astrocytes with TD (Fig. 
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7C) and restored glutamate uptake capacity (Fig. 7D).  
To determine if accumulation of TNF-α in the medium from TD-treated astrocytes 
contributes to the glutamate transporter downregulation observed in astrocytes exposed to this 
conditioned media, naïve cells exposed to conditioned media were co-treated with either anti-TNF-α 
neutralizing antibody or PDTC. Figure 8 shows that inhibition of either TNF-α activity or NFκB 
activation in astrocytes failed to prevent the decrease in glutamate uptake observed with conditioned 
media treatment.  
 
4. DISCUSSION 
Excitatory amino acid transporters located on astrocytes play a crucial role in maintaining 
normal levels of extracellular glutamate. Loss of these transporters in TD has been reported from our 
lab previously Hazell et. al., 2001,2003; Jhala et. al., 2011). However, the mechanism of the loss of 
transporters under conditions of TD remains unresolved. Previous studies have identified that 
soluble factors released by neurons can influence levels of astrocytic glutamate transporters 
(Gegelashvili et al., 1997). Under conditions of impaired energy metabolism, astrocytes may 
produce chemical factors that not only can regulate glutamate transporter function from inside the 
cell, but these factors may also exit the cells and can potentially be measured and identified by their 
influence(s) on normal cells. In the present study, using our in vitro TD astrocyte culture model we 
investigated the effects of TD conditioned media on glutamate transport function. Our results 
indicate that naïve astrocytes treated with TD astrocyte culture media show a number of responses 
suggesting that soluble factors released by these cells under conditions of TD play a regulatory role 
in terms of glutamate transport function and mitochondrial integrity.  
Treatment of normal astrocytes with TD conditioned media resulted in a loss of glutamate 
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uptake and increased glutamate release from these cells. This indicates that certain factors in the 
media previously exposed to astrocytes with TD exert a regulatory influence on glutamate 
transporters in these cells. Stimulation of glutamate release may contribute to glutamate uptake 
inhibition. For example, under depolarizing conditions such as during increased  neuronal activity, 
high extracellular K+ concentration can produce reversal of glutamate transporters and a resulting 
increased release of glutamate, with the overall effect being a decrease in glutamate uptake 
(Kimelberg et al., 2005). Our findings that the decreased uptake with TD conditioned media is 
associated with  a decrease in the levels of GLT-1 in untreated astrocytes indicates that soluble 
factors are able to alter the protein expression of this transporter. Exactly how this regulation occurs 
is unclear but it can occur via a direct effect on gene expression or via an indirect effect involving 
other influences.  
An example of the latter possibility is lactate accumulation due to the resulting metabolic 
impairment associated with TD producing dysregulation of glutamate transport capacity. Increased 
accumulation of lactate under conditions of TD has been described in vulnerable areas of brain 
(Hakim, 1984; Navarro et. al., 2005) and C6-glioma cells, neuroblastoma cell lines and endothelial 
cells (Ham and Karska-Wysocki, 2005; Schwartz et. al., 1975). Previous studies have demomstrated 
that lactate production inhibits glutamate uptake (Bender et al., 1997) although the exact mechanism 
for this is still unclear. In the present study, we showed that lactate accumulates in the media during 
exposure of astrocytes to TD conditions, and that exogenous application of lactate to cells decreases 
glutamate uptake similar to the conditioned media. However, lactate did not decrease GLT-1 levels, 
suggesting the influence of lactate is likely restricted to alterations in activity of the transporter 
rather than a change in gene expression. Thus other factors are also likely to be involved in 
downregulation of GLT-1 in astrocytes exposed to TD conditioned media. 
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To further examine the nature of these soluble factors, an evaluation of the influence of 
these factors on mitochondrial functional integrity was performed. Impaired energy metabolism and 
mitochondrial dysfunction have been implicated in the pathogenesis of TD (Aikawa et al., 1984; 
Pannunzio et. al., 2000). We addressed this issue using conditioned media from TD astrocytes to see 
whether TD extracellular factors released by the astrocytes have the ability to induce mitochondrial 
dysfunction using the Δψm -dependent aggregate-forming lipophilic cation JC-1. Our findings 
indicate that factors present in the TD conditioned media are able to produce depolarization of Δψm 
within 24 hr following exposure of the media to cells. Therefore, these soluble factors rapidly exert 
an effect on mitochondrial integrity, likely leading to loss of GLT-1 due to the consequential 
negative effects on ATP production.  
Oxidative stress is a major contributing factor in the pathophysiology of TD (Jhala and 
Hazell, 2010) and increased production of ROS has been reported in TD animals (Langlais et al., 
1997). Treatment of the conditioned media with antioxidants did not alter the decrease in glutamate 
uptake, but reduced the increase in glutamate release in naïve astrocytes. This suggests an influence 
of oxidative stress on certain aspects of glutamate transport but not others, which indicates the action 
of ROS likely present in the media  is limited in its effects on the transporter protein under these 
conditions.  
The proinflammatory cytokine tumor necrosis factor-a (TNF-α) is a 17-kDa peptide and 
forms multimers that binds to TNF-α receptors which is expressed in both neurons and glia cells 
(Benveniste et. al., 1995). TNF-α can be synthesized and released in the brain by astrocytes, 
microglial, and some neurons and the increased expression and release of TNF-α have been reported 
in various pathological conditions, such as trauma, ischemia, and inflammatory diseases (Allan and 
Rothwell, 2001;  Liu et. al., 1994; Wang et. al., 1994). Clinical studies have found increased 
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expression of TNF-α in cerebrospinal fluid (CSF), plasma, or post mortem brain tissue in 
patients following stroke, brain injury, HIV dementia, alcoholism, and Alzheimer’s disease (Allan 
and Rothwell, 2001; Khoruts et. al., 1991). In addition, it has been suggested that increased level of 
TNF-α in the brain can also leads to the activation of nuclear transcription factor NFκB. Moreover, 
TNF-α dependent NFkB activation is also implicated in the pathogenesis of glutamate neurotoxicity 
(Zou and Crews, 2005). Furthermore, increased levels of TNF-α has been shown to inhibit glutamate 
transport activity in the organotypic hippocampal slice culture. In the present study, we showed that 
TNF-α dependent activation of NFκB transcription factor plays a major role in the regulation of  
glutamate transporter function in astrocytes under conditions of TD. Our findings suggest that TNF-
α and NFκB contribute to loss of glutamate transporter function in astrocytes with TD but that these 
factors are not effective in, or sufficient for, reducing transporter function in normal astrocytes 
exposed to TD-conditioned media. Further studies are required to investigate the ramifications of 
NFκB activation and the detailed basis of TNF-α dependent regulation of glutamate transporters 
during TD. 
Another potential mechanism by which lactic acid in TD conditioned media decreases 
glutamate uptake is due to lactic acid-induced swelling. Astrocyte swelling has been shown to 
inhibit glutamate uptake and increase glutamate release in the culture astrocytes (Kimelberg, et. al., 
1995). However, blocking astrocytic swelling by treatment with D-mannitol had no effect on lactic 
acid mediated decrease in glutamate uptake, suggesting swelling does not contribute to the 
mechanism of lactic acid-induced inhibition of glutamate uptake (Bender et. al., 1997).  
Excitotoxicity is an important event in the pathogenesis of TD. Thus it is essential for our 
understanding to study the signaling pathways that might be involved in the regulation of glutamate 
transporters. In previous studies we have reported increased extracellular glutamate concentration in 
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focal areas of damage in TD animals, and loss of glutamate transporters and their function under 
both in vivo and in vitro conditions. Findings from the present study thus provide an alternative 
mechanism of release of soluble factors from astrocytes during TD that might contribute to 
glutamate transporter regulation under these conditions.  
In conclusion, major findings of this study indicate that the release of lactic acid, TNF-α and 
other soluble factors may contribute to decreased glutamate transport capacity during TD. Additional 
studies are required to further investigate the nature of these factors released by metabolically 
impaired astrocytes and their precise role in glutamate transporter loss in TD.   
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FIGURE LEGENDS 
 
Figure 1. Representative cultures of astrocytes immunostained for GFAP. Cells exposed to 
dBcAMP for one week to induce the GLT-1 transporter protein were subsequently treated with 
either TD conditions for 10 days (B) or TD conditioned media for 24h (C). Compared to control 
astrocytes (A), cells exposed to TD conditions exhibited a reduction in processes, appearing to 
partially revert towards a less fibrous (non- dBcAMP treated) morphology, while treatment with 
conditioned media (CM) from TD treated astrocytes for 24h produced no obvious change in 
morphology. Bar, 50 µm. 
 
Figure 2. Treatment of TD conditioned media in naïve astrocytes resulted in a decrease in glutamate 
uptake and increased glutamate release. 
 
Figure 3. Effect of TD conditioned media on glutamate transporter levels in naïve astrocytes. Cells 
exposed to conditioned media showed loss of GLT-1 with immunoblotting (A) which was confirmed 
with flow cytometry analysis (B,C). 
 
Figure 4. Effect of lactate on glutamate transporter integrity in astrocytes. A) Lactate levels in the 
media of astrocytes treated with TD over 10 days. Extracellular lacate concentration increased 
during TD. B) Treatment with TD conditioned media or lactic acid (25mM) both inhibited glutamate 
uptake to a similar extent. C) Immunoblot analysis of GLT-1 protein showed that lactic acid 
treatment for 24 h did not alter GLT-1 levels from controls. 
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Figure 5. I) Analysis of mitochondrial membrane potential (Δψm) in astrocytes with TD or after 
treatment of naïve astrocytes with TD conditioned media. Δψm was analyzed using the membrane 
potential-dependent aggregate-forming lipophilic cation JC-1. Red fluorescence indicates JC-1 
aggregates (a) representing mitochondria with intact membrane potential whereas green fluorescence 
indicates JC-1 monomers (b) representing de-energized mitochondria. Images show treatment of A) 
naïve astrocytes treated with the mitochondrial membrane potential disrupter CCCP, B) control 
astrocytes, C) naïve astrocytes treated with TD, and D) naïve astrocytes treated with TD conditioned 
media. II) Flow cytometric determination of Δψm changes in control astrocytes (i), astrocytes 
exposed to TD (ii), and naïve astrocytes treated with TD conditioned media (iii). TD media treated 
astrocytes quantified by FACScan flow cytometry. Values represent mean intensity ± SEM of Alexa 
Fluor 488, green fluorescence, for n=6.  
 
Figure 6. Influence of antioxidants on the effects of TD conditioned media on glutamate transport 
function in astrocytes. A) Co-treatment of naïve astrocytes with conditioned media and the 
antioxidants DTT or reduced glutathione (GSH) showed no effect on the inhibition of glutamate 
uptake produced by conditioned media treatment alone. B) Co-treatment with DTT or GSH 
ameliorated the increase in glutamate release produced by TD conditioned media on astrocytes.   
 
Figure 7. Involvement of TNF-α dependent NFkB activation in glutamate transport dysfunction. TD 
increased TNF-α production in astrocytes (A) and resulted in increased activation of NFkB (B). 
Inhibition of TNF-α using an anti-TNF-α neutralizing antibody blocked the heightened activation of 
NFkB. Pharmacological inhibition of NFkB using the specific NFkB inhibitor PDTC (100µM) 
reduced the GLT-1 loss in TD astrocytes (C) and restored the glutamate uptake capacity of the TD 
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astrocytes (D). 
 
Figure 8. Involvement of TNF-α dependent NFkB activation in glutamate transporter dysfunction in 
naïve astrocytes treated with TD conditioned media. Inhibition of TNF-α using anti-TNF-α 
neutralizing antibody or direct inhibition of NFkB using PDTC (100µM) showed no effects on 
glutamate uptake inhibition by TD conditioned media (TDcm) treated naïve astrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
136
 
 
 
 
 
 
 
 
      
 
 
 
  
 
      FIGURE 1 
 
 
 
 
   
 
 
137
 
 
 
 
FIGURE 2 
 
 
 
 
   
 
 
138
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 
 
 
 
 
   
 
 
139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 
 
 
 
 
 
   
 
 
140
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 
 
 
 
 
 
 
   
 
 
141
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 
 
 
 
 
 
   
 
 
142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      FIGURE 7 
 
 
 
 
   
 
 
143
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
FIGURE 8  
 
 
 
 
 CHAPTER 5 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 145
5.1 REGULATION OF ASTROCYTIC GLUTAMATE TRANSPORTERS 
DURING THIAMINE DEFICIENCY 
 
This section constitutes a discussion and overview of the main findings of the three 
articles presented in the thesis. 
 
5.1 Ceftriaxone protects against GLT1b splice variant loss in TD 
Data presented in the first article examined the effects of ceftriaxone on the 
glutamate transporter splice variant GLT-1b in TD and in cultured astrocytes under 
conditions of TD. The results of this study suggest that TD results in the loss of GLT-1b 
in the vulnerable thalamus and inferior colliculus, while no change was observed in the 
non vulnerable frontal cortex. Similar findings were obtained with TD treated astrocyte 
cultures. Concomitantly, significant reductions in the uptake of D-aspartate (a non-
metabolizable analog of glutamate) was observed. These findings extend earlier 
observations of suppressed high affinity glutamate/D-aspartate uptake and loss of 
glutamate transporters under conditions of TD described by Hazell et. al (2003). 
Recently, Rothstein and colleagues (2005) have investigated the effects of ceftriaxone, a 
β-lactam antibiotic on GLT-1 expression. The authors reported that ceftriaxone confers 
neuroprotection against ischemic and motor neuron degeneration by GLT-1 upregulation. 
We attempted to extend this hypothesis under conditions of TD. Results of our study 
indicate that ceftriaxone upregulates GLT1-b levels in the inferior colliculus, with no 
significant changes in the thalamus and frontal cortex in TD rats.  In addition, ceftriaxone 
also stimulated glutamate uptake and upregulated GLT-1b levels in astrocytes during TD. 
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Decreased uptake of D-aspartate/glutamate may be a result of a loss in glutamate 
transporter uptake capacity or due to decreased expression of glutamate transporters.  
Since protein levels of the GLT-1b splice variant were significantly altered under 
conditions of TD, this suggests that the TD suppressive effect on astrocytic glutamate 
uptake occurs at the level of transporter expression. Next, to extend this possibility we 
analysed the GLT-1b mRNA expression, the results of which showed no significant 
change in the expression pattern. Thus in contrast to GLT-1b protein levels, the lack of 
alteration in GLT-1b expression indicates that effects of TD on astrocytic glutamate 
uptake are likely determined by post-translational mechanisms. The decrease in 
glutamate transporter protein levels with no change in the mRNA expression is consistent 
with previous studies, e.g. glutamate-mediated increase in GLAST protein levels was not 
accompanied by an increase in the expression of mRNA (Swanson et .al., 1999). Such 
loss of glutamate transporters is regulated at different levels through different signalling 
pathways depending on the stimulating factors. 
Ceftriaxone has proven to be a protective strategy against excitotoxicity and 
oxidative stress in stroke, cocaine relapse, hypobaric hypoxia and Huntington’s disease. 
Consistent with the earlier findings of ceftriaxone mediated neuroprotection, results of 
our study suggest that ceftriaxone mediated neuroprotection against excitotoxicity also 
operates under conditions of TD.  
These region specific effects of ceftriaxone are potentially due to selective 
vulnerability of certain brain areas to local differences of blood supply (Gibson et. al., 
1997), differences in tissue requirements for TPP (Dreyfus, 1959), differences in GLT-1 
content (Danbolt et. al., 1998) in the inferior colliculus and thalamus during TD. In 
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addition, activation of NF-κB by ceftriaxone, a transcription factor that plays a role in 
regulating immune responses and cell survival, has been proposed as an alternative 
mechanism in the regulation of glutamate transporter, GLT-1 by ceftriaxone. It has been 
reported that ceftriaxone acts as a potential stimulator of NF-κB activation and its 
translocation into the nucleus resulting in increased GLT-1 promoter activity (Lee et. al. 
2008). However, TD results in no significant alterations in GLT-1 mRNA levels, thus it 
is likely that ceftriaxone mediated effects on the increased protein levels of GLT-1b is 
due to its effects on posttranslational mechanisms. Furthermore, it is interesting in this 
regard that palmitoylation, a process by which proteins are inserted into cellular 
membranes, is reduced for GLT-1 under certain pathological conditions (Huang and El-
Husseini, 2005; Huang et. al., 2010), it would be interesting to see if ceftriaxone 
increases GLT-1 palmitoylation during TD.   
 
5.2 Regulation of glutamate transporters by PARP-1 and NF-κB signaling pathways 
The second article presented in my thesis deals with the mechanisms involved in 
the loss of glutamate transporters under conditions of TD. It is evident from past studies 
that NF-κB can act both as a positive or negative modulator of glutamate transporter 
regulation. The action of NF-κB as a positive regulator of glutamate transporters has been 
linked to ceftriaxone, brain-derived neurotrophic factor, β-amyloid, amitriptyline, EGF, 
TGF-α, and dbcAMP, as well as bromo-cAMP dependent upregulation of GLT-1 (Lee et 
al., 2008). On the contrary, inhibition of NF-κB signalling pathways has been shown to 
restore GLT-1 promoter activity during treatment with TNF-α. This was further 
confirmed with the identification of a consensus sequence for NF-κB binding within the 
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5′-untranslated region of the GLT-1 complementary DNA (cDNA) clones (Meyer et al. 
1996). Thus, NF-κB activation is a diverse phenomenon in the regulation of glutamate 
transporters and it may act both as a repressor or activator depending on the nature of 
pathological stimuli. Based on the previous findings we hypothesized that NF-κB 
dependent signaling pathways contribute to the loss of glutamate transporters in TD, and 
NF-κB signaling in astrocytes in part is regulated by PARP-1 mechanisms. Support for 
this possibility was provided by our demonstration that TD results in activation of PARP-
1 both in vivo and in vitro and inhibition of PARP-1 activity significantly blocked NF-κB 
activation and protects against the loss of GLT-1 transporters in the astrocytes.  
Data presented in this study revealed a potential link between glutamate signaling 
and NF-kB activation in relation to poly (ADP) ribosylation under conditions of TD. 
Excessive oxidative DNA strand breaks lead to PARP-1-induced depletion of cellular 
NAD, glycolytic rate, ATP levels, and eventual cell death. Blocking PARP-1 activity 
using knock-out or siRNA for PARP-1 has shown protective effects on cell survival 
under various conditions, including streptozotocin-induced diabetes (Pieper et al., 1999) 
and cardiac and renal ischemia–reperfusion injuries (Pieper et al., 2000). While the 
mechanism involved in PARP-1 mediated cell death is not completely understood, a few 
studies have reported protective effects of PARP-1 inhibitors on the activation of NF-κB 
(Czapski et. al., 2004). Our flow cytometry and immunoblot data results suggest that 
PARP-1 inhibition using a pharmacological inhibitor, DPQ, significantly blocked the 
activation of NF-κB in the primary astrocyte culture under TD conditions. Blocking NF-
κB activation showed no significant change in the PARP-1 activity, suggesting that 
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PARP-1 activation is an independent mechanism and is employed during metabolic 
inhibition such as that observed under TD conditions.  
Overactivation of NF-κB is implicated in the pathogenesis of excitotoxicity and 
glutamate transporter dysregulation. Efficient glutamate transmission requires continued 
uptake of glutamate via energy dependent transporters located on the astrocytes, and our 
findings suggest that activation of astrocytic PARP-1 due to DNA damage leads to 
glutamate transporter downregulation by NF-κB dependent signaling pathways. 
 
5.3 Effects of lactate accumulation on glutamate transporters during TD 
Metabolic inhibition with substantial lactate production in brain is a classical 
feature of TD and WE. Lactic acid is known to cause astrocyte swelling, a feature of the 
disorder, and since swelling of these cells has previously been shown to inhibit glutamate 
uptake (Kimelberg et. al., 1990), we examined whether excessive lactate production 
during TD may contribute to excitotoxicity by inhibition of astrocytic glutamate 
transporter function. The findings presented in the third article demonstrate that 
conditioned media from TD astrocytes produced a downregulation of GLT-1 (GLT-1b 
splice variant) and loss of glutamate uptake capacity of the astrocytes. Measurement of 
lactate concentration in the media showed increased lactate levels under conditions of 
TD.  
Previous studies have reported increased glutamate release and decrease in 
glutamate uptake after exogenous lactate administration in primary astrocyte cultures 
(Bender et. al., 1997). Given the bulk of extracellular lactate accumulation during TD, we 
wanted to determine whether the lactate accumulation during TD might be responsible 
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for glutamate transporter dysfunction. Thus we investigated the role of lactate 
accumulation in the regulation of glutamate transporters in astrocytes. Using a specific 
inhibitor for the monocarboxylic acid transporter which transports lactate, 4-CIN, we 
determined that lactate by itself is not a major contributor in glutamate transporter 
dysfunction. Thus lactate induced decrease in glutamate uptake may be due to the acidic 
factors associated with lactate accumulation. 
 It is evident that acidosis due to excessive accumulation of lactic acid may inhibit 
glutamate uptake directly by its effect on the transporters, possibly by affecting the 
charged groups on the glutamate carrier proteins thereby altering the tertiary structure of 
the transporter (Barbour et. al., 1988). Thus, decreased glutamate uptake could also result 
due to ionic imbalance. Hence, accumulation of lactic acid and other soluble factors may 
contribute to decreased glutamate uptake capacity and may be involved in GLT-1 loss in 
astrocytes during TD.   
 
5.4 Effects of mitochondrial dysfunction on glutamate transporters in TD 
Mitochondria are important integrators of cellular function that plays an important role in 
producing ATP through oxidative phosphorylation, control of cytosolic Ca2+ 
concentration and energy metabolism. Mitochondria are also one of the major cellular 
producers of reactive oxygen species (ROS). Many of these functions of mitochondria are 
regulated by the electrochemical gradient across the mitochondrial membrane or 
mitochondrial membrane potential (Δψm). Neuronal injury leading to excitotoxicity can 
produce a profound depolarization of mitochondrial membrane including alterations in 
intracellular calcium dynamics and the opening of mitochondrial permeability transition 
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pore (MPTP) (Ankarcrona et al., 1995). Mitochondrial permeability transition (MPT) is a 
key event in the pathology of TD due to altered Ca2+ homeostasis, enhanced ROS 
production and decreased ATP synthesis leading to neuronal loss in the specific brain 
regions (Leong et al., 1994; Bettendorff et. al., 1995).    
Early mitochondrial damage is a critical downstream event in glutamate-mediated 
excitotoxicity (White and Reynolds 1996). We now propose that mitochondria may be an 
early target of injury in the cascade of events that leads to WE. This is confirmed with 
our findings that the exposure of naïve astrocytes to TD conditioned media for 12h to 24h 
leads to increased Δψm. While this finding in TD is perhaps not that surprising given our 
understanding that TD results in decreased ATP levels in vulnerable brain regions 
(Aikawa et al., 1984), indicating failure of energy metabolism, it is particularly 
interesting that 12-24h treatment of naïve astrocytes with TD conditioned media results in 
disruption/collapse of Δψm in these cells. This suggests that the soluble factors 
responsible for downregulating GLT-1 are likely particularly efficacious in their effects 
on mitochondrial functions under conditions of TD. Thus, an early compromise in 
mitochondrial function (e.g., the induction of the permeability transition) may leave cells 
ill-prepared to deal with the later cellular energy drain associated with TD. 
The reversibility of mitochondrial potential to normal levels after an insult 
depends on the extent of MPT. If MPT occurs to only a slight extent, the cell may 
recover, whereas if it occurs more it may undergo apoptosis. If it occurs to an even larger 
degree the cell is likely to undergo necrotic cell death (Honda and Ping, 2006). Given that 
severe energy depletion is a major event in the TD pathology, it appears that TD results 
in more severe impairment of mitochondrial function. This is supported by our present 
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findings that showed the effects of astrocytic soluble factors on Δψm, in addition 
enhanced activation of the PARP-1 enzyme that drain astroglial reserves of ATP and 
nicotinamide nucleotides. There are several studies in the past that indicate that the 
factors that increase the likelihood of MPT induction are altered during TD (Bettendorff 
et. al., 1995). Most importantly, TD induces a decrease in the activity of KGDH, leading 
to inhibition of mitochondrial energy metabolism and decreased ATP production, leading 
to MPT induction in this disease pathophysiology. Consequently, MPT increases ROS 
production, Ca2+ influx and causes Ca2+overload that promote excitotoxic brain damage 
in TD pathophysiology. Earlier studies (Zhang et al., 1994) complement our present 
findings and invites speculation with respect to the mechanism of cell death under 
conditions of TD.  
 
5.5 Effects of TNF-α production and NF-κB activity on glutamate transporters 
during TD 
Increased expression and release of TNF-α has been reported in cerebrospinal 
fluid (CSF), plasma, or post mortem brain tissue in patients following stroke, brain 
injury, HIV dementia, alcoholism, and Alzheimer’s disease, trauma, ischemia, and 
inflammatory diseases (Allan and Rothwell, 2001). Since TNF-α in the brain can also 
stimulate NF-κB activity which is implicated in the regulation of glutamate transporters, 
we investigated if TD progresses with increased release of TNF-α in the medium in order 
to see if a TNF-α mediated NF-κB dependent process is involved in the regulation of 
glutamate transporters in naïve astrocytes treated with conditioned media. Our data 
indicate that TNF-α is released into the media but that inhibition of TNF-α had no effect 
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on the reduced glutamate uptake capacity in naïve treated astrocytes. On the other hand, 
TNF-α inhibition in astrocytes with TD showed protection against the loss of GLT-1 
protein and restored glutamate uptake capacity. However, TNF-α inhibition significantly 
reduced NF-κB activation in the astrocytes during TD, and inhibition of NF-κB 
ameliorated the decrease in GLT-1 due to TD. Thus, regulation of astrocytic glutamate 
transporters is determined by a TNF-α-mediated NF-κB dependent process.  
 
5.6 Consequences of glutamate transporter downregulation in TD 
Excitatory amino acid transporters are considered to be a potential target for 
neuroprotection against excitotoxicity. GLT-1 is considered as the major glutamate 
transporter responsible for clearance of glutamate from the extracellular space (Lehre and 
Danbolt, 1998). In addition, considerable evidence indicates that GLT-1 contributes to 
excitotoxicity and neuronal death in a number of neurological disorders, including 
ischemic stroke, traumatic brain injury, and amyotrophic lateral sclerosis (Allen et al., 
2004; Maragakis and Rothstein, 2004). Previous studies indicate that extracellular 
glutamate concentration is increased in vulnerable brain regions in TD (Hazell et al., 
1993, Langlais and Zhang, 1993). This effect of TD on glutamate transporter levels was 
also demonstrated in primary cultures of astrocytes (Hazell et. al., 2003). Furthermore, it 
has recently been demonstrated that loss of GLT-1 and GLAST also occurs in the 
cerebral cortex of human cases of WE (Hazell et. al., 2010). These studies indicate that 
downregulation of glutamate transporters likely leads to an excitotoxic event in TD.  
Focal accumulation of lactic acid is a classical feature of TD and one of its major 
consequences is gliotoxicity (Navarro et. al., 2005). Astrocytes are particularly sensitive 
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to lactate and exposing them to extended periods of lactic acidosis leads to an inability of 
these cells to maintain ATP production (Bender et. al., 1997). The resulting decrease in 
ATP levels then causes a collapse of the ionic gradients across the astrocyte cell 
membrane due to suppression of Na+ /K+ ATPase activity, leading to movement of Na+ 
into the cell along its concentration gradient. Elevated intracellular Na+ concentration 
results in transport of glutamate from the astrocyte to the extracellular space (Danbolt 
2001). Moreover, astrocytic swelling due to glutamate uptake or excessive K+ spatial 
buffering can lead to depolarization of these cells, resulting in the release of glutamate 
via transporter reversal (Danbolt 2001). The major consequence of this transporter 
reversal is an increase in extracellular glutamate concentration which is a major causative 
factor implicated in excitotoxicity (Danbolt 2001).  
Thus, severe impairment of reuptake of glutamate during TD could lead to 
elevated extracellular levels of glutamate.  Alternatively, glutamate uptake in astrocytes 
is primarily mediated by GLT-1 and GLAST glutamate transporters (Danbolt 2001). Loss 
of these transporters has been reported in vulnerable areas of the brain of rats with TD 
and in astrocytes with TD (Hazell et. al., 2001; 2003; Jhala et. al., 2011). Additionally, 
increased activity of the cystine-glutamate exchanger can play a role in excitotoxicity by 
exporting glutamate out of the astrocyte into the extracellular space while enhancing 
cystine uptake for purposes of increased synthesis of the antioxidant glutathione in the 
cell in response to increasing oxidative stress (Lewerenz et al., 2009). Focal cerebral 
vulnerability is therefore a major consequence of TD which is associated with excitotoxic 
mediated brain damage, and elevated interstitial glutamate concentration as a result of the 
energy deficit is one of the key factors involved in the pathogenesis of this disorder.  
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5.7 Implications for TD-induced loss of glutamate transporters 
Cerebral vulnerability to an excitotoxic insult is governed by the cellular 
processes responsible for the maintenance of glutamate (homeostatic) concentration in 
the extracellular space; these include glutamate transport/uptake and release mechanisms. 
Regulation of glutamate transporter activity in adverse conditions is a prerequisite for 
normal synaptic transmission. Any disturbance of these processes may lead to an 
irreversible process of cell death or excitotoxicity (Doble 1999; Danbolt 2001). 
Consequently, loss of glutamate uptake and the resultant elevation in extracellular 
glutamate levels plays a major role in the pathophysiology of TD (Fig. 6) (Hazell 2009). 
Elevations of extracellular glutamate may also be a contributing factor to seizure activity. 
Seizures can be observed at the late stage in experimental TD (Langlais et al., 2002) and 
are observed in rare cases of alcoholics with encephalopathy as SESA (Subacute 
encephalopathy with seizures in alcoholics) syndrome (Rothmeier et al., 2001; 
Fernández-Torre et al., 2006). Moreover, Tsuro et al. (2002) demonstrated that EAAT1-
knockout mice were more susceptible to amygdala-kindled seizures and displayed a more 
severe and prolonged type of seizure. Thus, it would be of scientific importance to 
investigate the nature of seizure activity observed in TD and establish if seizures are a 
cause or consequence of loss of glutamate transporters.  
Based on earlier studies, viable approaches to overcome excitotoxicity might be to 
upregulate the activity of the predominant GLT-1 subtype either at the level of small-
molecule activators (e.g. ceftriaxone) or by independently promoting gene expression. In 
addition, better pharmacological tools are required to define the precise contributions of 
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GLT-1 to the regulation of extracellular glutamate concentration and to ultimately 
understand their potential role as drug targets.  
Antioxidant N-acetylcysteine treatment has been shown to be a protective strategy 
against the loss of glutamate transporters in TD (Hazell et. al., 2010). Moreover, the 
antioxidant potential of ceftriaxone is confirmed in the disease model of ischemic brain 
injury (Lewerenz et al., 2009). In relation to these earlier findings along with implications 
of PARP-1 and TNF-α dependent mechanisms presented in the second and third articles, 
it is possible that oxidative stress is the major contributing factor to TD-induced 
suppression of glutamate transporter activity.   
In the present studies it has been shown that impaired energy metabolism and its 
subsequent oxidative DNA damage can lead to overactivation of PARP-1 enzyme, 
enhanced lactate production and activation of TNF-α, leading to increased NF-κB 
signaling. NF-κB activation has been introduced as a major exacerbating factor in the 
pathogenesis of excitotoxicity in variety of neurodegenerative diseases, and is often 
considered as a major causal factor associated with excitotoxic insults. The experimental 
evidence provided in this thesis showing the interaction between energy impairment and 
excitotoxicity may therefore increase our understanding of how a vitamin deficiency can 
produce such devastating cerebral damage, and perhaps lead to new therapeutic 
approaches for the treatment of neurodegeneration as a whole.  
 
5.8 Mechanism of selective brain damage in TD 
Multiple mechanisms contribute to the selective brain lesions observed in WKS and 
experimental TD. Neuropathological evaluation of the brains of patients with WKS 
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reveals a highly selective damage primarily in diencephalic and brainstem structures. 
Moreover, bilateral symmetrical lesions are consistently observed in thalamic nuclei, 
inferior colliculi, inferior olivary nuclei, mammillary bodies, and lateral vestibular nuclei 
(Torvik et. al., 1985; 87). Other major structures, including cerebral cortex, caudate 
nuclei, and hippocampi manifest no significant damage in WKS (Troncoso et. al., 1981). 
This region selective brain damage is a consequence of a cascade of events in the 
pathology of TD. For example, brain structures that manifest selective vulnerability to 
TD are those with high thiamine turnover rates (Dreyfus, 1959) high rates of oxidative 
metabolism, selectively decreased activities of α- KGDH (Butterworth et. al., 1986), 
early microglial activation (Wang and Hazell, 2010) and increased free radical production 
(Hazell et. al., 1998).  Additionally, increase in the extracellular glutamate concentration 
concomitant with the loss of astrocytic glutamate transporter, GLAST and GLT-1 
localized to vulnerable brain regions have been reported earlier in TD (Hazell et al., 
1993; 2001; Langlais and Zhang, 1993). Furthermore, evidence were also provided for 
the excitotoxic-like lesions in damaged areas of the brain (Armstrong-James et al., 1988), 
suggesting an involvement of  glutamate-mediated excitotoxicity in pathophysiology. 
Major findings presented in this thesis project, suggesting the loss of the GLT-1 protein 
along with decreased glutamate transport kinetics both in TD astrocyte culture and animal 
model of the disorder, add further evidence for implication of a loss of glutamate 
transporter function in the selective vulnerability of brain damage in the pathophysiology 
of TD. Thus, the selective vulnerability to TD may be mediated by a glutamate-mediated 
excitotoxic process in affected structures, leading to alterations in mitochondrial  
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membrane potential due to inhibition of ATP synthesis and disturbances in calcium 
homeostasis.  
5.9 Contribution to knowledge  
A brief summary of the data presented in the three articles which constitute this 
thesis include the following: 
 
Loss of glutamate transporter splice variant GLT-1b and its protection by ceftriaxone 
Data provided in this thesis article demonstrate that TD results in the loss of 
glutamate transporter splice variant GLT-1b and thereby inhibits the glutamate uptake 
capacity of the astrocytes. Treatment with ceftriaxone significantly blocks this 
downregulation and restored glutamate uptake capacity. These findings suggest the 
enhanced interstitial brain glutamate levels observed in TD to some extent are a result of 
TD-induced downregulation of GLT-1b protein levels, and ceftriaxone may be a potential 
therapeutic strategy against the loss of these transporters. 
 
PARP-1 dependent activation of NFκB signalling pathways regulate glutamate 
transporters during TD 
The data presented in the second article suggest that impaired oxidative 
metabolism can lead to PARP-1 dependent activation of NF-κB signalling cascades 
leading to glutamate transporter dysfunction under conditions of TD. The major findings 
of this study suggest that excessive poly (ADP) ribosylation due to increased DNA 
damage promotes NF-κB activation and regulates glutamate transporters activity by 
protein modification.  
 159
 
Glutamate transporters are regulated by extracellular factors released from astrocytes 
Findings presented in the first and second articles demonstrated the loss of 
glutamate transporters under conditions of TD and a role for NF-κB in the regulation of 
glutamate transporters. In the third article we report an alternative mechanism that may 
operate under conditions of TD but also involving NF-κB. Major results of this study 
suggest that TNF-α mediated NF-κB is involved in the regulation of astrocytes under TD 
conditions. In addition, soluble factors and metabolic related substances accumulate 
extracellularly, contributing to astrocytic glutamate transporter dysfunction, e.g. 
increased lactic acidosis, or by ionic imbalance that affects functional characteristics of 
the  glutamate transporters. 
Based on the data presented in this thesis it is evident that glutamate transporters 
in TD are regulated by posttranslational influences or through protein-protein interactions 
with specific proteins (Fig. 5). The GLT-1 is known to be regulated by phosphorylation, 
ubiquitination, and glycosylation and therefore it would be interesting to examine the 
effect of TD on these posttranslational mechanisms. In addition there are several 
interacting molecules that could be examined, e.g. Sept2 is a molecule that interacts with 
GLAST and downregulates its function (Kinoshita et. al., 2004). JM4 is a homologue to 
JWA that downregulates the function of EAAT1-4 by interacting with exon9 and 
preventing ER exit (Schweneker et. al., 2005; Ruggiero et. al., 2008). CNTF is a 
molecule that increases expression of GLAST at the plasma membrane (Escartin et. al., 
2006). Analysis of these molecules would likely provide a more complete picture of the 
abnormalities in EAAT regulation in TD.  
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SUMMARY OF FINDINGS 
 
 
The objective of this thesis was to study the mechanisms of glutamate transporter 
downregulation in TD encephalopathy. Results of the studies presented suggest that 
downregulation of glutamate transporters, both in animal and cell culture models, can be 
attenuated by the administration of ceftriaxone, a β-lactam antibiotic. Poly (ADP) ribose 
mediated NF-kB activation is a major signaling pathway now linked to the loss of 
glutamate transporters during TD. Furthermore, the release of soluble factors from 
astrocytes exposed to TD conditions can influence their functional integrity at the level of 
these glutamate transporters.  
 
 
 
 
 
 
 
 
 
 161
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 162
Ahmed, A., Daida, Y., & Novotny, R. (2011). PS2-02: Micronutrient Deficiencies After 
Bariatric Surgery: Does Ethnicity Matter? Clin Med Res, 9(3-4), 165. 
Aikawa, H., Watanabe, I. S., Furuse, T., Iwasaki, Y., Satoyoshi, E., Sumi, T., et al. 
(1984). Low energy levels in thiamine-deficient encephalopathy. J Neuropathol Exp 
Neurol, 43(3), 276-287. 
Aisen, P. S., & Davis, K. L. (1994). Inflammatory mechanisms in Alzheimer's disease: 
implications for therapy. Am J Psychiatry, 151(8), 1105-1113. 
Al-Attas, O. S., Al-Daghri, N. M., Alfadda, A., Abd Al-Rahman, S. H., & Sabico, S. 
(2011). Blood Thiamine and Derivatives as measured by High-Performance Liquid 
Chromatography: Levels and Associations in DM Patients with Varying Degrees of 
Microalbuminuria. J Endocrinol Invest. 
Albrecht, J., Talbot, M., Kimelberg, H. K., & Aschner, M. (1993). The role of sulfhydryl 
groups and calcium in the mercuric chloride-induced inhibition of glutamate uptake in rat 
primary astrocyte cultures. Brain Res, 607(1-2), 249-254. 
Alexander, L., Pijoan, M. and Myerson, A. (1938). Beriberi and Scurvy. Trans. Am. 
Neurol. Assoc. , 64, 135-139. 
Allan, S. M., & Rothwell, N. J. (2001). Cytokines and acute neurodegeneration. Nat Rev 
Neurosci, 2(10), 734-744. 
Allen, D. N., Goldstein, G., & Seaton, B. E. (1997). Cognitive rehabilitation of chronic 
alcohol abusers. Neuropsychol Rev, 7(1), 21-39. 
 163
Allen, N. J., Karadottir, R., & Attwell, D. (2004). Reversal or reduction of glutamate and 
GABA transport in CNS pathology and therapy. Pflugers Arch, 449(2), 132-142. 
Anderson, S. H., Charles, T. J., & Nicol, A. D. (1985). Thiamine deficiency at a district 
general hospital: report of five cases. Q J Med, 55(216), 15-32. 
Ankarcrona, M., Dypbukt, J. M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S. 
A., et al. (1995). Glutamate-induced neuronal death: a succession of necrosis or apoptosis 
depending on mitochondrial function. Neuron, 15(4), 961-973. 
Armstrong-James, M., Ross, D. T., Chen, F., & Ebner, F. F. (1988). The effect of 
thiamine deficiency on the structure and physiology of the rat forebrain. Metab Brain Dis, 
3(2), 91-124. 
Arundine, M., & Tymianski, M. (2003). Molecular mechanisms of calcium-dependent 
neurodegeneration in excitotoxicity. Cell Calcium, 34(4-5), 325-337. 
Avdulov, N. A., Chochina, S. V., Igbavboa, U., O'Hare, E. O., Schroeder, F., Cleary, J. 
P., et al. (1997). Amyloid beta-peptides increase annular and bulk fluidity and induce 
lipid peroxidation in brain synaptic plasma membranes. J Neurochem, 68(5), 2086-2091. 
Baldwin, A. S., Jr. (1996). The NF-kappa B and I kappa B proteins: new discoveries and 
insights. Annu Rev Immunol, 14, 649-683. 
Barbour, B., Brew, H., & Attwell, D. (1988). Electrogenic glutamate uptake in glial cells 
is activated by intracellular potassium. Nature, 335(6189), 433-435. 
 164
Beauchesne, E., Desjardins, P., Hazell, A. S., & Butterworth, R. F. (2009). Altered 
expression of tight junction proteins and matrix metalloproteinases in thiamine-deficient 
mouse brain. Neurochem Int, 55(5), 275-281. 
Beauchesne, E., Desjardins, P., Hazell, A. S., & Butterworth, R. F. (2009). eNOS gene 
deletion restores blood-brain barrier integrity and attenuates neurodegeneration in the 
thiamine-deficient mouse brain. J Neurochem, 111(2), 452-459. 
Becher, A., White, J. H., & McIlhinney, R. A. (2001). The gamma-aminobutyric acid 
receptor B, but not the metabotropic glutamate receptor type-1, associates with lipid rafts 
in the rat cerebellum. J Neurochem, 79(4), 787-795. 
Behrens, P. F., Franz, P., Woodman, B., Lindenberg, K. S., & Landwehrmeyer, G. B. 
(2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream 
effects of the Huntington mutation. Brain, 125(Pt 8), 1908-1922. 
Bender, A. S., Young, L. P., & Norenberg, M. D. (1997). Effect of lactic acid on L-
glutamate uptake in cultured astrocytes: mechanistic considerations. Brain Res, 750(1-2), 
59-66. 
Bettendorff, L. (1994). The compartmentation of phosphorylated thiamine derivatives in 
cultured neuroblastoma cells. Biochim Biophys Acta, 1222(1), 7-14. 
Bettendorff, L., Goessens, G., Sluse, F., Wins, P., Bureau, M., Laschet, J., et al. (1995). 
Thiamine deficiency in cultured neuroblastoma cells: effect on mitochondrial function 
and peripheral benzodiazepine receptors. J Neurochem, 64(5), 2013-2021. 
 165
Bettendorff, L., & Wins, P. (1994). Mechanism of thiamine transport in neuroblastoma 
cells. Inhibition of a high affinity carrier by sodium channel activators and dependence of 
thiamine uptake on membrane potential and intracellular ATP. J Biol Chem, 269(20), 
14379-14385. 
Bojinov, S. (1971). Encephalitis with acute Parkinsonian syndrome and bilateral 
inflammatory necrosis of the substantia nigra. J Neurol Sci, 12(4), 383-415. 
Bowman, K., Goodhart, R. and Jolliffe, N. (1939). Observations of role of Vitamin B1 in 
the etiology and treatment of Korsakoff psychosis. J. Nerv. Ment. Dis. , 90, 569-575. 
Butchbach, M. E., Tian, G., Guo, H., & Lin, C. L. (2004). Association of excitatory 
amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft 
microdomains: importance for excitatory amino acid transporter localization and 
function. J Biol Chem, 279(33), 34388-34396. 
Butterworth, R. F., Giguere, J. F., & Besnard, A. M. (1986). Activities of thiamine-
dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 
2. alpha-Ketoglutarate dehydrogenase. Neurochem Res, 11(4), 567-577. 
Butterworth, R. F., & Heroux, M. (1989). Effect of pyrithiamine treatment and 
subsequent thiamine rehabilitation on regional cerebral amino acids and thiamine-
dependent enzymes. J Neurochem, 52(4), 1079-1084. 
 166
Calingasan, N. Y., Baker, H., Sheu, K. F., & Gibson, G. E. (1995). Blood-brain barrier 
abnormalities in vulnerable brain regions during thiamine deficiency. Exp Neurol, 
134(1), 64-72. 
Carrick, T., Dunlop, J., (1999). Protein kinase C modulation of the human excitatory 
amino acid transporter 2 subtype of glutamate transporter. Paper presented at the Society 
for Neuroscience  
Casado, M., Bendahan, A., Zafra, F., Danbolt, N. C., Aragon, C., Gimenez, C., et al. 
(1993). Phosphorylation and modulation of brain glutamate transporters by protein kinase 
C. J Biol Chem, 268(36), 27313-27317. 
Chadda, K., Raynard, B., Antoun, S., Thyrault, M., & Nitenberg, G. (2002). Acute lactic 
acidosis with Wernicke's encephalopathy due to acute thiamine deficiency. Intensive 
Care Med, 28(10), 1499. 
Chan, H., Butterworth, R. F., & Hazell, A. S. (2004). Primary cultures of rat astrocytes 
respond to thiamine deficiency-induced swelling by downregulating aquaporin-4 levels. 
Neurosci Lett, 366(3), 231-234. 
Chaudhry, F. A., Lehre, K. P., van Lookeren Campagne, M., Ottersen, O. P., Danbolt, N. 
C., & Storm-Mathisen, J. (1995). Glutamate transporters in glial plasma membranes: 
highly differentiated localizations revealed by quantitative ultrastructural 
immunocytochemistry. Neuron, 15(3), 711-720. 
 167
Chen, J. C., Hsu-Chou, H., Lu, J. L., Chiang, Y. C., Huang, H. M., Wang, H. L., et al. 
(2005). Down-regulation of the glial glutamate transporter GLT-1 in rat hippocampus and 
striatum and its modulation by a group III metabotropic glutamate receptor antagonist 
following transient global forebrain ischemia. Neuropharmacology, 49(5), 703-714. 
Choi, D. W. (1992). Excitotoxic cell death. J Neurobiol, 23(9), 1261-1276. 
Collins, G. H. (1967). Glial cell changes in the brain stem of thiamine-deficient rats. Am 
J Pathol, 50(5), 791-814. 
Colotta, F., Polentarutti, N., Sironi, M., & Mantovani, A. (1992). Expression and 
involvement of c-fos and c-jun protooncogenes in programmed cell death induced by 
growth factor deprivation in lymphoid cell lines. J Biol Chem, 267(26), 18278-18283. 
Combs, G. F. (1992). The vitamins: fundamental aspects in nutrition and health. . San 
Diego, California.: Academic Press. 
Conradt, M., & Stoffel, W. (1997). Inhibition of the high-affinity brain glutamate 
transporter GLAST-1 via direct phosphorylation. J Neurochem, 68(3), 1244-1251. 
Conradt, M., Storck, T., & Stoffel, W. (1995). Localization of N-glycosylation sites and 
functional role of the carbohydrate units of GLAST-1, a cloned rat brain L-glutamate/L-
aspartate transporter. Eur J Biochem, 229(3), 682-687. 
Conti, F., & Weinberg, R. J. (1999). Shaping excitation at glutamatergic synapses. Trends 
Neurosci, 22(10), 451-458. 
 168
Cooper, J. R., & Pincus, J. H. (1979). The role of thiamine in nervous tissue. Neurochem 
Res, 4(2), 223-239. 
Cooper, J. R., Roth, R. H., & Kini, M. M. (1963). BIOCHEMICAL AND 
PHYSIOLOGICAL FUNCTION OF THIAMINE IN NERVOUS TISSUE. Nature, 199, 
609-610. 
Czapski, G. A., Cakala, M., Kopczuk, D., & Strosznajder, J. B. (2004). Effect of 
poly(ADP-ribose) polymerase inhibitors on oxidative stress evoked hydroxyl radical 
level and macromolecules oxidation in cell free system of rat brain cortex. Neurosci Lett, 
356(1), 45-48. 
Danbolt, N. C. (2001). Glutamate uptake. Prog Neurobiol, 65(1), 1-105. 
Danbolt, N. C., Chaudhry, F. A., Dehnes, Y., Lehre, K. P., Levy, L. M., Ullensvang, K., 
et al. (1998). Properties and localization of glutamate transporters. Prog Brain Res, 116, 
23-43. 
De Wardener, H. E., Lennox, B. (1947). Cerebral beriberi (Wernicke’s Encephalopathy): 
review of 52 cases in a Singapore prisoner-of-war hospital. . Lancet, 1, 11-17. 
Doble, A. (1999). The role of excitotoxicity in neurodegenerative disease: implications 
for therapy. Pharmacol Ther, 81(3), 163-221. 
Dorandeu, F., Antier, D., Pernot-Marino, I., Lapeyre, P., & Lallement, G. (1998). Venom 
phospholipase A2-induced impairment of glutamate uptake: an indirect and nonselective 
effect related to phospholipid hydrolysis. J Neurosci Res, 51(3), 349-359. 
 169
Dragunow, M., Young, D., Hughes, P., MacGibbon, G., Lawlor, P., Singleton, K., et al. 
(1993). Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-
ischaemic brain injury? Brain Res Mol Brain Res, 18(4), 347-352. 
Drejer, J., Meier, E., & Schousboe, A. (1983). Novel neuron-related regulatory 
mechanisms for astrocytic glutamate and GABA high affinity uptake. Neurosci Lett, 
37(3), 301-306. 
Dreyfus, P. M. (1959). The quantitative histochemical distribution of thiamine in normal 
rat brain. J Neurochem, 4, 183-190. 
Dreyfus, P. M. (1959). The quantitative histochemical distribution of thiamine in normal 
rat brain. J. Neurochem., 4, 183-190. 
Dumuis, A., Sebben, M., Haynes, L., Pin, J. P., & Bockaert, J. (1988). NMDA receptors 
activate the arachidonic acid cascade system in striatal neurons. Nature, 336(6194), 68-
70. 
Escartin, C., Brouillet, E., Gubellini, P., Trioulier, Y., Jacquard, C., Smadja, C., et al. 
(2006). Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate 
transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling 
in vivo. J Neurosci, 26(22), 5978-5989. 
Estus, S., Zaks, W. J., Freeman, R. S., Gruda, M., Bravo, R., & Johnson, E. M., Jr. 
(1994). Altered gene expression in neurons during programmed cell death: identification 
of c-jun as necessary for neuronal apoptosis. J Cell Biol, 127(6 Pt 1), 1717-1727. 
 170
Feldman, E. B. (1988). Essentials of clinical nutrition. Philadelphia: F.A. Davis 
Company. 
Fernandez-Torre, J. L., Agirre, Z., Martinez-Martinez, M., & Rodriguez, E. (2006). 
Subacute encephalopathy with seizures in alcoholics (SESA syndrome): report of an 
unusual case. Clin EEG Neurosci, 37(3), 215-218. 
Figiel, M., & Engele, J. (2000). Pituitary adenylate cyclase-activating polypeptide 
(PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism. 
J Neurosci, 20(10), 3596-3605. 
Fox, J. M., & Duppel, W. (1975). The action of thiamine and its di- and triphosphates on 
the slow exponential decline of the ionic currents in the node of Ranvier. Brain Res, 
89(2), 287-302. 
Fukamachi, S., Furuta, A., Ikeda, T., Ikenoue, T., Kaneoka, T., Rothstein, J. D., et al. 
(2001). Altered expressions of glutamate transporter subtypes in rat model of neonatal 
cerebral hypoxia-ischemia. Brain Res Dev Brain Res, 132(2), 131-139. 
Gaitonde, M. K., Fayein, N. A., & Johnson, A. L. (1975). Decreased metabolism in vivo 
of glucose into amino acids of the brain of thiamine-deficient rats after treatment with 
pyrithiamine. J Neurochem, 24(6), 1215-1223. 
Garcia, J. H. (1975). The neuropathology of stroke. Hum Pathol, 6(5), 583-598. 
 171
Gegelashvili, G., Civenni, G., Racagni, G., Danbolt, N. C., Schousboe, I., & Schousboe, 
A. (1996). Glutamate receptor agonists up-regulate glutamate transporter GLAST in 
astrocytes. Neuroreport, 8(1), 261-265. 
Gegelashvili, G., Danbolt, N. C., & Schousboe, A. (1997). Neuronal soluble factors 
differentially regulate the expression of the GLT1 and GLAST glutamate transporters in 
cultured astroglia. J Neurochem, 69(6), 2612-2615. 
Genda, E. N., Jackson, J. G., Sheldon, A. L., Locke, S. F., Greco, T. M., O'Donnell, J. C., 
et al. (2011). Co-compartmentalization of the astroglial glutamate transporter, GLT-1, 
with glycolytic enzymes and mitochondria. J Neurosci, 31(50), 18275-18288. 
Gibson, G. E., Calingasan, N. Y., Baker, H., Gandy, S., & Sheu, K. F. (1997). Importance 
of vascular changes in selective neurodegeneration with thiamine deficiency. Ann N Y 
Acad Sci, 826, 516-519. 
Gibson, G. E., Ksiezak-Reding, H., Sheu, K. F., Mykytyn, V., & Blass, J. P. (1984). 
Correlation of enzymatic, metabolic, and behavioral deficits in thiamin deficiency and its 
reversal. Neurochem Res, 9(6), 803-814. 
Ginsberg, S. D., Martin, L. J., & Rothstein, J. D. (1995). Regional deafferentation down-
regulates subtypes of glutamate transporter proteins. J Neurochem, 65(6), 2800-2803. 
Greenwood, J., Love, E. R., & Pratt, O. E. (1982). Kinetics of thiamine transport across 
the blood-brain barrier in the rat. J Physiol, 327, 95-103. 
 172
Greenwood, J., Luthert, P. J., Pratt, O. E., & Lantos, P. L. (1986). Transport of thiamin 
across the blood-brain barrier of the rat in the absence of aerobic metabolism. Brain Res, 
399(1), 148-151. 
Gubler, C. J., Adams, B. L., Hammond, B., Yuan, E. C., Guo, S. M., & Bennion, M. 
(1974). Effect of thiamine deprivation and thiamine antagonists on the level of gamma-
aminobutyric acid and on 2-oxoglutarate metabolism in rat brain. J Neurochem, 22(5), 
831-836. 
Guenther, W., & Neu, I. S. (1984). Investigation of the blood-brain barrier for IgG in 
inflammatory syndromes of the central nervous system. Eur Neurol, 23(2), 132-136. 
Hakim, A. M. (1984). The induction and reversibility of cerebral acidosis in thiamine 
deficiency. Ann Neurol, 16(6), 673-679. 
Hazell, A. S., Hakim, A.M. (1994). Increase in extracellular glutamate concentration is a 
Ca2+-independent process in the thalamus of the thiamine deficient rat. J. Neurochem. 
(Suppl), 62, S-104. 
Hazell, A. S. (2007). Excitotoxic mechanisms in stroke: an update of concepts and 
treatment strategies. Neurochem Int, 50(7-8), 941-953. 
Hazell, A. S. (2009). Astrocytes are a major target in thiamine deficiency and Wernicke's 
encephalopathy. Neurochem Int, 55(1-3), 129-135. 
 173
Hazell, A. S., Butterworth, R. F., & Hakim, A. M. (1993). Cerebral vulnerability is 
associated with selective increase in extracellular glutamate concentration in 
experimental thiamine deficiency. J Neurochem, 61(3), 1155-1158. 
Hazell, A. S., Hakim, A. M., Senterman, M. K., & Hogan, M. J. (1998). Regional 
activation of L-type voltage-sensitive calcium channels in experimental thiamine 
deficiency. J Neurosci Res, 52(6), 742-749. 
Hazell, A. S., Itzhak, Y., Liu, H., & Norenberg, M. D. (1997). 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J 
Neurochem, 68(5), 2216-2219. 
Hazell, A. S., McGahan, L., Tetzlaff, W., Bedard, A. M., Robertson, G. S., Nakabeppu, 
Y., et al. (1998). Immediate-early gene expression in the brain of the thiamine-deficient 
rat. J Mol Neurosci, 10(1), 1-15. 
Hazell, A. S., Pannunzio, P., Rama Rao, K. V., Pow, D. V., & Rambaldi, A. (2003). 
Thiamine deficiency results in downregulation of the GLAST glutamate transporter in 
cultured astrocytes. Glia, 43(2), 175-184. 
Hazell, A. S., Rao, K. V., Danbolt, N. C., Pow, D. V., & Butterworth, R. F. (2001). 
Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST 
within the medial thalamus in experimental Wernicke's encephalopathy. J Neurochem, 
78(3), 560-568. 
 174
Hazell, A. S., Sheedy, D., Oanea, R., Aghourian, M., Sun, S., Jung, J. Y., et al. (2009). 
Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia, 58(2), 148-
156. 
Hazell, A. S., Sheedy, D., Oanea, R., Aghourian, M., Sun, S., Jung, J. Y., et al. (2010). 
Loss of astrocytic glutamate transporters in Wernicke encephalopathy. Glia, 58(2), 148-
156. 
Hazell, A. S., Todd, K. G., & Butterworth, R. F. (1998). Mechanisms of neuronal cell 
death in Wernicke's encephalopathy. Metab Brain Dis, 13(2), 97-122. 
Herman, M. A., & Jahr, C. E. (2007). Extracellular glutamate concentration in 
hippocampal slice. J Neurosci, 27(36), 9736-9741. 
Hoffman-LaRoche, F. (1994). Vitamins (Basics) (Vol. 1st edition). New York, USA: 
Seaboard Lithographers. 
. 
Holowach, J., Kauffman, F., Ikossi, M. G., Thomas, C., & McDougal, D. B., Jr. (1968). 
The effects of a thiamine antagonist, pyrithiamine, on levels of selected metabolic 
intermediates and on activities of thiamine-dependent enzymes in brain and liver. J 
Neurochem, 15(7), 621-631. 
Honda, H. M., & Ping, P. (2006). Mitochondrial permeability transition in cardiac cell 
injury and death. Cardiovasc Drugs Ther, 20(6), 425-432. 
 175
Huang, K., & El-Husseini, A. (2005). Modulation of neuronal protein trafficking and 
function by palmitoylation. Curr Opin Neurobiol, 15(5), 527-535. 
Huang, K., Kang, M. H., Askew, C., Kang, R., Sanders, S. S., Wan, J., et al. (2010). 
Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 
mouse model of Huntington disease. Neurobiol Dis, 40(1), 207-215. 
Inage, Y. W., Itoh, M., Wada, K., & Takashima, S. (1998). Expression of two glutamate 
transporters, GLAST and EAAT4, in the human cerebellum: their correlation in 
development and neonatal hypoxic-ischemic damage. J Neuropathol Exp Neurol, 57(6), 
554-562. 
Indraccolo, U., Gentile, G., Pomili, G., Luzi, G., & Villani, C. (2005). Thiamine 
deficiency and beriberi features in a patient with hyperemesis gravidarum. Nutrition, 
21(9), 967-968. 
Itokawa, Y., & Cooper, J. R. (1970). Ion movements and thiamine. II. The release of the 
vitamin from membrane fragments. Biochim Biophys Acta, 196(2), 274-284. 
Jackson, M., Song, W., Liu, M. Y., Jin, L., Dykes-Hoberg, M., Lin, C. I., et al. (2001). 
Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. 
Nature, 410(6824), 89-93. 
Jhala, S. S., & Hazell, A. S. (2010). Modeling neurodegenerative disease 
pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. 
Neurochem Int, 58(3), 248-260. 
 176
Jhala, S. S., & Hazell, A. S. (2011). Modeling neurodegenerative disease 
pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. 
Neurochem Int, 58(3), 248-260. 
Jhala, S. S., Wang, D., & Hazell, A. S. (2011). Loss of the glutamate transporter splice-
variant GLT-1b in inferior colliculus and its prevention by ceftriaxone in thiamine 
deficiency. Neurochem Int, 58(5), 558-563. 
Kalandadze, A., Wu, Y., Fournier, K., & Robinson, M. B. (2004). Identification of motifs 
involved in endoplasmic reticulum retention-forward trafficking of the GLT-1 subtype of 
glutamate transporter. J Neurosci, 24(22), 5183-5192. 
Kandel ER, Schwartz JH, Jessell TM. (2000). Principles of Neural Science, 4th 
ed. McGraw-Hill, New York. ISBN 0-8385-7701-6 
Karuppagounder, S. S., Shi, Q., Xu, H., & Gibson, G. E. (2007). Changes in 
inflammatory processes associated with selective vulnerability following mild 
impairment of oxidative metabolism. Neurobiol Dis, 26(2), 353-362. 
Ke, Z. J., Bowen, W. M., & Gibson, G. E. (2006). Peripheral inflammatory mechanisms 
modulate microglial activation in response to mild impairment of oxidative metabolism. 
Neurochem Int, 49(5), 548-556. 
Kimelberg, H. K., Barron, K. D., Bourke, R. S., Nelson, L. R., & Cragoe, E. J. (1990). 
Brain anti-cytoxic edema agents. Prog Clin Biol Res, 361, 363-385. 
 177
Kinnersley, H. W., & Peters, R. A. (1930). Carbohydrate metabolism in birds: Brain 
localisation of lactic acidosis in avitaminosis B, and its relation to the origin of 
symptoms. Biochem J, 24(3), 711-722. 
Kinoshita, N., Kimura, K., Matsumoto, N., Watanabe, M., Fukaya, M., & Ide, C. (2004). 
Mammalian septin Sept2 modulates the activity of GLAST, a glutamate transporter in 
astrocytes. Genes Cells, 9(1), 1-14. 
Kis, B., Deli, M. A., Kobayashi, H., Abraham, C. S., Yanagita, T., Kaiya, H., et al. 
(2001). Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport, 
12(18), 4139-4142. 
Knecht, K., Michalak, A., Rose, C., Rothstein, J. D., & Butterworth, R. F. (1997). 
Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute 
liver failure. Neurosci Lett, 229(3), 201-203. 
Kril, J. J. (1996). Neuropathology of thiamine deficiency disorders. Metab Brain Dis, 
11(1), 9-17. 
Langlais, P. J., & Mair, R. G. (1990). Protective effects of the glutamate antagonist MK-
801 on pyrithiamine-induced lesions and amino acid changes in rat brain. J Neurosci, 
10(5), 1664-1674. 
Langlais, P. J., Mandel, R. J., & Mair, R. G. (1992). Diencephalic lesions, learning 
impairments, and intact retrograde memory following acute thiamine deficiency in the 
rat. Behav Brain Res, 48(2), 177-185. 
 178
Langlais, P. J., McRee, R. C., Nalwalk, J. A., & Hough, L. B. (2002). Depletion of brain 
histamine produces regionally selective protection against thiamine deficiency-induced 
lesions in the rat. Metab Brain Dis, 17(3), 199-210. 
Langlais, P. J., & Zhang, S. X. (1993). Extracellular glutamate is increased in thalamus 
during thiamine deficiency-induced lesions and is blocked by MK-801. J Neurochem, 
61(6), 2175-2182. 
Langlais, P. J., Zhang, S. X., & Savage, L. M. (1996). Neuropathology of thiamine 
deficiency: an update on the comparative analysis of human disorders and experimental 
models. Metab Brain Dis, 11(1), 19-37. 
Le, O., Heroux, M., & Butterworth, R. F. (1991). Pyrithiamine-induced thiamine 
deficiency results in decreased Ca(2+)-dependent release of glutamate from rat 
hippocampal slices. Metab Brain Dis, 6(3), 125-132. 
Lee, S. G., Su, Z. Z., Emdad, L., Gupta, P., Sarkar, D., Borjabad, A., et al. (2008). 
Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression 
and glutamate uptake in primary human astrocytes. J Biol Chem, 283(19), 13116-13123. 
 
Lehre, K. P., & Danbolt, N. C. (1998). The number of glutamate transporter subtype 
molecules at glutamatergic synapses: chemical and stereological quantification in young 
adult rat brain. J Neurosci, 18(21), 8751-8757. 
 179
Lehre, K. P., Levy, L. M., Ottersen, O. P., Storm-Mathisen, J., & Danbolt, N. C. (1995). 
Differential expression of two glial glutamate transporters in the rat brain: quantitative 
and immunocytochemical observations. J Neurosci, 15(3 Pt 1), 1835-1853. 
Leong, D. K., Le, O., Oliva, L., & Butterworth, R. F. (1994). Increased densities of 
binding sites for the "peripheral-type" benzodiazepine receptor ligand [3H]PK11195 in 
vulnerable regions of the rat brain in thiamine deficiency encephalopathy. J Cereb Blood 
Flow Metab, 14(1), 100-105. 
Levitan, I. B. (2006). Signaling protein complexes associated with neuronal ion channels. 
Nat Neurosci, 9(3), 305-310. 
Lewerenz, J., Albrecht, P., Tien, M. L., Henke, N., Karumbayaram, S., Kornblum, H. I., 
et al. (2009). Induction of Nrf2 and xCT are involved in the action of the neuroprotective 
antibiotic ceftriaxone in vitro. J Neurochem, 111(2), 332-343. 
Liang, Z., Valla, J., Sefidvash-Hockley, S., Rogers, J., & Li, R. (2002). Effects of 
estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex 
of Alzheimer's disease patients. J Neurochem, 80(5), 807-814. 
Lin, C. L., Bristol, L. A., Jin, L., Dykes-Hoberg, M., Crawford, T., Clawson, L., et al. 
(1998). Aberrant RNA processing in a neurodegenerative disease: the cause for absent 
EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron, 20(3), 589-
602. 
 180
Lisovoski, F., Blot, S., Lacombe, C., Bellier, J. P., Dreyfus, P. A., & Junier, M. P. (1997). 
Transforming growth factor alpha expression as a response of murine motor neurons to 
axonal injury and mutation-induced degeneration. J Neuropathol Exp Neurol, 56(5), 459-
471. 
Lonsdale, D. (1990). Thiamine deficiency and sudden deaths. Lancet, 336(8711), 376. 
Lundy, D. F., & McBean, G. J. (1995). Pre-incubation of synaptosomes with arachidonic 
acid potentiates inhibition of [3H]D-aspartate transport. Eur J Pharmacol, 291(3), 273-
279. 
Manz, H. J., & Robertson, D. M. (1972). Vascular permeability to horseradish peroxidase 
in brainstem lesions of thiamine-deficient rats. Am J Pathol, 66(3), 565-576. 
Maragakis, N. J., & Rothstein, J. D. (2004). Glutamate transporters: animal models to 
neurologic disease. Neurobiol Dis, 15(3), 461-473. 
Marie, H., & Attwell, D. (1999). C-terminal interactions modulate the affinity of GLAST 
glutamate transporters in salamander retinal glial cells. J Physiol, 520 Pt 2, 393-397. 
Marie, H., Billups, D., Bedford, F. K., Dumoulin, A., Goyal, R. K., Longmore, G. D., et 
al. (2002). The amino terminus of the glial glutamate transporter GLT-1 interacts with the 
LIM protein Ajuba. Mol Cell Neurosci, 19(2), 152-164. 
Marks, J. (1975). A guide to the vitamins: their role in New York Academy of Sciences, 
1982, health and disease. (Vol. 378, pp. 137-144). Lancaster, UK. 
 181
: Medical & Technical Publishing Co. Ltd. 
Martin, L. J., Brambrink, A. M., Lehmann, C., Portera-Cailliau, C., Koehler, R., 
Rothstein, J., et al. (1997). Hypoxia-ischemia causes abnormalities in glutamate 
transporters and death of astroglia and neurons in newborn striatum. Ann Neurol, 42(3), 
335-348. 
Masliah, E., Alford, M., DeTeresa, R., Mallory, M., & Hansen, L. (1996). Deficient 
glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann 
Neurol, 40(5), 759-766. 
Masliah, E., Alford, M., Mallory, M., Rockenstein, E., Moechars, D., & Van Leuven, F. 
(2000). Abnormal glutamate transport function in mutant amyloid precursor protein 
transgenic mice. Exp Neurol, 163(2), 381-387. 
Masumoto, K., Esumi, G., Teshiba, R., Nagata, K., Nakatsuji, T., Nishimoto, Y., et al. 
(2009). Need for thiamine in peripheral parenteral nutrition after abdominal surgery in 
children. JPEN J Parenter Enteral Nutr, 33(4), 417-422. 
Mathern, G. W., Mendoza, D., Lozada, A., Pretorius, J. K., Dehnes, Y., Danbolt, N. C., et 
al. (1999). Hippocampal GABA and glutamate transporter immunoreactivity in patients 
with temporal lobe epilepsy. Neurology, 52(3), 453-472. 
Mathew, P., Graham, D. I., Bullock, R., Maxwell, W., McCulloch, J., & Teasdale, G. 
(1994). Focal brain injury: histological evidence of delayed inflammatory response in a 
 182
new rodent model of focal cortical injury. Acta Neurochir Suppl (Wien), 60, 428-430. 
 
Matrana, M. R., & Davis, W. E. (2009). Vitamin deficiency after gastric bypass surgery: 
a review. South Med J, 102(10), 1025-1031. 
McCandless, D. W. (1982). Energy metabolism in the lateral vestibular nucleus in 
pyrithiamin-induced thiamin deficiency. Ann N Y Acad Sci, 378, 355-364. 
McCandless, D. W., Schenker, S., & Cook, M. (1968). Encephalopathy of thiamine 
deficieny: studies of intracerebral mechanisms. J Clin Invest, 47(10), 2268-2280. 
Meyer, T., Speer, A., Meyer, B., Sitte, W., Kuther, G., & Ludolph, A. C. (1996). The 
glial glutamate transporter complementary DNA in patients with amyotrophic lateral 
sclerosis. Ann Neurol, 40(3), 456-459. 
Morgan, J. I., & Curran, T. (1986). Role of ion flux in the control of c-fos expression. 
Nature, 322(6079), 552-555. 
Moriyama, Y., & Omote, H. (2008). Vesicular glutamate transporter acts as a metabolic 
regulator. Biol Pharm Bull, 31(10), 1844-1846. 
Mulholland, P. J. (2006). Susceptibility of the cerebellum to thiamine deficiency. 
Cerebellum, 5(1), 55-63. 
 183
Muller, C. S., Haupt, A., Bildl, W., Schindler, J., Knaus, H. G., Meissner, M., et al. 
(2010). Quantitative proteomics of the Cav2 channel nano-environments in the 
mammalian brain. Proc Natl Acad Sci U S A, 107(34), 14950-14957. 
Munujos, P., Coll-Canti, J., Beleta, J., Gonzalez-Sastre, F., & Gella, F. J. (1996). Brain 
pyruvate oxidation in experimental thiamin-deficiency encephalopathy. Clin Chim Acta, 
255(1), 13-25. 
Murphy, T. H., Worley, P. F., & Baraban, J. M. (1991). L-type voltage-sensitive calcium 
channels mediate synaptic activation of immediate early genes. Neuron, 7(4), 625-635. 
Navarro, D., Zwingmann, C., Hazell, A. S., & Butterworth, R. F. (2005). Brain lactate 
synthesis in thiamine deficiency: a re-evaluation using 1H-13C nuclear magnetic 
resonance spectroscopy. J Neurosci Res, 79(1-2), 33-41. 
Ohtsubo, K., & Marth, J. D. (2006). Glycosylation in cellular mechanisms of health and 
disease. Cell, 126(5), 855-867. 
Olney, J. W. (1971). Glutamate-induced neuronal necrosis in the infant mouse 
hypothalamus. An electron microscopic study. J Neuropathol Exp Neurol, 30(1), 75-90. 
Pawlak, J., Brito, V., Kuppers, E., & Beyer, C. (2005). Regulation of glutamate 
transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol 
Brain Res, 138(1), 1-7. 
Pellerin, L. (2005). How astrocytes feed hungry neurons. Mol Neurobiol, 32(1), 59-72. 
 184
Pentschew, A., & Garro, F. (1966). Lead encephalo-myelopathy of the suckling rat and 
its implications on the porphyrinopathic nervous diseases. With special reference to the 
permeability disorders of the nervous system's capillaries. Acta Neuropathol, 6(3), 266-
278. 
Phillips, S. C., Harper, C. G., & Kril, J. (1987). A quantitative histological study of the 
cerebellar vermis in alcoholic patients. Brain, 110 ( Pt 2), 301-314. 
Phillips, S. C., Harper, C. G., & Kril, J. J. (1990). The contribution of Wernicke's 
encephalopathy to alcohol-related cerebellar damage. Drug Alcohol Rev, 9(1), 53-60. 
Pieper, A. A., Verma, A., Zhang, J., & Snyder, S. H. (1999). Poly (ADP-ribose) 
polymerase, nitric oxide and cell death. Trends Pharmacol Sci, 20(4), 171-181. 
Pieper, A. A., Walles, T., Wei, G., Clements, E. E., Verma, A., Snyder, S. H., et al. 
(2000). Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene 
disruption. Mol Med, 6(4), 271-282. 
Qin, L., He, J., Hanes, R. N., Pluzarev, O., Hong, J. S., & Crews, F. T. (2008). Increased 
systemic and brain cytokine production and neuroinflammation by endotoxin following 
ethanol treatment. J Neuroinflammation, 5, 10. 
Ritter, S. L., Asay, M. J., Paquet, M., Paavola, K. J., Reiff, R. E., Yun, C. C., et al. 
(2011). GLAST stability and activity are enhanced by interaction with the PDZ scaffold 
NHERF-2. Neurosci Lett, 487(1), 3-7. 
 185
Robertson, D. M., Wasan, S. M., & Skinner, D. B. (1968). Ultrastructural features of 
early brain stem lesions of thiamine-deficient rats. Am J Pathol, 52(5), 1081-1097. 
Rothmeier, J., Friese, M., Willemsen, F., & Froescher, W. (2001). Subacute 
encephalopathy with seizures in chronic alcoholism (SESA syndrome). Clin 
Electroencephalogr, 32(4), 186-190. 
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., et 
al. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport 
in excitotoxicity and clearance of glutamate. Neuron, 16(3), 675-686. 
Rothstein, J. D., Martin, L., Levey, A. I., Dykes-Hoberg, M., Jin, L., Wu, D., et al. 
(1994). Localization of neuronal and glial glutamate transporters. Neuron, 13(3), 713-
725. 
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., et 
al. (2005). Beta-lactam antibiotics offer neuroprotection by increasing glutamate 
transporter expression. Nature, 433(7021), 73-77. 
Ruggiero, A. M., Liu, Y., Vidensky, S., Maier, S., Jung, E., Farhan, H., et al. (2008). The 
endoplasmic reticulum exit of glutamate transporter is regulated by the inducible 
mammalian Yip6b/GTRAP3-18 protein. J Biol Chem, 283(10), 6175-6183. 
Sauberlich, H. E., Dowdy, R. P., & Skala, J. H. (1973). Laboratory tests for the 
assessment of nutritional status. CRC Crit Rev Clin Lab Sci, 4(3), 215-340. 
 186
Schanne, F. A., Kane, A. B., Young, E. E., & Farber, J. L. (1979). Calcium dependence 
of toxic cell death: a final common pathway. Science, 206(4419), 700-702. 
Schlag, B. D., Vondrasek, J. R., Munir, M., Kalandadze, A., Zelenaia, O. A., Rothstein, J. 
D., et al. (1998). Regulation of the glial Na+-dependent glutamate transporters by cyclic 
AMP analogs and neurons. Mol Pharmacol, 53(3), 355-369. 
Scholz, W. (1949). Histologische und topische Veränderungen und Vulnerabilitäts 
verhältnisse im menschlichen Gehirn bei Sauerstoffmangel, Ödem und plasmatischen 
Infiltration. I. Problemstellung und feingewebliche Situation. . Arch Psychiatr Nervenkr, 
181, 621-665. 
Schousboe, A. (1981). Transport and metabolism of glutamate and GABA in neurons are 
glial cells. Int Rev Neurobiol, 22, 1-45. 
Schroth, G., Wichmann, W., & Valavanis, A. (1991). Blood-brain-barrier disruption in 
acute Wernicke encephalopathy: MR findings. J Comput Assist Tomogr, 15(6), 1059-
1061. 
Schweneker, M., Bachmann, A. S., & Moelling, K. (2005). JM4 is a four-transmembrane 
protein binding to the CCR5 receptor. FEBS Lett, 579(7), 1751-1758. 
Sebrell, J. W. (1962). In A clinical evaluation of thiamine deficiency. (Vol. 98, pp. 563-
567): Annals of the New York Academy of Sciences. 
Sharma, S. K., & Quastel, J. H. (1965). Transport and metabolism of thiamine in rat brain 
cortex in vitro. Biochem J, 94, 790-800. 
 187
Siegel GJ, Agranoff BW, Albers RW, et al., editors. (1999). Basic Neurochemistry: 
Molecular, Cellular and Medical Aspects. 6th edition. Philadelphia: Lippincott-Raven. 
ISBN-10: 0-397-51820. 
Sitcheran, R., Gupta, P., Fisher, P. B., & Baldwin, A. S. (2005). Positive and negative 
regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled 
repression. EMBO J, 24(3), 510-520. 
Slotboom, D. J., Konings, W. N., & Lolkema, J. S. (1999). Structural features of the 
glutamate transporter family. Microbiol Mol Biol Rev, 63(2), 293-307. 
Snell R.S. (2009). Clinical Neuroanatomy, 7th ed. Lippincott Williams & Wilkins. ISBN-
10: 0781794277  
Spector, R. (1976). Thiamine transport in the central nervous system. Am J Physiol, 
230(4), 1101-1107. 
Stella, N., Tence, M., Glowinski, J., & Premont, J. (1994). Glutamate-evoked release of 
arachidonic acid from mouse brain astrocytes. J Neurosci, 14(2), 568-575. 
Swank, R. L. (1940). AVIAN THIAMIN DEFICIENCY : A CORRELATION OF THE 
PATHOLOGY AND CLINICAL BEHAVIOR. J Exp Med, 71(5), 683-702. 
Swanson, R. A., Liu, J., Miller, J. W., Rothstein, J. D., Farrell, K., Stein, B. A., et al. 
(1997). Neuronal regulation of glutamate transporter subtype expression in astrocytes. J 
Neurosci, 17(3), 932-940. 
 188
Tamahara, S., Inaba, M., Sato, K., Matsuki, N., Hikasa, Y., & Ono, K. (2002). Non-
essential roles of cysteine residues in functional expression and redox regulatory 
pathways for canine glutamate/aspartate transporter based on mutagenic analysis. 
Biochem J, 367(Pt 1), 107-111. 
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., et al. 
(1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate 
transporter GLT-1. Science, 276(5319), 1699-1702. 
Terasawa, M., Nakahara, T., Tsukada, N., Sugawara, A., & Itokawa, Y. (1999). The 
relationship between thiamine deficiency and performance of a learning task in rats. 
Metab Brain Dis, 14(3), 137-148. 
Todd, K., & Butterworth, R. F. (1999). Mechanisms of selective neuronal cell death due 
to thiamine deficiency. Ann N Y Acad Sci, 893, 404-411. 
Todd, K. G., & Butterworth, R. F. (1998). Evaluation of the role of NMDA-mediated 
excitotoxicity in the selective neuronal loss in experimental Wernicke encephalopathy. 
Exp Neurol, 149(1), 130-138. 
Torvik, A. (1985). Two types of brain lesions in Wernicke's encephalopathy. Neuropathol 
Appl Neurobiol, 11(3), 179-190. 
Torvik, A. (1987). Brain lesions in alcoholics: neuropathological observations. Acta Med 
Scand Suppl, 717, 47-54. 
 189
Torvik, A. (1987). Topographic distribution and severity of brain lesions in Wernicke's 
encephalopathy. Clin Neuropathol, 6(1), 25-29. 
Tran, N. D., Correale, J., Schreiber, S. S., & Fisher, M. (1999). Transforming growth 
factor-beta mediates astrocyte-specific regulation of brain endothelial anticoagulant 
factors. Stroke, 30(8), 1671-1678. 
Troncoso, J. C., Johnston, M. V., Hess, K. M., Griffin, J. W., & Price, D. L. (1981). 
Model of Wernicke's encephalopathy. Arch Neurol, 38(6), 350-354. 
Trotti, D., Danbolt, N. C., & Volterra, A. (1998). Glutamate transporters are oxidant-
vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? 
Trends Pharmacol Sci, 19(8), 328-334. 
Tsuru, N., Ueda, Y., & Doi, T. (2002). Amygdaloid kindling in glutamate transporter 
(GLAST) knockout mice. Epilepsia, 43(8), 805-811. 
Vallejo-Illarramendi, A., Domercq, M., & Matute, C. (2005). A novel alternative splicing 
form of excitatory amino acid transporter 1 is a negative regulator of glutamate uptake. J 
Neurochem, 95(2), 341-348. 
Vemuganti, R., Kalluri, H., Yi, J. H., Bowen, K. K., & Hazell, A. S. (2006). Gene 
expression changes in thalamus and inferior colliculus associated with inflammation, 
cellular stress, metabolism and structural damage in thiamine deficiency. Eur J Neurosci, 
23(5), 1172-1188. 
 190
Victor M., A. R. a. C. G. (1989). The Wernicke-Korsakoff syndrome and related 
neurologic disorders due to alcoholism and malnutrition. (2nd ed. ed.). Philadelphia, PA.: 
FA Davis. 
Volterra, A., Trotti, D., Floridi, S., & Racagni, G. (1994). Reactive oxygen species inhibit 
high-affinity glutamate uptake: molecular mechanism and neuropathological 
implications. Ann N Y Acad Sci, 738, 153-162. 
Vortmeyer, A. O., & Colmant, H. J. (1988). Differentiation between brain lesions in 
experimental thiamine deficiency. Virchows Arch A Pathol Anat Histopathol, 414(1), 61-
67. 
Wang, D., & Hazell, A. S. (2010). Microglial activation is a major contributor to 
neurologic dysfunction in thiamine deficiency. Biochem Biophys Res Commun, 402(1), 
123-128. 
Warnock, L. G., & Burkhalter, V. J. (1968). Evidence of malfunctioning blood-brain 
barrier in experimental thiamine deficiency in rats. J Nutr, 94(2), 256-260. 
Watanabe, I., Tomita, T., Hung, K. S., & Iwasaki, Y. (1981). Edematous necrosis in 
thiamine-deficient encephalopathy of the mouse. J Neuropathol Exp Neurol, 40(4), 454-
471. 
Watanabe M, R. M., Kalandadze A, Rothstein JD. (2003). GPS1, interacting protein with 
GLT-1. Paper presented at the Society for Neuroscience.  
 191
Watanabe M, U. T., Jackson M, Ruggiero AM, Sawa A, Kalandadze A, Robinson MB., 
Rothstein JD. (2004). CSN1 Downregulates GLT-1 activity. . Paper presented at the 
Society for Neuroscience.  
Wendel, U., Lombeck, I., & Bremer, H. J. (1983). Maple-syrup-urine disease. N Engl J 
Med, 308(18), 1100-1101. 
White, R. J., & Reynolds, I. J. (1996). Mitochondrial depolarization in glutamate-
stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci, 16(18), 
5688-5697. 
William, R. R. (1961). Toward the conquest of beriberi. . Cambridge, Massachusets.: 
Harvard University Press. 
Witt, E. D. (1985). Neuroanatomical consequences of thiamine deficiency: a comparative 
analysis. Alcohol Alcohol, 20(2), 201-221. 
Yamamoto, Y., & Gaynor, R. B. (2004). IkappaB kinases: key regulators of the NF-
kappaB pathway. Trends Biochem Sci, 29(2), 72-79. 
Yamashita, M., & Yamamoto, T. (1995). Wernicke encephalopathy with symmetric 
pericentral involvement: MR findings. J Comput Assist Tomogr, 19(2), 306-308. 
Yernool, D., Boudker, O., Jin, Y., & Gouaux, E. (2004). Structure of a glutamate 
transporter homologue from Pyrococcus horikoshii. Nature, 431(7010), 811-818. 
 192
Yi, J. H., & Hazell, A. S. (2006). Excitotoxic mechanisms and the role of astrocytic 
glutamate transporters in traumatic brain injury. Neurochem Int, 48(5), 394-403. 
Zelenaia, O., Schlag, B. D., Gochenauer, G. E., Ganel, R., Song, W., Beesley, J. S., et al. 
(2000). Epidermal growth factor receptor agonists increase expression of glutamate 
transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-
kinase and transcription factor NF-kappaB. Mol Pharmacol, 57(4), 667-678. 
Zelenaia, O. A., & Robinson, M. B. (2000). Degradation of glial glutamate transporter 
mRNAs is selectively blocked by inhibition of cellular transcription. J Neurochem, 75(6), 
2252-2258. 
Zigmond M.J., Bloom F.E., Landis S.C., Roberts J.L., Squire L.R. (1999). Fundamental 
neuroscience, Ist ed. Academic Press, ISBN-10: 0127808701 
Zhang, J., Dawson, V. L., Dawson, T. M., & Snyder, S. H. (1994). Nitric oxide activation 
of poly(ADP-ribose) synthetase in neurotoxicity. Science, 263(5147), 687-689. 
Zhang, S. X., Weilersbacher, G. S., Henderson, S. W., Corso, T., Olney, J. W., & 
Langlais, P. J. (1995). Excitotoxic cytopathology, progression, and reversibility of 
thiamine deficiency-induced diencephalic lesions. J Neuropathol Exp Neurol, 54(2), 255-
267. 
Zhou, J., & Sutherland, M. L. (2004). Glutamate transporter cluster formation in 
astrocytic processes regulates glutamate uptake activity. J Neurosci, 24(28), 6301-6306. 
 193
Zink, M., Schmitt, A., Henn, F. A., & Gass, P. (2004). Differential expression of 
glutamate transporters EAAT1 and EAAT2 in mice deficient for PACAP-type I receptor. 
J Neural Transm, 111(12), 1537-1542. 
 
